var title_f28_6_28768="Erythema induratum";
var content_f28_6_28768=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F53596&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F53596&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Erythema induratum (nodular vasculitis)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple nodules are present on the posterior lower legs.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_6_28768=[""].join("\n");
var outline_f28_6_28768=null;
var title_f28_6_28769="Patient information: Presbyopia and refractive errors (The Basics)";
var content_f28_6_28769=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"21\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16331\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/10/14498\">",
"         Snellen chart to test visual acuity",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?11/35/11826\">",
"         Patient information: Age-related vision loss (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Presbyopia and refractive errors (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/presbyopia-and-refractive-errors-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H10437430\">",
"      <span class=\"h1\">",
"       What is presbyopia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Presbyopia is a condition that impairs vision. It often occurs during normal aging. People who have presbyopia have trouble focusing on things that are up close. They often have to hold things at arm&rsquo;s length to see them well.",
"     </p>",
"     <p>",
"      Presbyopia is often grouped together with a set of disorders called &ldquo;refractive errors,&rdquo; which are explained below.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10437437\">",
"      <span class=\"h1\">",
"       What are refractive errors?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Refractive errors are a group of disorders that impair vision. These disorders happen because the eye cannot focus light onto the back of the eye the right way. The most common refractive errors are:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Myopia, or near-sightedness &mdash; People who are near-sighted can see clearly up close, but things at a distance look blurry.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Hyperopia, or far-sightedness &mdash; People who are far-sighted can see clearly far away, but things up close look blurry.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Astigmatism &mdash; People with astigmatism see things as blurry at any distance.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10437444\">",
"      <span class=\"h1\">",
"       Is there a test for presbyopia and refractive errors?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse can check how well you see by having you read a standard eye chart (",
"      <a class=\"graphic graphic_figure graphicRef50810 \" href=\"UTD.htm?14/10/14498\">",
"       figure 1",
"      </a>",
"      ). Depending on how you do reading the chart, he or she might also suggest that you see an eye doctor for a &ldquo;comprehensive eye exam.&rdquo; During a comprehensive eye exam, the doctor can look for different causes of vision loss. That&rsquo;s important, because people can have more than 1 thing wrong with their eyes.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10437451\">",
"      <span class=\"h1\">",
"       Should I see a doctor?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If your vision is blurry or you have trouble seeing things up close or far away, you should see a doctor.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10437458\">",
"      <span class=\"h1\">",
"       How are presbyopia and refractive errors treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Presbyopia and refractive errors can usually be corrected with eyeglasses or contact lenses. In some cases, people do well with glasses sold at the drug store without a prescription. Keep in mind that the needs of your eyes can change as you get older. You might need to change prescriptions every so often. &nbsp; &nbsp;",
"     </p>",
"     <p>",
"      Some people with refractive errors can have a form of surgery that is done with a laser, called &ldquo;LASIK.&rdquo; During this surgery, the doctor uses the laser to reshape the outer layer of the eye, called the &ldquo;cornea.&rdquo; &nbsp; &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10437540\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/35/11826?source=see_link\">",
"       Patient information: Age-related vision loss (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?28/6/28769?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16331 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-42B8F45CE1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_6_28769=[""].join("\n");
var outline_f28_6_28769=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10437430\">",
"      What is presbyopia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10437437\">",
"      What are refractive errors?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10437444\">",
"      Is there a test for presbyopia and refractive errors?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10437451\">",
"      Should I see a doctor?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10437458\">",
"      How are presbyopia and refractive errors treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10437540\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16331\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/10/14498\">",
"      Snellen chart to test visual acuity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/35/11826?source=related_link\">",
"      Patient information: Age-related vision loss (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_6_28770="Auditory canal embryology";
var content_f28_6_28770=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F67764&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F67764&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Auditory canal embryology",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 416px; height: 362px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The medial-developing external auditory canal becomes filled with the meatal plug, consisting of proliferating ectodermal cells that subsequently recanalize. The tubotympanic recess has deepened to form the tympanic cavity. The otic vesicle forms the endolymphatic duct and sac, early semicircular canals, and cochlear diverticulum. The membranous labyrinth induces surrounding mesenchyme to condense and ultimately form the stapes, incus, and malleus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_6_28770=[""].join("\n");
var outline_f28_6_28770=null;
var title_f28_6_28771="Anterior blepharitis";
var content_f28_6_28771=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F64540&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F64540&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anterior blepharitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 278px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lower lid with inflammation with characteristic scales on the eyelashes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_6_28771=[""].join("\n");
var outline_f28_6_28771=null;
var title_f28_6_28772="Melanoma treatment; localized melanoma";
var content_f28_6_28772=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Melanoma treatment; localized melanoma (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?28/6/28772/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/6/28772/contributors\" id=\"au7457\">",
"       Jeffrey A Sosman, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?28/6/28772/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/6/28772/contributors\" id=\"se4430\">",
"       Michael B Atkins, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?28/6/28772/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/6/28772/contributors\" id=\"de7369\">",
"       Michael E Ross, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?28/6/28772?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      MELANOMA OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Melanoma is a serious form of skin cancer that starts in the pigment-producing skin cells (melanocytes). Melanoma is the sixth most common cancer in the United States, and the number of melanoma cases diagnosed annually is increasing faster than for any other cancer. Although the explanation for this is unknown, it may be related to increased recreational sun exposure and global changes such as ozone depletion.",
"    </p>",
"    <p>",
"     In contrast to other types of skin cancers (eg, squamous cell or basal cell cancers) that usually develop on sun-exposed areas of the body, melanomas can develop anywhere on the skin surface, as well as on the mucous membranes lining the mouth, nose, and genital areas. If left untreated, melanoma can spread (metastasize) to other parts of the body much more frequently than is typical for other types of skin cancers. Fortunately, when detected at an early stage, melanoma treatment is often effective in limiting the spread of the disease.",
"    </p>",
"    <p>",
"     This topic reviews the diagnosis and treatment of localized melanoma. A separate topic discusses the treatment of advanced and metastatic melanoma. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/8/39042?source=see_link\">",
"      \"Patient information: Melanoma treatment; advanced or metastatic melanoma (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      MELANOMA DIAGNOSIS",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Appearance of lesion",
"     </span>",
"     &nbsp;&mdash;&nbsp;Similar to other types of skin cancer, melanoma is diagnosed based upon the appearance of a skin lesion. Melanomas can occur anywhere on the skin surface, but it frequently develops on the back and other areas that may be easy to miss with self-inspection. Abnormal findings can be described with an acronym, ABCDE (",
"     <a class=\"graphic graphic_picture graphicRef52518 \" href=\"UTD.htm?40/11/41143\">",
"      picture 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       A &mdash; Asymmetry (one side is different from opposite side) (",
"       <a class=\"graphic graphic_picture graphicRef66667 \" href=\"UTD.htm?41/9/42141\">",
"        picture 2",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       B &mdash; Border irregularities (jagged, uneven edge) (",
"       <a class=\"graphic graphic_picture graphicRef79649 \" href=\"UTD.htm?25/18/25902\">",
"        picture 3",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       C &mdash; Color variegation (ie, different colors within the same region) (",
"       <a class=\"graphic graphic_picture graphicRef75736 \" href=\"UTD.htm?27/15/27902\">",
"        picture 4",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       D &mdash; Diameter greater than 6 mm (if larger than a pencil eraser, evaluation recommended)",
"      </li>",
"      <li>",
"       E &mdash; Evolution (change) in color, shape, or symptoms over time (",
"       <a class=\"graphic graphic_picture graphicRef75572 \" href=\"UTD.htm?27/63/28670\">",
"        picture 5",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Other abnormal features include inflammation (swelling) and bleeding or crusting. The melanoma lesion frequently is described by patients as looking like a &ldquo;blood blister&rdquo; or a &ldquo;tick bite&rdquo;. A person who notices any of these changes should make an appointment with a healthcare provider as soon as possible. Referral to a dermatologist (physician who specializes in skin conditions) may be recommended.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Biopsy",
"     </span>",
"     &nbsp;&mdash;&nbsp;To determine if the abnormality is a melanoma, a small piece of the area (or if it is small, the entire area) is removed and examined under a microscope to determine if precancerous or cancerous cells are present.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      MELANOMA CLINICAL STAGING",
"     </span>",
"    </p>",
"    <p>",
"     After melanoma is diagnosed, the next step is to determine the clinical stage or extent of disease spread. Accurate staging is important to determine the most appropriate treatment.",
"    </p>",
"    <p>",
"     The American Joint Committee on Cancer has defined a staging system for melanoma that takes into consideration the following characteristics:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The thickness of the tumor",
"      </li>",
"      <li>",
"       Ulceration (loss of skin) over the surface of the melanoma",
"      </li>",
"      <li>",
"       Involvement of the draining lymphatics",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       \"regional\" lymph nodes",
"      </li>",
"      <li>",
"       Evidence of tumor spread beyond the lymph nodes (distant metastases)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     A thorough physical examination, chest X-ray, and blood tests are typically performed to evaluate the possibility of lymph node or distant spread of the tumor.",
"    </p>",
"    <p>",
"     Additional radiologic examinations (such as a CT scan) may also be recommended, particularly for patients with advanced melanoma, those with a previous melanoma, and those with signs or symptoms of metastasis. These scan are usually performed after the lymph nodes are evaluated and shown to be involved (see",
"     <a class=\"local\" href=\"#H7\">",
"      'Evaluating the lymph nodes'",
"     </a>",
"     below).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Surgery",
"     </span>",
"     &nbsp;&mdash;&nbsp;In most patients, surgery is required to remove (or excise) the entire melanoma. Generally, one to two centimeters of normal skin surrounding the lesion must also be removed. This procedure is termed a wide local excision. This decreases the chance that the melanoma will recur at the same site.",
"    </p>",
"    <p>",
"     The type of physician (eg, dermatologist or general surgeon) who will perform the surgery depends upon the location and size of the wide local excision. Most procedures are performed as a day surgery in a hospital or surgical center. Most patients are able to go home later the same day.",
"    </p>",
"    <p>",
"     Occasionally, skin grafting may be necessary to promote healing and replace skin that has been removed. In some patients (such as those with a melanoma on the face or neck), it may be difficult to remove a sufficient amount of normal skin to ensure adequate margins. In this case, radiation therapy may be recommended after surgery.",
"    </p>",
"    <p>",
"     If an enlarged lymph node (gland) is present, it may be biopsied at the time of the wide local excision. Even if enlarged lymph nodes cannot be detected, the lymph nodes may be evaluated during or after the surgical removal of the melanoma.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Evaluating the lymph nodes",
"     </span>",
"     &nbsp;&mdash;&nbsp;The most common site of melanoma spread is the surrounding lymph nodes. Sometimes, lymph node involvement is obvious because an enlarged lymph node can be felt. In this case, removal of all the lymph nodes in that area (called a therapeutic node dissection) is the standard approach. Therapeutic node dissection provides an opportunity for cure the melanoma, particularly when used in conjunction with adjuvant systemic (body-wide) therapy (see",
"     <a class=\"local\" href=\"#H11\">",
"      'Melanoma adjuvant therapy'",
"     </a>",
"     below).",
"    </p>",
"    <p>",
"     In the majority of cases, enlarged lymph nodes are not visible, and the only way to determine if lymph nodes are affected is to take a sample of the lymph node during surgery. This is typically accomplished with a surgical technique known as sentinel lymph node (SLN) biopsy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h3\">",
"      Sentinel lymph node biopsy",
"     </span>",
"     &nbsp;&mdash;&nbsp;The sentinel lymph node (SLN) technique is based upon the theory that when tumor cells migrate, they spread to one or a few lymph nodes before involving other nodes. These nodes can be identified by injecting a blue dye or radioactive material around the primary tumor before the wide local excision, and then searching for the node that has absorbed the dye or the radioactive tracer at the time of surgery. This is known as lymphatic mapping.",
"    </p>",
"    <p>",
"     Sentinel lymph node biopsy and lymphatic mapping are usually done at the time of the wide local excision. Most procedures are performed in a hospital after the patient is given general anesthesia to induce sleep and prevent pain. The patient may go home later the same day or the following day.",
"    </p>",
"    <p>",
"     The status of this first draining (sentinel) lymph node accurately predicts the status of the remaining regional lymph nodes. Because only one, or at most, a few lymph nodes, is removed, the risk of this procedure is lower and the accuracy is greater than a full lymph node dissection. &nbsp;After the lymph node is removed, it is then examined under a microscope to determine if abnormal cells are present.",
"    </p>",
"    <p>",
"     The success of SLN biopsy is dependent upon the skill of the surgeon and the other physicians involved with the procedure. If later tests reveal that the cancer has spread to the SLN, a second procedure, termed a completion node dissection, is performed to remove the remaining lymph nodes. If the SLN is negative for tumor involvement, further lymph node dissection is usually not performed since the likelihood of finding tumor involvement is 5 percent or less.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h3\">",
"      When is SLN biopsy recommended?",
"     </span>",
"     &nbsp;&mdash;&nbsp;SLN biopsy has become the standard technique for assessing the regional lymph nodes and is recommended for staging of most people with newly diagnosed melanomas. However, people whose melanomas are less than 1 mm in thickness (thin melanomas) may not require SLN, since the likelihood of tumor spread to the regional lymph nodes is less than 10 percent.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      MELANOMA PATHOLOGIC STAGING",
"     </span>",
"    </p>",
"    <p>",
"     Once the staging work-up is complete, a pathologic disease stage between I and IV is assigned. A higher stage indicates more extensive disease.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <strong>",
"        Stage I or IIA disease",
"       </strong>",
"       &mdash; The tumor is less than 4 millimeters thick without ulceration, or less than 2 millimeters thick if ulceration is present. This is considered to be localized disease. Surgery alone is curative in 70 to 90 percent of cases.",
"      </li>",
"      <li>",
"       <strong>",
"        Stage IIB or IIC disease",
"       </strong>",
"       &mdash; The tumor is 2.1 to 4 millimeters thick with ulceration, or 4 or more millimeters thick with or without ulceration. This is considered to be localized disease. Patients are at a higher risk of recurrence, even after the tumor has been completely surgically removed. Adjuvant (additional) therapy is often recommended, especially for tumors that are 4 or more millimeters thick. (See",
"       <a class=\"local\" href=\"#H11\">",
"        'Melanoma adjuvant therapy'",
"       </a>",
"       below.)",
"      </li>",
"      <li>",
"       <strong>",
"        Stage III disease",
"       </strong>",
"       &mdash; There is evidence of melanoma spread in the lymphatic channels surrounding the tumor (called satellites) or nearby lymph nodes. The tumor may be any thickness. Adjuvant therapy is strongly recommended.",
"      </li>",
"      <li>",
"       <strong>",
"        Stage IV disease",
"       </strong>",
"       &mdash; The melanoma has metastasized to more distant locations in the body, which may or may not include the lymph nodes. The tumor may be any thickness. This is referred to as advanced disease. For a full discussion of treatment of advanced disease, (see",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?38/8/39042?source=see_link\">",
"        \"Patient information: Melanoma treatment; advanced or metastatic melanoma (Beyond the Basics)\"",
"       </a>",
"       ).",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Based upon the pathologic disease stage, the optimal treatment is chosen. For patients with localized disease who have no evidence of distant metastases, the goals of treatment are:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Complete surgical removal of the primary melanoma",
"      </li>",
"      <li>",
"       Evaluation of regional lymph nodes for evidence of tumor involvement",
"      </li>",
"      <li>",
"       Preventing further spread or disease recurrence",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     In patients with involved sentinel lymph nodes following the staging the standard of care is to completely remove all the remaining regional lymph nodes with a completion lymphadenectomy. The benefit of this standard procedure has been questioned, especially for patients with thin primary melanomas and very few tumor cells in their sentinel lymph node biopsy. Consequently, there is an ongoing international trial comparing completion lymph node biopsy to regional ultrasound evaluation of the lymph node basin on a scheduled basis. The study is determining whether survival is better with completion lymph node dissection.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      MELANOMA ADJUVANT THERAPY",
"     </span>",
"    </p>",
"    <p>",
"     The term adjuvant therapy refers to any additional anticancer treatment that is given after a cancer is surgically removed. The objective of adjuvant treatment is to stop or slow the growth of any remaining cancer cells that were not removed during surgery.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Immunotherapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Interferon alpha (IFNa) is the agent most commonly used to treat patients with melanoma who are at high risk for recurrence. Research has shown that IFNa, a form of immunotherapy, can help to decrease the chance of melanoma recurrence and improve a person's chance of survival [",
"     <a class=\"abstract\" href=\"UTD.htm?28/6/28772/abstract/1\">",
"      1",
"     </a>",
"     ]. Immunotherapy may boost the patient's immune response so that it can more effectively fight the cancer.",
"    </p>",
"    <p>",
"     Treatment with IFNa begins after surgery and may continue for up to 12 months. The best way of giving adjuvant IFNa is not clear. The following IFNa regimen is the standard for people with high-risk melanoma. It includes two parts, which are given for up to 12 months.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       High dose intravenous therapy is given five days per week for four weeks.",
"      </li>",
"      <li>",
"       A lower dose of IFNa is given by injection under the skin (subcutaneously) three times weekly for up to 11 additional months. This injection can be given by the patient or a family member.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Although other regimens and doses have been studied, none has been shown to be as effective as this regimen. Because adjuvant IFNa therapy helps only a minority of patients at risk for melanoma recurrence and is frequently associated with significant side effects, patients are encouraged, whenever possible, to enroll in clinical trials testing adjuvant strategies aimed at improving the outcomes of treatment with IFNa (see",
"     <a class=\"local\" href=\"#H20\">",
"      'Clinical trials'",
"     </a>",
"     below).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h3\">",
"      Benefits",
"     </span>",
"     &nbsp;&mdash;&nbsp;In one trial [",
"     <a class=\"abstract\" href=\"UTD.htm?28/6/28772/abstract/1\">",
"      1",
"     </a>",
"     ], benefit from IFNa seemed to be limited to patients who had lymph node involvement (stage III disease). In this group of patients, there was an approximately twofold increase in the number of patients who were free of disease recurrence at five years (called recurrence free survival).",
"    </p>",
"    <p>",
"     However, in subsequent trials, an improvement in recurrence-free survival (approximately 20 to 40 percent better) was also seen in people with a lower risk of disease recurrence (stage IIB) as well [",
"     <a class=\"abstract\" href=\"UTD.htm?28/6/28772/abstract/2\">",
"      2",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     We recommend adjuvant IFNa therapy for people at high risk of relapse (stage IIB, IIC, and III) who have no serious underlying medical problems and who have a life expectancy of 10 years of more.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h3\">",
"      Side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;IFNa can have potentially toxic side effects, although the type and severity of side effects varies from one person to another. Because people have differing tolerances for side effects and differing ideas about the importance of quality versus quantity of life, the decision to undergo treatment with adjuvant IFNa is an individual one, especially for people who have node-negative but otherwise high-risk melanoma.",
"    </p>",
"    <p>",
"     Side effects may include flu-like symptoms (low grade fever, muscle and joint aches, chills, fatigue), depression, a drop in the number of white blood cells, and temporary liver enzyme abnormalities. The majority of these effects can be managed with supportive care",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     a temporarily reduced dose of IFNa. Most reactions are completely reversible when treatment is stopped.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Future directions",
"     </span>",
"     &nbsp;&mdash;&nbsp;Research is ongoing to identify other therapies that are effective in treating melanoma. It is hoped that combining interferon with a melanoma vaccine, radiation therapy, or other agents will result in a treatment that is more or equally effective and less toxic. As noted above, everyone with melanoma is encouraged, when possible, to enroll in a clinical trial (see",
"     <a class=\"local\" href=\"#H20\">",
"      'Clinical trials'",
"     </a>",
"     below).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      MELANOMA MONITORING",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Clinician monitoring",
"     </span>",
"     &nbsp;&mdash;&nbsp;Because melanoma can recur in the same location or in new sites, routine follow-up and monitoring are very important. Seeing a healthcare provider regularly is the most important aspect of follow-up since most recurrences are discovered when the patient is seen and examined at regular intervals after treatment.",
"    </p>",
"    <p>",
"     Blood tests and a chest X-ray may be performed at periodic intervals to evaluate the possibility of distant spread of melanoma. Other imaging studies (eg, CT or PET scans) are usually recommended only if new symptoms develop.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Self-examination",
"     </span>",
"     &nbsp;&mdash;&nbsp;In addition to visits with a healthcare provider, monthly self-examination is recommended to identify any new or changing skin lesions. If a new or changing lesion is detected, contact a healthcare provider to determine if further evaluation is needed.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       To perform self-examination, stand in an area that is brightly lit. Use a hand-held mirror to examine the face, including the nose, lips, mouth, and ears. Face away from a full-length mirror and hold up the hand-held mirror to see the back of the head, ears, and neck.",
"      </li>",
"      <li>",
"       Examine both sides of the hands and arms, including between the findings and under the fingernails. Use the full-length mirror to examine the undersides and back of the arms and armpits. Examine the neck, chest, and abdomen. Women should lift the breasts to examine underneath.",
"      </li>",
"      <li>",
"       Using both mirrors, examine the shoulders, upper back, and upper arms. Scan the lower back, buttocks (including between the buttocks), and backs of both legs.",
"      </li>",
"      <li>",
"       Sit down, and rest one foot on a chair. Examine the legs, including the ankles, top and bottom of the feet, between the toes, and under the toenails. Switch legs and repeat. Use a hand-held mirror to examine the genitals.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Prevention of future melanoma",
"     </span>",
"     &nbsp;&mdash;&nbsp;People who have had melanoma are at increased risk of developing melanoma again. Ways to reduce exposure to UV radiation from sunlight are discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/60/33729?source=see_link\">",
"      \"Patient information: Sunburn prevention (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H20\">",
"     <span class=\"h1\">",
"      CLINICAL TRIALS",
"     </span>",
"    </p>",
"    <p>",
"     Progress in treating cancer requires that better treatments be identified through clinical trials, which are conducted all over the world. A clinical trial is a carefully controlled way to study the effectiveness of new treatments or new combinations of known therapies. Ask for more information about clinical trials, or read about clinical trials at:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://www.cancer.gov/clinicaltrials/education/main/page1\">",
"        file://www.cancer.gov/clinicaltrials/education/main/Page1",
"       </a>",
"      </li>",
"      <li>",
"       <a class=\"external\" href=\"file://www.cancer.gov/clinicaltrials\">",
"        www.cancer.gov/clinicaltrials",
"       </a>",
"      </li>",
"      <li>",
"       <a class=\"external\" href=\"file://clinicaltrials.gov/\">",
"        file://clinicaltrials.gov/",
"       </a>",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H21\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H211\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5514424\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/46/42722?source=see_link\">",
"      Patient information: Melanoma skin cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/20/23874?source=see_link\">",
"      Patient information: Sunburn (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/51/818?source=see_link\">",
"      Patient information: Seborrheic keratosis (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5514432\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/8/39042?source=see_link\">",
"      Patient information: Melanoma treatment; advanced or metastatic melanoma (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/60/33729?source=see_link\">",
"      Patient information: Sunburn prevention (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44711?source=see_link\">",
"      Adjuvant immunotherapy for melanoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29831?source=see_link\">",
"      Approach to the patient with macular skin lesions",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27081?source=see_link\">",
"      Cutaneous melanoma: Management of in transit metastases",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34007?source=see_link\">",
"      Cutaneous melanoma: Management of local recurrence",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/2/26664?source=see_link\">",
"      Evaluation and treatment of regional lymph nodes in melanoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/5/15450?source=see_link\">",
"      Imaging studies in melanoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/26/6569?source=see_link\">",
"      Inherited susceptibility to melanoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26585?source=see_link\">",
"      Initial surgical management of melanoma of the skin and unusual sites",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/63/39927?source=see_link\">",
"      Management of brain metastases in melanoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/59/8122?source=see_link\">",
"      Ocular melanoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22009?source=see_link\">",
"      Pathologic characteristics of melanoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18073?source=see_link\">",
"      Primary prevention of melanoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=see_link\">",
"      Risk factors for the development of melanoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8713?source=see_link\">",
"      Role of radiation therapy in the management of melanoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/16/16650?source=see_link\">",
"      Screening and early detection of melanoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/15/35065?source=see_link\">",
"      Staging work-up and surveillance after treatment of melanoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/8/2183?source=see_link\">",
"      Surgical management of metastatic melanoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19944?source=see_link\">",
"      Molecularly targeted therapy for metastatic melanoma",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Cancer Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; 1-800-4-CANCER",
"     <br/>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.cancer.gov/\">",
"      www.cancer.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Society of Clinical Oncology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.net/portal/site/patient\">",
"      www.cancer.net/portal/site/patient",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Comprehensive Cancer Network",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nccn.com/\">",
"      www.nccn.com",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Cancer Society",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; 1-800-ACS-2345",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.org/\">",
"      www.cancer.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Melanoma Center, University of Pittsburgh Cancer Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.melanomacenter.org/\">",
"      www.melanomacenter.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Skin Cancer Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.skincancer.org/\">",
"      www.skincancer.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Melanoma Research Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.melanoma.org/\">",
"      www.melanoma.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?28/6/28772/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 16, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?28/6/28772?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28772/abstract/1\">",
"      Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28772/abstract/2\">",
"      Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001; 19:2370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28772/abstract/3\">",
"      Kirkwood JM, Bender C, Agarwala S, et al. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol 2002; 20:3703.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f28_6_28772=[""].join("\n");
var outline_f28_6_28772=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           MELANOMA OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           MELANOMA DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           MELANOMA CLINICAL STAGING",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           MELANOMA PATHOLOGIC STAGING",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           MELANOMA ADJUVANT THERAPY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           MELANOMA MONITORING",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H20\">",
"           CLINICAL TRIALS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H21\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/11/41143\" title=\"picture 1\">",
"           ABCs of melanoma PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/9/42141\" title=\"picture 2\">",
"           Melanoma 1 PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/18/25902\" title=\"picture 3\">",
"           Lentigo maligna melanoma PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/15/27902\" title=\"picture 4\">",
"           Spreading melanoma PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/63/28670\" title=\"picture 5\">",
"           Nodular melanoma PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f28_6_28773="Mometasone (oral inhalation): Pediatric drug information";
var content_f28_6_28773=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Mometasone (oral inhalation): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?34/11/34998?source=see_link\">",
"    see \"Mometasone (oral inhalation): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?7/30/7654?source=see_link\">",
"    see \"Mometasone (oral inhalation): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9461865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Asmanex&reg; Twisthaler&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13935718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Asmanex&reg; Twisthaler&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10502944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anti-inflammatory Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiasthmatic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Corticosteroid, Inhalant (Oral)",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Glucocorticoid",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10503024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/11/34998?source=see_link\">",
"      see \"Mometasone (oral inhalation): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Maximum effects may not be seen until 1-2 weeks or longer; doses should be titrated to the lowest effective dose once asthma is controlled.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 4-11 years (regardless of prior therapy):",
"     <b>",
"      Note:",
"     </b>",
"     Use 110 mcg inhaler: Initial: 1 inhalation (110 mcg) once daily, administered in the evening. Maximum dose: 1 inhalation/day (110 mcg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;12 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Patients previously treated with bronchodilators only or with inhaled corticosteroids: Initial: 1 inhalation (220 mcg) once daily, administered in the evening; may increase dose after 2 weeks if adequate response not obtained. Maximum dose: 2 inhalations/day (440 mcg/day); may be administered as 1 inhalation twice daily or 2 inhalations once daily in the evening",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Patients previously treated with oral corticosteroids: Initial: 2 inhalations (440 mcg) twice daily. Maximum dose: 4 inhalations/day (880 mcg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NIH Asthma Guidelines (NAEPP, 2007) (give in divided doses):",
"     <b>",
"      Note:",
"     </b>",
"     220 mcg inhaler delivers 200 mcg mometasone furoate per actuation; NAEPP uses doses based on delivery, while manufacturer recommended doses are based on inhaler amount; Children &ge;12 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     \"Low\" dose: 200 mcg/day (200 mcg/puff: 1 puff/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     \"Medium\" dose: 400 mcg/day (200 mcg/puff: 2 puffs/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     \"High\" dose: &gt;400 mcg/day (200 mcg/puff: &gt;2 puffs/day)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9461992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, for oral inhalation, as furoate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Asmanex&reg; Twisthaler&reg;: 110 mcg (7 doses, 30 doses) [contains lactose; delivers 100 mcg/actuation]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Asmanex&reg; Twisthaler&reg;: 220 mcg (14 doses, 30 doses, 60 doses, 120 doses) [contains lactose; delivers 200 mcg/actuation]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9461868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10503026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Remove inhaler from foil pouch; write date on cap label. Keep inhaler upright while removing cap, twisting in a counterclockwise direction; lifting the cap loads the device with the medication. Exhale fully prior to bringing the inhaler up to the mouth. Place inhaler in mouth, while holding it in a horizontal position. Close lips around the mouthpiece and inhale quickly and deeply. Remove the inhaler from your mouth and hold your breath for about 10 seconds, if possible. Do not exhale into inhaler. Wipe the mouthpiece dry and replace the cap immediately after each inhalation; rotate fully until click is heard. Rinse mouth with water (without swallowing) after inhalation to decrease chance of oral candidiasis. Avoid contact of the inhaler with any liquids; do not wash; wipe with dry cloth or tissue if needed. Discard the inhaler 45 days after opening foil pouch or when dose counter reads \"00.\"",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10502984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral inhaler: Store at 25&deg;C (77&deg;F) in a dry place; excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); discard inhaler 45 days after opening foil pouch (or when dose counter reads \"00\")",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10502964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maintenance treatment of asthma as prophylactic therapy (FDA approved in ages &ge;4 years and adults);",
"     <b>",
"      NOT",
"     </b>",
"     indicated for the relief of acute bronchospasm. Also used to help reduce or discontinue oral corticosteroid therapy in patients with bronchial asthma.",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F9461919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Depression, fatigue, fever (children), headache, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Bruising (children)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, dry throat (oral inhalation), dyspepsia, gastroenteritis, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Dysmenorrhea, urinary tract infection (children)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain, musculoskeletal pain, myalgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Cataracts, ocular pressure increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Earache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dysphonia, epistaxis, nasal irritation, pharyngitis, rhinitis, sinus congestion, sinusitis, upper respiratory tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome, infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Anaphylaxis, angioedema, asthma aggravated, bronchospasm, cough, dyspnea, growth suppression, hypersensitivity, pruritus, rash, wheezing",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10502965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to mometasone or any component; hypersensitivity to milk proteins; primary treatment of status asthmaticus or acute bronchospasm",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10502967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid using higher than recommended doses; suppression of HPA axis function, suppression of linear growth (ie, reduction of growth velocity), reduced bone mineral density, hypercorticism (Cushing's syndrome), hyperglycemia, or glucosuria may occur; titrate to lowest effective dose. Use with extreme caution in patients with respiratory tuberculosis, untreated systemic infections, or ocular herpes simplex. Rare cases of increased IOP, glaucoma, or cataracts have been reported with inhaled corticosteroids, including mometasone. Local oropharyngeal",
"     <i>",
"      Candida",
"     </i>",
"     infections have been reported; if they occur, treat appropriately while continuing mometasone therapy; however, therapy may need to be interrupted in some patients. Patients should be instructed to rinse mouth after each use.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10502966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fatalities have occurred due to adrenal insufficiency in asthmatic patients during and after switching from systemic corticosteroids to aerosol steroids; several months may be required for full recovery of hypothalamic-pituitary-adrenal (HPA) function; patients receiving higher doses of systemic corticosteroids (eg, adults receiving &ge;20 mg of prednisone per day) may be at greater risk; during this period of HPA suppression, aerosol steroids do not provide the systemic glucocorticoid or mineralocorticoid activity needed to treat patients requiring stress doses (ie, patients with major stress, such as trauma, surgery, infections, or other conditions associated with severe electrolyte loss). When used at high doses or for a prolonged time, hypercorticism and HPA suppression (including adrenal crisis) may occur; use with inhaled or systemic corticosteroids (even alternate-day dosing) may increase risk of HPA suppression. Acute adrenal insufficiency may occur with abrupt withdrawal after long-term use or with stress; withdrawal and discontinuation of corticosteroids should be done carefully; patients with HPA axis suppression may require doses of systemic glucocorticosteroids prior to, during, and after unusual stress (eg, surgery). Immunosuppression may occur; patients may be more susceptible to infections; avoid exposure to chickenpox and measles. Switching patients from systemic corticosteroids to aerosol steroids may unmask allergic conditions previously treated by the systemic steroid. Bronchospasm may occur after use of inhaled asthma medications; a fast-acting bronchodilator may be used to treat; discontinue mometasone and initiate alternative chronic therapy",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Allergic reactions, including anaphylaxis, angioedema, pruritus, and rash, have been reported. If these symptoms occur, discontinue use. Powder for oral inhalation (Asmanex&reg; Twisthaler&reg;) contains lactose (milk proteins) which may cause allergic reactions (including anaphylaxis) in patients with milk protein allergy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9461922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9461923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Corticosteroids (Orally Inhaled) may diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Corticosteroids (Orally Inhaled). Management: Monitor for signs and symptoms of adrenal suppression if inhaled budesonide or mometasone are coadministered with a strong CYP3A4 inhibitor.  Avoid combining inhaled fluticasone with any strong CYP3A4 inhibitor.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9461909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9461910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal studies following topical and SubQ administration. Hypoadrenalism may occur in infants born to women receiving corticosteroids during pregnancy. Monitor these infants closely after birth. A decrease in fetal growth has not been observed with inhaled corticosteroid use during pregnancy. Inhaled corticosteroids are recommended for the treatment of asthma (most information available using budesonide) during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10503065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor growth in pediatric patients. Check mucous membranes for signs of fungal infection. Monitor pulmonary function tests (eg, FEV",
"     <sub>",
"      1",
"     </sub>",
"     , peak flow).",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10502985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Controls the rate of protein synthesis, depresses the migration of polymorphonuclear leukocytes and fibroblasts, reverses capillary permeability, and stabilizes lysosomal membranes at the cellular level to prevent or control inflammation",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F10502986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Clinical effects are due to direct local effect, rather than systemic absorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maximum effect: 1-2 weeks or more",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration after discontinuation: Several days or more",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10502987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Systemic absorption: Single dose: &lt;1%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      dss",
"     </sub>",
"     : Adults: 152 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 98% to 99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Extensive in the liver to multiple metabolites; no major metabolites are detectable in the plasma;",
"     <i>",
"      in vitro",
"     </i>",
"     incubation studies identified one minor metabolite, 6 Beta-hydroxymometasone furoate, formed via cytochrome P450 CYP3A4 pathway",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: Single dose: &lt;1%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life: Mean: 5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: Metabolites are excreted primarily via the bile with a limited amount via urine; after oral inhalation, 74% of the dose was excreted in the feces and 8% in the urine (none as unchanged drug)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10503066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/30/7654?source=see_link\">",
"      see \"Mometasone (oral inhalation): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Notify physician if you are allergic to milk before starting therapy. Once therapy starts, notify physician if condition being treated persists or worsens. Do not decrease dose or discontinue without physician approval. Avoid exposure to chickenpox or measles; if exposed, seek medical advice without delay.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Not a bronchodilator and not indicated for relief of bronchospasm or acute episodes of asthma. May take 1-2 weeks before effects of medication are seen. May cause systemic effects, including hypercorticism, adrenal suppression, reduced growth velocity in children, or reduction in bone mineral density. Notify healthcare provider immediately if serious allergic reaction occurs, including skin rash; swelling of face, mouth, or tongue; or breathing problems. Report sore mouth or mouth lesions to physician. Carefully read and follow the Patient's Instructions for Use leaflet that accompanies the product.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F10503067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     When using mometasone oral inhalation to help reduce or discontinue oral corticosteroid therapy, begin prednisone taper after at least 1 week of mometasone inhalation therapy; do not decrease prednisone faster than 2.5 mg/day on a weekly basis; monitor patients for signs of asthma instability and adrenal insufficiency; decrease mometasone to lowest effective dose after prednisone reduction is complete.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      National Asthma Education and Prevention Program (NAEPP), \"Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma,\"",
"      <i>",
"       Clinical Practice Guidelines",
"      </i>",
"      , National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007. Available at",
"      <a href=\"file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm\" target=\"_blank\">",
"       file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm",
"      </a>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16022 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-1D72A0B336-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_6_28773=[""].join("\n");
var outline_f28_6_28773=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9461865\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13935718\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10502944\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503024\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9461992\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9461868\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503026\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10502984\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10502964\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9461919\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10502965\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10502967\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10502966\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9461922\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9461923\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9461909\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9461910\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503065\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10502985\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10502986\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10502987\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503066\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503067\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16022\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16022|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/23/38261?source=related_link\">",
"      Mometasone (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/4/7236?source=related_link\">",
"      Mometasone (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/20/42307?source=related_link\">",
"      Mometasone (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/11/34998?source=related_link\">",
"      Mometasone (oral inhalation): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/30/7654?source=related_link\">",
"      Mometasone (oral inhalation): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/46/43748?source=related_link\">",
"      Mometasone (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/61/13268?source=related_link\">",
"      Mometasone (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/8/13444?source=related_link\">",
"      Mometasone (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_6_28774="Chalazion upper eyelid";
var content_f28_6_28774=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F80892&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F80892&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Chalazion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A nodular lesion is present on the upper eyelid.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_6_28774=[""].join("\n");
var outline_f28_6_28774=null;
var title_f28_6_28775="Clinical features and management of heel pain in the young athlete";
var content_f28_6_28775=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features and management of heel pain in the young athlete",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/6/28775/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/6/28775/contributors\">",
"     Joseph Chorley, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/6/28775/contributors\">",
"     Christopher R Powers, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/6/28775/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/6/28775/contributors\">",
"     Albert C Hergenroeder, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/6/28775/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/6/28775/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/6/28775/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/6/28775/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 20 percent of musculoskeletal complaints are related to the foot and ankle, which is not surprising considering the functions of the foot:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      It provides a stable base on which the body can stand.",
"     </li>",
"     <li>",
"      It acts as a rigid lever to propel the body forward during walking.",
"     </li>",
"     <li>",
"      It provides shock absorption for the force generated during walking and running (approximately two to six times an individual's body weight).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Heel pain in the young athlete can originate in the bones (fractures), ligaments (sprains), muscles and tendons (tendinitis), or fascia. Careful localization of the pain can help to narrow the differential diagnosis (",
"    <a class=\"graphic graphic_figure graphicRef63409 \" href=\"UTD.htm?0/44/711\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14711?source=see_link\">",
"     \"Evaluation of foot and ankle pain in the young athlete\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical features and management of heel pain in the young athlete will be reviewed here. Pain in other parts of the foot and ankle pain in the young athlete are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23190?source=see_link\">",
"     \"Clinical features and management of foot pain in the young athlete\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/20/31050?source=see_link\">",
"     \"Clinical features and management of ankle pain in the young athlete\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Causes of heel pain in the young athlete include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Calcaneal apophysitis (Sever's disease)",
"     </li>",
"     <li>",
"      Plantar fasciitis",
"     </li>",
"     <li>",
"      Painful heel pad syndrome",
"     </li>",
"     <li>",
"      Calcaneal apophyseal fracture or calcaneal stress fracture",
"     </li>",
"     <li>",
"      Calcaneal osteomyelitis",
"     </li>",
"     <li>",
"      Bone tumors",
"     </li>",
"     <li>",
"      Unicameral (simple) bone cyst",
"     </li>",
"     <li>",
"      Spondyloarthropathy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Calcaneal apophysitis, plantar fasciitis, and painful heel pad syndrome are discussed here.",
"   </p>",
"   <p>",
"    Calcaneus apophyseal fractures are relatively uncommon events, but they do occur [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28775/abstract/1\">",
"     1",
"    </a>",
"    ]. Calcaneal stress fractures are the most common stress fracture in the pediatric rear foot and are seen more commonly in runners and in young military recruits [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28775/abstract/2\">",
"     2",
"    </a>",
"    ]. There is a higher frequency in female adolescents who have osteopenia related to inadequate caloric intake and secondary amenorrhea. While radiographs may show stress reaction and callus formation, MRI is more sensitive to early changes, but may have false positives that do not correlate with the clinical exam [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28775/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Osteomyelitis in the calcaneus can cause heel pain. Although the clinical presentation of osteomyelitis can be nonspecific, signs of infection (ie, localized erythema and warmth",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    elevated erythrocyte sedimentation rate and C-reactive protein levels) may be present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33289?source=see_link\">",
"     \"Evaluation and diagnosis of hematogenous osteomyelitis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most bone tumors that present with heel pain are benign [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28775/abstract/4\">",
"     4",
"    </a>",
"    ]. Between 5 and 8 percent of osteoid osteomas occur in the foot. The classic presentation is of night pain that is responsive to salicylates. Ewing sarcoma may be seen in the calcaneus and may be difficult to distinguish from osteomyelitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24522?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of benign bone tumors in children and adolescents\", section on 'Osteoid osteoma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37769?source=see_link\">",
"     \"Clinical presentation, staging, and prognostic factors of the Ewing sarcoma family of tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33289?source=see_link&amp;anchor=H27#H27\">",
"     \"Evaluation and diagnosis of hematogenous osteomyelitis in children\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most unicameral bone cysts are asymptomatic and are discovered incidentally. However, larger ones may require orthopedic referral for curettage and bone graft. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24522?source=see_link&amp;anchor=H26#H26\">",
"     \"Overview of benign bone tumors in children and adolescents\", section on 'Unicameral bone cyst'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The onset of spondyloarthropathy in childhood often coincides with a period of increased sports activity in the second decade. Although the knee and the hip are the joints most commonly involved at the time of presentation, recurrent ankle or heel pain can also occur. Diagnosis of spondyloarthropathy may be delayed if complaints of pain are attributed to recurrent sprains or strains. The detection of painful tendon or ligament insertions (enthesitis) around additional joints is a prominent feature in approximately 75 percent of cases and is an important diagnostic finding [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28775/abstract/5\">",
"     5",
"    </a>",
"    ]. Achilles tendinitis and plantar fasciitis are commonly identified if sought. As an example, in one retrospective cohort of 32 children who were newly diagnosed with enthesitis-related arthritis, tenderness at the plantar fascial or Achilles tendon insertion of the calcaneus was described in 19 patients and was most frequently bilateral. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8696?source=see_link\">",
"     \"Spondyloarthropathy in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/31/24056?source=see_link&amp;anchor=H2#H2\">",
"     \"Pauciarticular onset juvenile idiopathic arthritis\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CALCANEAL APOPHYSITIS (SEVER DISEASE)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcaneal apophysitis is one of the most common causes of heel pain in young athletes, particularly those who play soccer and basketball or participate in gymnastics or",
"    <span class=\"nowrap\">",
"     track/running",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28775/abstract/6\">",
"     6",
"    </a>",
"    ]. The mean age of presentation is 8 to 12 years; boys are affected more often than are girls; the condition is bilateral in 40 to 61 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28775/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An apophysis is a growth plate that does not contribute to the linear growth of the bone. The calcaneal apophysis, located on the posterior inferior aspect of the calcaneus, is the growth plate at the insertion of the Achilles tendon (",
"    <a class=\"graphic graphic_figure graphicRef63409 \" href=\"UTD.htm?0/44/711\">",
"     figure 1",
"    </a>",
"    ). It normally develops at an earlier age in girls than in boys (6 versus 8 years of age, respectively) and is present for approximately three to four years.",
"   </p>",
"   <p>",
"    The pain in calcaneal apophysitis is the result of inflammation that can be caused by several factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The increased metabolic activity in the growth plate during periods of rapid growth may cause pain.",
"     </li>",
"     <li>",
"      Footwear that lacks heel cushioning may provide inadequate protection.",
"     </li>",
"     <li>",
"      Footwear with heel cleats (particularly soccer cleats) may center the force of impact on the heel.",
"     </li>",
"     <li>",
"      Overuse in sports that involve jumping and running may result in repetitive microtrauma that can exacerbate the condition.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of calcaneal apophysitis is clinical. The characteristic history is one of chronic heel pain that is related to activity and of insidious onset.",
"   </p>",
"   <p>",
"    The physical examination demonstrates decreased gastrocnemius-soleus flexibility; approximately 25 percent of patients have a flat foot or rigid foot alignment. Heel pain may be reproduced by direct digital palpation over the apophysis (",
"    <a class=\"graphic graphic_figure graphicRef63409 \" href=\"UTD.htm?0/44/711\">",
"     figure 1",
"    </a>",
"    ) or the calcaneal compression test. In the calcaneal compression test, the examiner holds the affected heel in his or her palm with the fingers enveloping the upper portion of the heel and then squeezes to compress the heel in the transverse plane.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiographs are not required to make the diagnosis of calcaneal apophysitis but should be obtained to exclude other disorders if the presentation is atypical or if the patient fails to make appropriate clinical progress (eg, inability to bear weight, acute onset, or associated constitutional symptoms, no improvement in four to eight weeks). Plain radiographs in patients with calcaneal apophysitis may show sclerosis and widening of the growth plate. These findings are more typical of a developmental stage than of a pathologic process and can also be seen in nonpainful heels. Magnetic resonance imaging (MRI) is more sensitive to identify stress related changes in the calcaneal metaphysis that can complicate cases that are more severe or chronic or those that do not respond to routine management [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28775/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of calcaneal apophysitis is aimed at decreasing the inflammation and stress placed on the apophysis. Decreasing the volume and intensity of activity will help to decrease the pain. Stretching the gastrocnemius-soleus complex, the use of a heel cup or",
"    <span class=\"nowrap\">",
"     1/4-inch",
"    </span>",
"    heel lift, and use of proper footwear will help to decrease the traction force on the apophysis.",
"   </p>",
"   <p>",
"    Daily icing for 20 minutes, even after symptoms have begun to improve, will help to decrease inflammation. Although NSAIDs may be helpful for pain control during early management, they should not be used before exercise or to increase the amount of activity that the athlete can tolerate.",
"   </p>",
"   <p>",
"    For the compliant patient whose symptoms fail to improve within four to eight weeks, short-term (three to four weeks) short-leg casting may help to resolve painful symptoms related to stress associated bone changes. Physical therapy and slow progressive return to activity are important to recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28775/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PLANTAR FASCIITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plantar fasciitis is the most common cause of inferior heel pain in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28775/abstract/10\">",
"     10",
"    </a>",
"    ]. It occurs less commonly in children and adolescents, but it does occur in athletes (particularly distance runners and dancers) and in sedentary, obese children. Excessive, prolonged pronation is a predisposing factor. Plantar fasciitis in adults is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44681?source=see_link\">",
"     \"Plantar fasciitis and other causes of heel pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The plantar fascia is a thick, strong aponeurosis that inserts on the calcaneal tuberosity, extends longitudinally down the long axis of the foot, and has distal insertions on each of the five digits (",
"    <a class=\"graphic graphic_figure graphicRef61931 \" href=\"UTD.htm?19/7/19573\">",
"     figure 2",
"    </a>",
"    ). The strongest and most clinically important portion of the plantar fascia is the medial portion that inserts on the medial condyle of the calcaneus.",
"   </p>",
"   <p>",
"    The causes of plantar fasciitis are related to acute inflammation or chronic degenerative changes and include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mechanical &ndash; Acute overuse, pes planus, pes cavus, footwear",
"     </li>",
"     <li>",
"      Degenerative &ndash; Chronic overuse, steroid injection, obesity",
"     </li>",
"     <li>",
"      Systemic &ndash; Spondyloarthropathy, rheumatoid arthritis, Lofgren syndrome",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Plantar fasciitis may be related to training error or marked increase in physical activity; use of shoes that provide inadequate medial hindfoot and longitudinal arch support; pes planus (the role of the plantar fascia in resupinating the foot by the windlass effect is amplified when the foot over-pronates in patients with flat feet); or tight gastrocnemius-soleus complex (because of increased pull on the plantar fascia and flattening of the fat pad). Among patients with plantar fasciitis, 70 percent have pes planus or fat pad flattening [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28775/abstract/11\">",
"     11",
"    </a>",
"    ]. Systemic causes must be considered when there is bilateral involvement or failure to respond to appropriate initial management, as discussed below. Plantar fasciitis and Achilles tendinitis are common findings in patients with seronegative spondyloarthropathies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28775/abstract/5,12\">",
"     5,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with plantar fasciitis have the \"first step in the morning\" symptom, in which the pain occurs for the first few minutes after getting out of bed and then resolves. This first step may be easily confused with morning stiffness associated with spondyloarthropathies. As the course of plantar fasciitis progresses, pain may return at the end of the day. The patient may describe the pain by complaining that it feels as if there is a rock in his or her shoe. The pain is lessened if the patient walks on the outside of the foot.",
"   </p>",
"   <p>",
"    The area of maximal tenderness typically is over the medial calcaneal tubercle and, less commonly, into the arch (usually in patients with pes cavus). Pain is best appreciated when the great toe is passively dorsiflexed, causing the plantar fascia to become taut and easy to palpate (",
"    <a class=\"graphic graphic_picture graphicRef76161 \" href=\"UTD.htm?21/12/21696\">",
"     picture 1",
"    </a>",
"    ). Examination also should include evaluation for tight gastrocnemius and pes planus because the treatment plan may vary if these conditions are present.",
"   </p>",
"   <p>",
"    Posterior heel pain is not part of the usual presentation of plantar fasciitis, a characteristic that can be used to differentiate it from many of the other conditions that cause heel pain. Inflammation of the medial calcaneal branch of the tibial nerve (a type of tarsal tunnel syndrome) can mimic plantar fasciitis. However, patients with this pathology will not have the \"for step of the morning\" sign, will often manifest a positive Tinel sign (tapping over the tibial nerve causes pain and paresthesia), and may have altered sensation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23190?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical features and management of foot pain in the young athlete\", section on 'Pes cavus'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H2\">",
"     'Causes'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of plantar fasciitis usually can be made clinically. In atypical cases, radiographs may be used to rule out other disorders. Lateral and axial views should be obtained. Spurring of the inferior calcaneus may be noted (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58778 \" href=\"UTD.htm?27/51/28478\">",
"     image 1",
"    </a>",
"    ). Calcaneal spurs are present in 50 percent of patients with a painful heel and 16 percent of asymptomatic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28775/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Heel spurs are associated with pain, but they are thought to be a degenerative reaction in and above the plantar fascia rather than the underlying etiology of the pain [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28775/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ultrasonography is not routinely necessary, but may be used to evaluate the thickness and quality of the plantar fascia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28775/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. The thickness of the fascia is increased in plantar fasciitis (measuring 5 to 7mm, with 2 to 4 mm being normal). In addition, local or diffuse hypoechogenicity at the calcaneal insertion may be noted.",
"   </p>",
"   <p>",
"    MRI has been used to define the anatomy of the plantar fascia when there is concern regarding partial rupture of the fascia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28775/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. Marked increased signal intensity may be suggestive of spondyloarthropathies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28775/abstract/22\">",
"     22",
"    </a>",
"    ]. Technetium scintigraphy has also been used to localize the inflammatory focus and rule out stress fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28775/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory testing is not helpful in the diagnosis of plantar fasciitis. Tests for inflammation will be normal unless there is coexistent inflammatory disease. On the other hand, if infectious, oncologic, or rheumatologic etiologies for heel pain are being considered, laboratory evaluation should be performed. Suggested studies include CBC, ESR, ANA, RF, CRP, and HLA-B27 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28775/abstract/12\">",
"     12",
"    </a>",
"    ]. Electromyography may be necessary if nerve entrapment is suspected; the yield is greater in cases in which pain has persisted for weeks to months [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28775/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ninety to 95 percent of all patients have success with conservative treatment. Between 6 and 12 months of step-wise therapy (",
"    <a class=\"graphic graphic_table graphicRef55469 \" href=\"UTD.htm?6/58/7084\">",
"     table 1",
"    </a>",
"    ) may be necessary to achieve successful return to premorbid activity.",
"   </p>",
"   <p>",
"    First-line therapy typically involves management of pain and inflammation, proper foot gear, avoidance of activities that cause pain, and exercises to strengthen the intrinsic muscles (eg, toe towel curls (",
"    <a class=\"graphic graphic_picture graphicRef55497 \" href=\"UTD.htm?25/0/25615\">",
"     picture 2",
"    </a>",
"    )) and stretching of the plantar fascia (",
"    <a class=\"graphic graphic_figure graphicRef77277 \" href=\"UTD.htm?22/37/23121\">",
"     figure 3",
"    </a>",
"    ) in conjunction with ice massage [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28775/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In second-line treatments, physical therapy is added. One randomized controlled study suggested that iontophoresis (the use of electrical current to drive medications through the skin to areas of disease) three times per week for two weeks with 0.4 percent",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    &nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/47/36599?source=see_link\">",
"     sodium phosphate",
"    </a>",
"    improved short-term pain and foot function [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28775/abstract/26\">",
"     26",
"    </a>",
"    ]. However, one month after completion of therapy, no difference was found between the treatment and control groups.",
"   </p>",
"   <p>",
"    Second-line therapy also may involve ultrasound with deep tissue cross friction massage. Orthotics may be helpful in patients who have biomechanical abnormalities that cause excessive rearfoot motion, calcaneal valgus, or pes planus. However, low dye taping to increase arch support, decreasing the pull on the plantar fascia, is usually preferred. Low dye taping is a technique that tries to reform the arch by applying tape to the sole of the foot (",
"    <a class=\"graphic graphic_picture graphicRef70684 \" href=\"UTD.htm?17/12/17603\">",
"     picture 3",
"    </a>",
"    ). Night splints with 5 degrees of dorsiflexion at the ankle and as much as 30 degrees at the MTP joint for 30 days are effective but cumbersome. Adherence to this therapy is poor, but it should be considered in patients with persistent \"first step\" symptoms.",
"   </p>",
"   <p>",
"    Third-line therapy may include cortisone injections for recalcitrant cases. Ultrasound guidance can be helpful for the inexperienced practitioner. The major risks of injection include accelerated fat pad atrophy and plantar fascial rupture. In one series of 122 plantar fascial injections, rupture occurred in 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28775/abstract/27\">",
"     27",
"    </a>",
"    ]. In a series of 37 patients with a presumptive diagnosis of plantar fascial rupture, all patients had been previously injected with cortisone [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28775/abstract/28\">",
"     28",
"    </a>",
"    ]. Application of a short-leg walking cast for two to four weeks is another second-line intervention that patients find to be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28775/abstract/29\">",
"     29",
"    </a>",
"    ]. Finally, steel-shank rocker bottom shoes may be considered in patients with recalcitrant pain despite the above interventions.",
"   </p>",
"   <p>",
"    In randomized trials, extracorporeal shockwave therapy does not appear to reduce the pain of plantar fasciitis significantly more than placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28775/abstract/30\">",
"     30",
"    </a>",
"    ]. However, in one randomized trial involving runners, morning symptoms were improved significantly [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28775/abstract/31\">",
"     31",
"    </a>",
"    ]. Shockwave therapy has been shown to decrease heel pain scores in some case series that did not include comparison groups. It may be considered as a third-line therapy as an alternative to surgery.",
"   </p>",
"   <p>",
"    Radiotherapy has been used in parts of Europe for the treatment of \"heel spur syndrome\", but there have been no randomized studies to evaluate its efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28775/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgical intervention may be necessary for as many as 5 percent of patients. Favorable outcomes have been reported in up to 75 percent of the patients who underwent the surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28775/abstract/30\">",
"     30",
"    </a>",
"    ]. Indications for surgery include failure of at least one year of conservative management or lack of response to conservative measures with evidence of impingement of the nerve to the abductor digiti minimi, a branch of the lateral branch of the plantar nerve. Impingement of this nerve is suggested if tapping over the nerve (Tinel test) at the lateral aspect of the heel reproduces or accentuates the paresthesia. The surgical procedure varies depending upon the etiology of pain and may include heel spur resection, calcaneal drilling, plantar fascia release,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neurolysis of the nerve to the abductor digiti minimi muscle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PAINFUL HEEL PAD SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The painful heel pad syndrome most often occurs in marathon runners. A subcalcaneal fat pad protects the weightbearing surface of the calcaneus. This fat pad has fibrous septae that act as coil-like mattress pads to absorb shock each time the heel strikes the ground. Painful heel pad syndrome may result from disruption of the fibrous septae that compartmentalize the fat in the heel pad.",
"   </p>",
"   <p>",
"    Pain is localized to the heel pad; the plantar fascia is not tender, and pain is not accentuated as the examiner dorsiflexes the toes. Insertion of heel cups [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28775/abstract/33\">",
"     33",
"    </a>",
"    ] and polyethylene block foam material (eg, Plastizote&reg;) that is individually molded to the patient's heel may be helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28775/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8591725\">",
"    <span class=\"h1\">",
"     ACHILLES TENDINITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insertional tendinopathy from Achilles tendinitis (peritendinitis or pantendinitis) typically causes &ldquo;posterior and superior heel pain (",
"    <a class=\"graphic graphic_figure graphicRef63409 \" href=\"UTD.htm?0/44/711\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef58376 \" href=\"UTD.htm?27/42/28326\">",
"     figure 4",
"    </a>",
"    ) and may be an important marker for inflammatory enthesitis (eg, juvenile idiopathic arthritis). Achilles tendonitis is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/20/31050?source=see_link&amp;anchor=H45#H45\">",
"     \"Clinical features and management of ankle pain in the young athlete\", section on 'Achilles tendinitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15676189\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Heel pain in the young athlete can originate in the bones (fractures), apophyses, muscles and tendons (tendinitis), nerve, or fascia. Careful localization of the pain can help to narrow the differential diagnosis (",
"      <a class=\"graphic graphic_figure graphicRef63409 \" href=\"UTD.htm?0/44/711\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Causes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Calcaneal apophysitis (Sever's disease) is one of the most common causes of heel pain in young athletes, particularly those who play soccer and basketball or participate in gymnastics or track. The diagnosis is made clinically. Treatment consists of activity modification, gastrocnemius-soleus complex stretching, a heel cup or lift, and efforts to decrease inflammation. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Calcaneal apophysitis (Sever disease)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Plantar fasciitis occurs less commonly in children than in adults. Runners, dancers, and sedentary, obese children are most commonly affected. This diagnosis is typically made based on clinical features. Stepwise nonsurgical therapy is successful in most patients (",
"      <a class=\"graphic graphic_table graphicRef55469 \" href=\"UTD.htm?6/58/7084\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Plantar fasciitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Painful heel pad syndrome is primarily seen in long distance runners. The diagnosis is made by history and physical examination. Treatment consists of rest and heel orthotics. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Painful heel pad syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Insertional tendinopathy from Achilles tendinitis (peritendinitis or pantendinitis) typically causes &ldquo;posterior and superior heel pain (",
"      <a class=\"graphic graphic_figure graphicRef63409 \" href=\"UTD.htm?0/44/711\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef58376 \" href=\"UTD.htm?27/42/28326\">",
"       figure 4",
"      </a>",
"      ) and may be an important marker for inflammatory enthesitis (eg, juvenile idiopathic arthritis). Achilles tendonitis is discussed in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/20/31050?source=see_link&amp;anchor=H45#H45\">",
"       \"Clinical features and management of ankle pain in the young athlete\", section on 'Achilles tendinitis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28775/abstract/1\">",
"      Walling AK, Grogan DP, Carty CT, Ogden JA. Fractures of the calcaneal apophysis. J Orthop Trauma 1990; 4:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28775/abstract/2\">",
"      Oestreich AE, Bhojwani N. Stress fractures of ankle and wrist in childhood: nature and frequency. Pediatr Radiol 2010; 40:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28775/abstract/3\">",
"      Niva MH, Sormaala MJ, Kiuru MJ, et al. Bone stress injuries of the ankle and foot: an 86-month magnetic resonance imaging-based study of physically active young adults. Am J Sports Med 2007; 35:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28775/abstract/4\">",
"      Harty MP. Imaging of pediatric foot disorders. Radiol Clin North Am 2001; 39:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28775/abstract/5\">",
"      Jacobs JC, Berdon WE, Johnston AD. HLA-B27-associated spondyloarthritis and enthesopathy in childhood: clinical, pathologic, and radiographic observations in 58 patients. J Pediatr 1982; 100:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28775/abstract/6\">",
"      Micheli LJ, Ireland ML. Prevention and management of calcaneal apophysitis in children: an overuse syndrome. J Pediatr Orthop 1987; 7:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28775/abstract/7\">",
"      Kose O. Do we really need radiographic assessment for the diagnosis of non-specific heel pain (calcaneal apophysitis) in children? Skeletal Radiol 2010; 39:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28775/abstract/8\">",
"      Rachel JN, Williams JB, Sawyer JR, et al. Is radiographic evaluation necessary in children with a clinical diagnosis of calcaneal apophysitis (sever disease)? J Pediatr Orthop 2011; 31:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28775/abstract/9\">",
"      Ogden JA, Ganey TM, Hill JD, Jaakkola JI. Sever's injury: a stress fracture of the immature calcaneal metaphysis. J Pediatr Orthop 2004; 24:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28775/abstract/10\">",
"      Shmokler RL, Bravo AA, Lynch FR, Newman LM. A new use of instrumentation in fluoroscopy controlled heel spur surgery. J Am Podiatr Med Assoc 1988; 78:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28775/abstract/11\">",
"      Amis J, Jennings L, Graham D, Graham CE. Painful heel syndrome: radiographic and treatment assessment. Foot Ankle 1988; 9:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28775/abstract/12\">",
"      Gerster JC. Plantar fasciitis and Achilles tendinitis among 150 cases of seronegative spondarthritis. Rheumatol Rehabil 1980; 19:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28775/abstract/13\">",
"      Tanz SS. Heel pain. Clin Orthop Relat Res 1963; 28:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28775/abstract/14\">",
"      Snook GA, Chrisman OD. The management of subcalcaneal pain. Clin Orthop Relat Res 1972; 82:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28775/abstract/15\">",
"      Barrett SL, Day SV, Pignetti TT, Egly BR. Endoscopic heel anatomy: analysis of 200 fresh frozen specimens. J Foot Ankle Surg 1995; 34:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28775/abstract/16\">",
"      Kumai T, Benjamin M. Heel spur formation and the subcalcaneal enthesis of the plantar fascia. J Rheumatol 2002; 29:1957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28775/abstract/17\">",
"      Gibbon WW, Long G. Ultrasound of the plantar aponeurosis (fascia). Skeletal Radiol 1999; 28:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28775/abstract/18\">",
"      Groshar, D, Alperson, M, Toubi, A, et al. Plantar fasciitis: detection with ultrasonography versus bonescintigraphy. Foot 2000; 10:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28775/abstract/19\">",
"      Theodorou DJ, Theodorou SJ, Kakitsubata Y, et al. Plantar fasciitis and fascial rupture: MR imaging findings in 26 patients supplemented with anatomic data in cadavers. Radiographics 2000; 20 Spec No:S181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28775/abstract/20\">",
"      Helie O, Dubayle P, Boyer B, Pharaboz C. [Magnetic resonance imaging of lesions of the superficial plantar fasciitis]. J Radiol 1995; 76:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28775/abstract/21\">",
"      Narv&aacute;ez JA, Narv&aacute;ez J, Ortega R, et al. Painful heel: MR imaging findings. Radiographics 2000; 20:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28775/abstract/22\">",
"      McGonagle D, Marzo-Ortega H, O'Connor P, et al. The role of biomechanical factors and HLA-B27 in magnetic resonance imaging-determined bone changes in plantar fascia enthesopathy. Arthritis Rheum 2002; 46:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28775/abstract/23\">",
"      Dasgupta B, Bowles J. Scintigraphic localisation of steroid injection site in plantar fasciitis. Lancet 1995; 346:1400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28775/abstract/24\">",
"      Schon LC, Glennon TP, Baxter DE. Heel pain syndrome: electrodiagnostic support for nerve entrapment. Foot Ankle 1993; 14:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28775/abstract/25\">",
"      Digiovanni BF, Nawoczenski DA, Malay DP, et al. Plantar fascia-specific stretching exercise improves outcomes in patients with chronic plantar fasciitis. A prospective clinical trial with two-year follow-up. J Bone Joint Surg Am 2006; 88:1775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28775/abstract/26\">",
"      Gudeman SD, Eisele SA, Heidt RS Jr, et al. Treatment of plantar fasciitis by iontophoresis of 0.4% dexamethasone. A randomized, double-blind, placebo-controlled study. Am J Sports Med 1997; 25:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28775/abstract/27\">",
"      Acevedo JI, Beskin JL. Complications of plantar fascia rupture associated with corticosteroid injection. Foot Ankle Int 1998; 19:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28775/abstract/28\">",
"      Sellman JR. Plantar fascia rupture associated with corticosteroid injection. Foot Ankle Int 1994; 15:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28775/abstract/29\">",
"      Spiegl PV, Johnson KA. Heel pain syndrome: Which treatments to choose? J Musculoskel Med 1984; 1:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28775/abstract/30\">",
"      Buchbinder R. Clinical practice. Plantar fasciitis. N Engl J Med 2004; 350:2159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28775/abstract/31\">",
"      Rompe JD, Decking J, Schoellner C, Nafe B. Shock wave application for chronic plantar fasciitis in running athletes. A prospective, randomized, placebo-controlled trial. Am J Sports Med 2003; 31:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28775/abstract/32\">",
"      Micke O, Seegenschmiedt MH, German Cooperative Group on Radiotherapy for Benign Diseases. Radiotherapy in painful heel spurs (plantar fasciitis)--results of a national patterns of care study. Int J Radiat Oncol Biol Phys 2004; 58:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28775/abstract/33\">",
"      Katoh Y, Chao EY, Morrey BF, Laughman RK. Objective technique for evaluating painful heel syndrome and its treatment. Foot Ankle 1983; 3:227.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6522 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-5849588C53-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_6_28775=[""].join("\n");
var outline_f28_6_28775=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15676189\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CAUSES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CALCANEAL APOPHYSITIS (SEVER DISEASE)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PLANTAR FASCIITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PAINFUL HEEL PAD SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8591725\">",
"      ACHILLES TENDINITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15676189\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6522\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6522|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?27/51/28478\" title=\"diagnostic image 1\">",
"      Heel spur",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6522|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/44/711\" title=\"figure 1\">",
"      Location foot ankle pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/7/19573\" title=\"figure 2\">",
"      Plantar anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/37/23121\" title=\"figure 3\">",
"      Planter fascia stretching exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/42/28326\" title=\"figure 4\">",
"      Achilles tendon anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6522|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/12/21696\" title=\"picture 1\">",
"      Palpating the plantar fascia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/0/25615\" title=\"picture 2\">",
"      Toe towel curls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/12/17603\" title=\"picture 3\">",
"      Low Dye foot taping",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6522|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/58/7084\" title=\"table 1\">",
"      Stepwise Rx plantar fasciitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/20/31050?source=related_link\">",
"      Clinical features and management of ankle pain in the young athlete",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23190?source=related_link\">",
"      Clinical features and management of foot pain in the young athlete",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37769?source=related_link\">",
"      Clinical presentation, staging, and prognostic factors of the Ewing sarcoma family of tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33289?source=related_link\">",
"      Evaluation and diagnosis of hematogenous osteomyelitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14711?source=related_link\">",
"      Evaluation of foot and ankle pain in the young athlete",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24522?source=related_link\">",
"      Overview of benign bone tumors in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/31/24056?source=related_link\">",
"      Pauciarticular onset juvenile idiopathic arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44681?source=related_link\">",
"      Plantar fasciitis and other causes of heel pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8696?source=related_link\">",
"      Spondyloarthropathy in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_6_28776="Infliximab: Drug information";
var content_f28_6_28776=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Infliximab: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?2/23/2422?source=see_link\">",
"    see \"Infliximab: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/51/21303?source=see_link\">",
"    see \"Infliximab: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F182756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Remicade&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F182757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Remicade&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F182785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antirheumatic, Disease Modifying;",
"     </li>",
"     <li>",
"      Gastrointestinal Agent, Miscellaneous;",
"     </li>",
"     <li>",
"      Immunosuppressant Agent;",
"     </li>",
"     <li>",
"      Monoclonal Antibody;",
"     </li>",
"     <li>",
"      Tumor Necrosis Factor (TNF) Blocking Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F182760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Premedication with antihistamines (H",
"     <sub>",
"      1",
"     </sub>",
"     -antagonist +/- H",
"     <sub>",
"      2",
"     </sub>",
"     -antagonist), acetaminophen, and/or corticosteroids may be considered to prevent and/or manage infusion-related reactions:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Crohn's disease:",
"     </b>",
"     I.V.: 5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter; dose may be increased to 10 mg/kg in patients who respond but then lose their response. If no response by week 14, consider discontinuing therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Psoriatic arthritis (with or without methotrexate):",
"     </b>",
"     I.V.: 5 mg/kg at 0,2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Rheumatoid arthritis (in combination with methotrexate therapy):",
"     </b>",
"     I.V. 3 mg/kg at 0, 2, and 6 weeks, followed by 3 mg/kg every 8 weeks thereafter; doses have ranged from 3-10 mg/kg repeated at 4- to 8-week intervals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ankylosing spondylitis:",
"     </b>",
"     I.V.: 5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 6 weeks thereafter (Canadian labeling recommends every 6-8 weeks thereafter)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Plaque psoriasis:",
"     </b>",
"     I.V.: 5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ulcerative colitis:",
"     </b>",
"     I.V.: 5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment with heart failure (HF):",
"     </b>",
"     Weigh risk versus benefits for individual patient:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Moderate-to-severe (NYHA Class III or IV):",
"     </i>",
"     &le;5 mg/kg",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F182775\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/51/21303?source=see_link\">",
"      see \"Infliximab: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Premedication with antihistamines (H",
"     <sub>",
"      1",
"     </sub>",
"     -antagonist +/- H",
"     <sub>",
"      2",
"     </sub>",
"     -antagonist), acetaminophen, and/or corticosteroids may be considered to prevent and/or manage infusion-related reactions:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Crohn&rsquo;s disease:",
"     </b>",
"     I.V.: Children and Adolescents: U.S. labeling &ge;6 years, Canadian labeling &ge;9 years: 5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter; if no response by week 14, consider discontinuing therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ulcerative colitis:",
"     </b>",
"     I.V.: Children &ge;6 years and Adolescents: 5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F182761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F182762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F182763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F182738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Remicade&reg;: 100 mg [contains polysorbate 80, sucrose 500 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F182723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at file://www.remicade.com/remicade/assets/Med_Guide.pdf, must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F182740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The infusion should begin within 3 hours of reconstitution and dilution. Infuse over at least 2 hours; do not infuse with other agents; use in-line low protein binding filter (&le;1.2 micron). Temporarily discontinue or decrease infusion rate with infusion-related reactions. Antihistamines (H",
"     <sub>",
"      1",
"     </sub>",
"     -antagonist +/- H",
"     <sub>",
"      2",
"     </sub>",
"     -antagonist), acetaminophen and/or corticosteroids may be used to manage reactions. Infusion may be reinitiated at a lower rate upon resolution of mild-to-moderate symptoms.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling (not approved in U.S. labeling): Infusion of doses &le;6 mg/kg over not less than 1 hour may be considered in patients treated for rheumatoid arthritis who have initially tolerated 3 infusions each over 2 hours. Safety of shortened infusion has not been studied with doses &gt;6 mg/kg.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Guidelines for the treatment and prophylaxis of infusion reactions:",
"     </b>",
"     (",
"     <b>",
"      Note:",
"     </b>",
"     Limited to adult patients and dosages used in Crohn's; prospective data for other populations [pediatrics, other indications/dosing] are not available).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;margin-top:2em;\">",
"     A protocol for the treatment of infusion reactions, as well as prophylactic therapy for repeat infusions, has been published (Mayer, 2006).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;margin-top:2em;\">",
"     <i>",
"      Treatment of infusion reactions:",
"     </i>",
"     Medications for the treatment of hypersensitivity reactions should be available for immediate use. For mild reactions, the rate of infusion should be decreased to 10 mL/hour. Initiate a normal saline infusion (500-1000 mL/hour) and appropriate symptomatic treatment (eg, acetaminophen and diphenhydramine); monitor vital signs every 10 minutes until normal. After 20 minutes, the infusion may be increased at 15-minute intervals, as tolerated, to completion  (initial increase to 20 mL/hour, then 40 mL/hour, then 80 mL/hour, etc [maximum of 125 mL/hour]). For moderate reactions, the infusion should be stopped or slowed. Initiate a normal saline infusion (500-1000 mL/hour) and appropriate symptomatic treatment. Monitor vital signs every 5 minutes until normal. After 20 minutes, the infusion may be reinstituted at 10 mL/hour; then increased at 15-minute intervals, as tolerated, to completion  (initial increase 20 mL/hour, then 40 mL/hour, then 80 mL/hour, etc [maximum of 125 mL/hour]). For severe reactions, the infusion should be stopped with administration of appropriate symptomatic treatment (eg, hydrocortisone/methylprednisolone, diphenhydramine and epinephrine) and frequent monitoring of vitals (consult institutional policies, if available). Retreatment after a severe reaction should only be done if the benefits outweigh the risks and with appropriate prophylaxis. Delayed infusion reactions typically occur 1-7 days after an infusion. Treatment should consist of appropriate symptomatic treatment (eg. acetaminophen, antihistamine, methylprednisolone).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;margin-top:2em;\">",
"     <i>",
"      Prophylaxis of infusion reactions:",
"     </i>",
"     Premedication with acetaminophen and diphenhydramine 90 minutes prior to infusion may be considered in all patients with prior infusion reactions, and in patients with severe reactions corticosteroid administration is recommended. Steroid dosing may be oral (prednisone 50 mg orally every 12 hours for 3 doses prior to infusion) or intravenous (a single dose of hydrocortisone 100 mg or methylprednisolone 20-40 mg administered 20 minutes prior to the infusion). On initiation of the infusion, begin with a test dose at 10 mL/hour for 15 minutes. Thereafter, the infusion may be increased at 15-minute intervals, as tolerated, to completion (initial increase 20 mL/hour, then 40 mL/hour, then 80 mL/hour, etc). A maximum rate of 125 mL/hour is recommended in patients who experienced prior mild-moderate reactions and 100 mL/hour is recommended in patients who experienced prior severe reactions. In patients with cutaneous flushing, aspirin may be considered (Becker, 2004). For delayed infusion reactions, premedicate with acetaminophen and diphenhydramine 90 minutes prior to infusion. On initiation of the infusion, begin with a test dose at 10 mL/hour for 15 minutes. Thereafter, the infusion may be increased to infuse over 3 hours. Postinfusion therapy with acetaminophen for 3 days and an antihistamine for 7 days is recommended.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F182791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS; do not infuse with other agents.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F182739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Treatment of moderately- to severely-active rheumatoid arthritis (with methotrexate) (to reduce signs/symptoms of active arthritis and inhibit progression of structural damage and improve physical function)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Treatment of moderately- to severely-active Crohn's disease with inadequate response to conventional therapy (to reduce signs/symptoms and induce and maintain clinical remission) or to reduce the number of draining enterocutaneous and rectovaginal fistulas and maintain fistula closure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Treatment of psoriatic arthritis (to reduce signs/symptoms of active arthritis and inhibit progression of structural damage and improve physical function)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Treatment of chronic severe (extensive and/or disabling) plaque psoriasis as an alternative to other systemic therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Treatment of active ankylosing spondylitis (to reduce signs/symptoms)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Treatment of moderately- to severely-active ulcerative colitis with inadequate response to conventional therapy (to reduce signs/symptoms and induce and maintain clinical remission, mucosal healing and eliminate corticosteroid use)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F182793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       InFLIXimab may be confused with riTUXimab",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Remicade&reg; may be confused with Renacidin&reg;, Rituxan&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F182783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Although profile is similar, frequency of adverse effects may vary with disease state. Except where noted, percentages reported in adults with rheumatoid arthritis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (21%), diarrhea (12%), abdominal pain (12%, Crohn&rsquo;s 26%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: ALT increased (risk increased with concomitant methotrexate)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory tract infection (32%), sinusitis (14%), cough (12%), pharyngitis (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Development of antinuclear antibodies (~50%), infection (36%), infusion reactions (20%; severe &lt;1%), development of antibodies to double-stranded DNA (20%), development of new abscess (Crohn's patients with fistulizing disease: 15%), anti-infliximab antibodies (variable; ~10% to 15% [range: 6% to 61%]; Mayer, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     5% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypertension (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (9%), pain (8%), fever (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (1% to 10%), pruritus (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Dyspepsia (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (1% to 8%), back pain (8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Bronchitis (10%), rhinitis (8%), dyspnea (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Moniliasis (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;5%: Abscess, adult respiratory distress syndrome, allergic reaction, anemia, arrhythmia, basal cell carcinoma, biliary pain, bradycardia, brain infarction, breast cancer, cardiac arrest, cellulitis, cholecystitis, cholelithiasis, circulatory failure, confusion, constipation, dehydration, delayed hypersensitivity (plaque psoriasis), diaphoresis increased, dizziness, edema, gastrointestinal hemorrhage, heart failure, hemolytic anemia, hepatitis, hypersensitivity reactions, hypotension, ileus, intervertebral disk herniation, intestinal obstruction, intestinal perforation, intestinal stenosis, leukopenia, lupus-like syndrome, lymphadenopathy, lymphoma, malignancies, meningitis, menstrual irregularity, MI, myalgia, neuritis, pancreatitis, pancytopenia, peripheral neuropathy, peritonitis, pleural effusion, pleurisy, proctalgia, pulmonary edema, pulmonary embolism, renal calculus, renal failure, respiratory insufficiency, sarcoidosis, seizure, sepsis, serum sickness, suicide attempt, syncope, tachycardia, tendon disorder, thrombocytopenia, thrombophlebitis (deep), ulceration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      The following adverse events were reported in children with Crohn&rsquo;s disease and were found more frequently in children than adults:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Liver enzymes increased (18%; &ge;5 times ULN: 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infections (56%; more common with every 8-week versus every 12-week infusions)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Flushing (9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Blood in stool (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Leukopenia (9%), neutropenia (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Bone fracture (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Respiratory tract allergic reaction (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Viral infection (8%), bacterial infection (6%), antibodies to infliximab (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Postmarketing and/or case reports (adults or children):",
"     </b>",
"     Agranulocytosis, anaphylactic reactions, anaphylactic shock, angina, angioedema, autoimmune hepatitis, bronchospasm, central demyelinating disorders (eg, multiple sclerosis, optic neuritis); cholestasis, drug-induced lupus-like syndrome, erythema multiforme, heart failure (worsening), hepatic carcinoma, hepatitis B reactivation, hepatocellular damage, hepatosplenic T-cell lymphoma (HSTCL), Hodgkin&rsquo;s disease, idiopathic thrombocytopenia purpura, interstitial fibrosis, interstitial pneumonitis, jaundice, laryngeal/pharyngeal edema, latent tuberculosis reactivation, leiomyosarcoma, leukemias, liver failure, liver function tests increased, melanoma, neuropathy, numbness, opportunistic infection, pericardial effusion, peripheral demyelinating disorders (eg, Guillain-Barr&eacute; syndrome, chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy); pneumonia, psoriasis (including new onset, palmoplantar, pustular, or exacerbation), renal cell carcinoma, seizure, Stevens-Johnson syndrome, thrombotic thrombocytopenia purpura, taste abnormal, tingling, toxic epidermal necrolysis, transverse myelitis, tuberculosis, urticaria, vasculitis (systemic and cutaneous)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F182743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to infliximab, murine proteins or any component of the formulation; doses &gt;5 mg/kg in patients with moderate or severe heart failure (NYHA Class III/IV)",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Severe infections (eg, sepsis, abscesses, tuberculosis, and opportunistic infections)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F182727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Autoimmune disorder: Positive antinuclear antibody titers have been detected in patients (with negative baselines). Rare cases of autoimmune disorder, including lupus-like syndrome, have been reported; monitor and discontinue if symptoms develop.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic disorders: Hematologic toxicities (eg, leukopenia, neutropenia, thrombocytopenia, pancytopenia) have been reported. Patients must be advised to seek medical attention if they develop signs and symptoms suggestive of blood dyscrasias; discontinue if significant hematologic abnormalities are confirmed. Use with caution in patients with history of hematologic abnormalities.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic reactions: Severe hepatic reactions (including hepatitis, jaundice, acute hepatic failure, and cholestasis) have been reported during treatment; discontinue with jaundice or marked increase in liver enzymes (&ge;5 times ULN).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatitis B: Rare reactivation of hepatitis B virus (HBV) has occurred in chronic carriers of the virus, usually in patients receiving concomitant immunosuppressants; evaluate for HBV prior to initiation in all patients.  Monitor during and for several months following discontinuation of treatment in HBV carriers; interrupt therapy if reactivation occurs and treat appropriately with antiviral therapy; if resumption of therapy is deemed necessary, exercise caution and monitor patient closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity or infusion reactions: Acute infusion reactions may occur. Hypersensitivity reaction may occur within 2 hours of infusion. Medication and equipment for management of hypersensitivity reaction should be available for immediate use. Interruptions and/or reinstitution at a slower rate may be required (consult protocols). Pretreatment may be considered, and may be warranted in all patients with prior infusion reactions. Serum sickness-like reactions have occurred; may be associated with a decreased response to treatment. The development of antibodies to infliximab may increase the risk of hypersensitivity and/or infusion reactions; concomitant use of immunosuppressants may lessen the development of anti-infliximab antibodies. The risk of infusion reactions may be increased with retreatment after an interruption or discontinuation of prior maintenance therapy. Retreatment in psoriasis patients should be resumed as a scheduled maintenance regimen without any induction doses; use of an induction regimen should be used cautiously for retreatment of all other patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infections:",
"     <b>",
"      [U.S. Boxed Warning]: Patients receiving infliximab are at increased risk for serious infections which may result in hospitalization and/or fatality; infections usually developed in patients receiving concomitant immunosuppressive agents (eg, methotrexate or corticosteroids) and may present as disseminated (rather than local) disease. Active tuberculosis (or reactivation of latent tuberculosis), invasive fungal (including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, and pneumocystosis) and bacterial, viral or other opportunistic infections (including legionellosis and listeriosis) have been reported in patients receiving TNF-blocking agents, including infliximab. Monitor closely for signs/symptoms of infection. Discontinue for serious infection or sepsis. Consider risks versus benefits prior to use in patients with a history of chronic or recurrent infection. Consider empiric antifungal therapy in patients who are at risk for invasive fungal infection and develop severe systemic illness.",
"     </b>",
"     Caution should be exercised when considering use in the elderly or in patients with conditions that predispose them to infections (eg, diabetes) or residence/travel from areas of endemic mycoses (blastomycosis, coccidioidomycosis, histoplasmosis), or with latent or localized infections. Do not initiate infliximab therapy with an active infection, including clinically important localized infection. Patients who develop a new infection while undergoing treatment should be monitored closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Malignancy:",
"     <b>",
"      [U.S. Boxed Warning]: Lymphoma and other malignancies have been reported in children and adolescent patients receiving TNF-blocking agents including infliximab.",
"     </b>",
"     Half the cases are lymphomas (Hodgkin&rsquo;s and non-Hodgkin&rsquo;s) and the other cases are varied but include malignancies not typically observed in this population.",
"     <b>",
"      [U.S. Boxed Warning]: Hepatosplenic T-cell lymphoma has been reported in patients with Crohn&rsquo;s disease or ulcerative colitis treated with infliximab and concurrent or prior azathioprine or mercaptopurine use, usually reported in adolescent and young adult males.",
"     </b>",
"     The impact of infliximab on the development and course of malignancies is not fully defined, but may be dose dependent. As compared to the general population, an increased risk of lymphoma has been noted in clinical trials; however, rheumatoid arthritis alone has been previously associated with an increased rate of lymphoma. Use caution in patients with a history of COPD, higher rates of malignancy were reported in COPD patients treated with infliximab. Psoriasis patients with a history of phototherapy had a higher incidence of nonmelanoma skin cancers.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tuberculosis:",
"     <b>",
"      [U.S. Boxed Warning]: Infliximab treatment has been associated with active tuberculosis (may be disseminated or extrapulmonary) or reactivation of latent infections. Evaluate patients for tuberculosis risk factors and latent tuberculosis infection (with a tuberculin skin test) prior to and during therapy. Treatment of latent tuberculosis should be initiated before use. Patients with initial negative tuberculin skin tests should receive continued monitoring for tuberculosis throughout treatment.",
"     </b>",
"     Most cases of reactivation have been reported within the first 3-6 months of treatment. Caution should be exercised when considering the use in patients who have been exposed to tuberculosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Demyelinating CNS disease: Use with caution in patients with pre-existing or recent onset CNS demyelinating disorders; rare cases of optic neuritis and demyelinating disease (including multiple sclerosis, systemic vasculitis, and Guillain-Barr&eacute; syndrome) have been reported; consider discontinuation of therapy if patient develops significant CNS reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure (HF): Use with caution in patients with mild HF (NYHA Class I, II) or decreased left ventricular function; worsening and new-onset HF has been reported; doses &gt;5 mg/kg should not be administered in patients with moderate-to-severe heart failure (NYHA Class III/IV); discontinue therapy with onset of new or worsening symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorders: Use with caution in patients with a history of seizures; discontinue if significant CNS adverse reactions develop.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abatacept: Serious infections were reported when abatacept was used with other TNF-blocking agents; therefore, concurrent use of infliximab and abatacept is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anakinra: Serious infections were reported when anakinra was used with another TNF-blocking agent (etanercept); therefore, concurrent use of infliximab and anakinra is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Biological disease-modifying antirheumatic drugs (DMARDs): Use caution when switching from one biologic DMARD to another; overlapping biological activities may further increase the risk of infection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Malignancies have been reported among children and adolescents receiving TNF-blocking agents. Efficacy was not established in a study to evaluate infliximab use in juvenile idiopathic arthritis (JIA). Safety and efficacy for use in plaque psoriasis or ulcerative colitis have not been established in children.",
"     <b>",
"      Note:",
"     </b>",
"     For use in Crohn&rsquo;s disease: Safety and efficacy have not been established in children &lt;6 years of age (U.S. labeling) and in children &lt;9 years of age (Canadian labeling).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunizations: Patients should be brought up to date with all immunizations before initiating therapy. Live vaccines should not be given concurrently; there is no data available concerning secondary transmission of live vaccines in patients receiving therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F182732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abatacept: Anti-TNF Agents may enhance the adverse/toxic effect of Abatacept. An increased risk of serious infection during concomitant use has been reported.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abciximab: May enhance the potential for allergic or hypersensitivity reactions to Monoclonal Antibodies. Also may cause thrombocytopenia or diminished therapeutic effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anakinra: Anti-TNF Agents may enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canakinumab: Anti-TNF Agents may enhance the adverse/toxic effect of Canakinumab. Specifically, the risk for serious infections and/or neutropenia may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Certolizumab Pegol: Anti-TNF Agents may enhance the immunosuppressive effect of Certolizumab Pegol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilonacept: Anti-TNF Agents may enhance the adverse/toxic effect of Rilonacept.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May enhance the immunosuppressive effect of Anti-TNF Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Anti-TNF Agents may enhance the adverse/toxic effect of Tofacitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F2984405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Herb/Nutraceutical: Avoid echinacea (may diminish the therapeutic effect of infliximab).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F182734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F182745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Infliximab crosses the placenta and can be detected in the serum of infants for up to 6 months following",
"     <i>",
"      in utero",
"     </i>",
"     exposure. The safety of administering live or live-attenuated vaccines to exposed infants is not known.  A Rheumatoid Arthritis and Pregnancy Registry has been established for women exposed to infliximab during pregnancy (Organization of Teratology Information Services, 877-311-8972).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F182766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F182746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known whether infliximab is secreted in human milk. Because many immunoglobulins are secreted in milk and the potential for serious adverse reactions exists, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F4370699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Remicade Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (1): $974.27",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F182736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor improvement of symptoms and physical function assessments.  During infusion, if reaction is noted, monitor vital signs every 2-10 minutes, depending on reaction severity, until normal. Latent TB screening prior to initiating and during therapy; signs/symptoms of infection (prior to, during, and following therapy); CBC with differential; signs/symptoms/worsening of heart failure; HBV screening prior to initiating (all patients), HBV carriers (during and for several months following therapy); signs and symptoms of hypersensitivity reaction; symptoms of lupus-like syndrome; LFTs (discontinue if &gt;5 times ULN); signs and symptoms of malignancy (eg, splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Psoriasis patients with history of phototherapy should be monitored for nonmelanoma skin cancer.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F182747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Remicade (AR, AT, AU, BE, BG, BR, CH, CL, CN, CO, CR, CZ, DE, DK, DO, EC, EE, ES, FI, FR, GB, GR, HK, HN, ID, IE, IL, IT, KP, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PT, RU, SE, SG, SK, SV, TH, TR, UY, VE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F182726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Infliximab is a chimeric monoclonal antibody that binds to human tumor necrosis factor alpha (TNF&alpha;), thereby interfering with endogenous TNF&alpha; activity. Elevated TNF&alpha; levels have been found in involved tissues/fluids of patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, Crohn&rsquo;s disease and ulcerative colitis. Biological activities of TNF&alpha; include the induction of proinflammatory cytokines (interleukins), enhancement of leukocyte migration, activation of neutrophils and eosinophils, and the induction of acute phase reactants and tissue degrading enzymes. Animal models have shown TNF&alpha; expression causes polyarthritis, and infliximab can prevent disease as well as allow diseased joints to heal.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F182742\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Crohn's disease: ~2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 3-6 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 7-12 days",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Antoni CE, Kavanaugh A, Kirkham B, et al, &ldquo;Sustained Benefits of Infliximab Therapy for Dermatologic and Articular Manifestations of Psoriatic Arthritis: Results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT),&rdquo;",
"      <i>",
"       Arthritis Rheum",
"      </i>",
"      , 2005, 52(4):1227-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/6/28776/abstract-text/15818699/pubmed\" id=\"15818699\" target=\"_blank\">",
"        15818699",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Becker M, Rose CD, and McIlvain-Simpson G, &ldquo;Niacin-Like Reaction to Infliximab Infusion in Systemic Juvenile Rheumatoid Arthritis,&rdquo;",
"      <i>",
"       J Rheumatol",
"      </i>",
"      , 2004, 31(12):2529-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/6/28776/abstract-text/15570667/pubmed\" id=\"15570667\" target=\"_blank\">",
"        15570667",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bongartz T, Sutton AJ, Sweeting MJ, et al, &ldquo;Anti-TNF Antibody Therapy In Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies: Systematic Review and Meta-Analysis of Rare Harmful Effects in Randomized Controlled Trials,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2006, 295(19):2275-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/6/28776/abstract-text/16705109/pubmed\" id=\"16705109\" target=\"_blank\">",
"        16705109",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Buch MH, Bryer D, Lindsay S, et al, &ldquo;Shortening Infusion Times for Infliximab Administration,&rdquo;",
"      <i>",
"       Rheumatology (Oxford)",
"      </i>",
"      , 2006, 45(4):485-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/6/28776/abstract-text/16352636/pubmed\" id=\"16352636\" target=\"_blank\">",
"        16352636",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Carpenter PA and Sanders JE, &ldquo;Steroid-Refractory Graft-vs-Host Disease: Past, Present and Future,&rdquo;",
"      <i>",
"       Pediatr Transplant.",
"      </i>",
"      2003, 7(Suppl 3):19-31.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control, &ldquo;Testing and Treatment of Latent Tuberculosis Infection,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2000, 49(RR-6).",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chung ES, Packer M, Lo KH, et al, &ldquo;Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-Alpha, in Patients with Moderate-to-Severe Heart Failure: Results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) Trial,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2003, 107(25):3133-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/6/28776/abstract-text/12796126/pubmed\" id=\"12796126\" target=\"_blank\">",
"        12796126",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Couriel D, Saliba R, Hicks K, et al, &ldquo;Tumor Necrosis Factor-Alpha Blockade for the Treatment of Acute GVHD,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2004, 104(3):649-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/6/28776/abstract-text/15069017/pubmed\" id=\"15069017\" target=\"_blank\">",
"        15069017",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Diagnostic Standards and Classification of Tuberculosis in Adults and Children. Official Statement of the American Thoracic Society and the Centers for Disease Control and Prevention,&rdquo;",
"      <i>",
"       Am J Respir Crit Care Med",
"      </i>",
"      , 2000, 161:1376-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/6/28776/abstract-text/10764337/pubmed\" id=\"10764337\" target=\"_blank\">",
"        10764337",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dommasch E and Gelfand JM, &ldquo;Is There Truly a Risk of Lymphoma From Biologic Therapies?&rdquo;",
"      <i>",
"       Dermatol Ther",
"      </i>",
"      , 2009, 22 (5):418-30.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gerloni V, Pontikaki I, Gattinara M, et al, &ldquo;Efficacy of Repeated Intravenous Infusions of an Anti-Tumor Necrosis Factor Alpha Monoclonal Antibody, Infliximab, in Persistently Active, Refractory Juvenile Idiopathic Arthritis,&rdquo;",
"      <i>",
"       Arthritis Rheum",
"      </i>",
"      , 2005, 52(2):548-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/6/28776/abstract-text/15693004/pubmed\" id=\"15693004\" target=\"_blank\">",
"        15693004",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Klotz U, Teml A, and Schwab M, &ldquo;Clinical Pharmacokinetics and Use of Infliximab,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 2007, 45(8):645-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/6/28776/abstract-text/17655372/pubmed\" id=\"17655372\" target=\"_blank\">",
"        17655372",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kornbluth A and Sachar DB, &ldquo;Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2010, 105(3):501-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/6/28776/abstract-text/20068560/pubmed\" id=\"20068560\" target=\"_blank\">",
"        20068560",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lichtenstein GR, Hanauer SB, and Sandborn WJ, &ldquo;Management of Crohn's Disease in Adults,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2009, 104(2):465-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/6/28776/abstract-text/19174807/pubmed\" id=\"19174807\" target=\"_blank\">",
"        19174807",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lopez-Oilvo MA, Tayar JH, Martinez-Lopez JA, et al, &ldquo;Risk of Malignancies in Patients With Rheumatoid Arthritis Treated With Biologic Therapy: A Meta-Analysis,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2012, 308(9): 898-908.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/6/28776/abstract-text/22948700/pubmed\" id=\"22948700\" target=\"_blank\">",
"        22948700",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mayer L and Young Y, &ldquo;Infusion Reactions and Their Management,&rdquo;",
"      <i>",
"       Gastroenterol Clin North Am",
"      </i>",
"      , 2006, 35(4):857-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/6/28776/abstract-text/17129817/pubmed\" id=\"17129817\" target=\"_blank\">",
"        17129817",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Parakkal D, Sifuentes H, Semer R, et al, &ldquo;Hepatosplenic T-Cell Lymphoma in Patients Receiving TNF-&alpha; Inhibitor Therapy: Expanding the Groups at Risk,&rdquo;",
"      <i>",
"       Eur J Gastroenterol Hepatol",
"      </i>",
"      , 2011, 23(12):1150-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/6/28776/abstract-text/21941193/pubmed\" id=\"21941193\" target=\"_blank\">",
"        21941193",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ruperto N, Lovell DJ, Cuttica R, et al, &ldquo;A Randomized, Placebo-Controlled Trial of Infliximab Plus Methotrexate for the Treatment of Polyarticular-Course Juvenile Rheumatoid Arthritis,&rdquo;",
"      <i>",
"       Arthritis Rheum",
"      </i>",
"      , 2007, 56(9):3096-106.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/6/28776/abstract-text/17763439/pubmed\" id=\"17763439\" target=\"_blank\">",
"        17763439",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shergy WJ, Isern RA, Cooley DA, et al, &ldquo;Open Label Study to Assess Infliximab Safety and Timing of Onset of Clinical Benefit among Patients With Rheumatoid Arthritis,&rdquo;",
"      <i>",
"       J Rheumatol",
"      </i>",
"      , 2002, 29(4):667-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/6/28776/abstract-text/11950005/pubmed\" id=\"11950005\" target=\"_blank\">",
"        11950005",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Singh JA, Furst DE, Bharat A, et al, &ldquo;2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis,&rdquo;",
"      <i>",
"       Arthritis Care Res (Hoboken)",
"      </i>",
"      , 2012, 64(5):625-39.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/6/28776/abstract-text/22473917/pubmed\" id=\"22473917\" target=\"_blank\">",
"        22473917",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thayu M, Markowitz JE, Mamula P, et al, &ldquo;Hepatosplenic T-Cell Lymphoma in an Adolescent Patient After Immunomodulator and Biologic Therapy for Crohn Disease,&rdquo;",
"      <i>",
"       J Pediatr Gastroenterol Nutr",
"      </i>",
"      , 2005, 40(2):220-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/6/28776/abstract-text/15699701/pubmed\" id=\"15699701\" target=\"_blank\">",
"        15699701",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Van Vollenhoven RF, Gullstrom E, and Klareskog L, &ldquo;Feasibility of 1 Hour Infliximab Infusions,&rdquo;",
"      <i>",
"       Ann Rheum Dis",
"      </i>",
"      , 2005, 64(4):654.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/6/28776/abstract-text/15769930/pubmed\" id=\"15769930\" target=\"_blank\">",
"        15769930",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8984 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-EBC78AF0D7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_6_28776=[""].join("\n");
var outline_f28_6_28776=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708921\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182756\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182757\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182785\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182760\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182775\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182761\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182762\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182763\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182738\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182723\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874621\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182740\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182791\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182739\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182793\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182783\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182743\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182727\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299517\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182732\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984405\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182734\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182745\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182766\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182746\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4370699\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182736\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182747\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182726\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182742\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8984\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8984|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/23/2422?source=related_link\">",
"      Infliximab: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/51/21303?source=related_link\">",
"      Infliximab: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_6_28777="Clostridium difficile infection in children: Approach to diagnosis";
var content_f28_6_28777=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clostridium difficile infection in children: Approach to diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/6/28777/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/6/28777/contributors\">",
"     Michael S Cooperstock, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/6/28777/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/6/28777/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/6/28777/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/6/28777/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/6/28777/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to diagnosis of",
"    <em>",
"     Clostridium difficile",
"    </em>",
"    infection in children will be discussed here. The microbiology, pathogenesis, epidemiology, clinical features, treatment, and prevention are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/22/16745?source=see_link\">",
"     \"Clostridium difficile infection in children: Microbiology, pathogenesis, and epidemiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/16/11528?source=see_link\">",
"     \"Clostridium difficile infection in children: Clinical features\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/5/14426?source=see_link\">",
"     \"Clostridium difficile infection in children: Treatment and prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <em>",
"     C. difficile",
"    </em>",
"    infection in adults also is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36137?source=see_link\">",
"     \"Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=see_link\">",
"     \"Clostridium difficile in adults: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/29/20954?source=see_link\">",
"     \"Clostridium difficile in adults: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW OF APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of",
"    <em>",
"     C. difficile",
"    </em>",
"    infection should include the presence of symptoms, typically diarrhea that is severe, prolonged, or unexplained by other causes, to distinguish colonization from infection, and either [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A stool test positive for",
"      <em>",
"       C. difficile",
"      </em>",
"      toxins or toxigenic",
"      <em>",
"       C. difficile",
"      </em>",
"      , or",
"     </li>",
"     <li>",
"      Endoscopic gross and histologic findings of pseudomembranous colitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinical decisions in children are sometimes problematic, given current gaps in knowledge about the spectrum of childhood disease caused by",
"    <em>",
"     C. difficile",
"    </em>",
"    and about the most appropriate diagnostic tests [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/7\">",
"     7",
"    </a>",
"    ]. &nbsp;The approach outlined below is largely consistent with that of the American Academy of Pediatrics [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/1,6\">",
"     1,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INITIAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation of diarrhea in children, including indications for laboratory testing and radiologic imaging, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/13/13529?source=see_link\">",
"     \"Evaluation of diarrhea in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is important to emphasize that",
"    <em>",
"     C. difficile",
"    </em>",
"    can be an incidental finding, particularly in infants and younger children. Thus, in virtually every case, even if",
"    <em>",
"     C. difficile",
"    </em>",
"    is identified, other causes of diarrhea in children should also be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/13/13529?source=see_link\">",
"     \"Evaluation of diarrhea in children\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H25\">",
"     'Differential diagnosis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/16/11528?source=see_link\">",
"     \"Clostridium difficile infection in children: Clinical features\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Low suspicion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because positive tests for",
"    <em>",
"     C. difficile",
"    </em>",
"    may be misleading in children, it is important to limit testing for, and antimicrobial treatment of,",
"    <em>",
"     C. difficile",
"    </em>",
"    infections to children with a probability of clinically meaningful disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/7\">",
"     7",
"    </a>",
"    ]. Testing of children younger than one to two years of age should generally be avoided, given the high rate of asymptomatic carriage in this age group and the relative rarity of severe",
"    <em>",
"     C. difficile",
"    </em>",
"    disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/5\">",
"     5",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/16/11528?source=see_link\">",
"     \"Clostridium difficile infection in children: Clinical features\"",
"    </a>",
"    ). Further, the probability of clinically important",
"    <em>",
"     C. difficile",
"    </em>",
"    disease is low in children two to five years of age; in most children with a brief history of community-acquired diarrhea, including antibiotic-associated diarrhea; in children with little or no fever and relatively mild illness; and when clinical features associated with higher suspicion of",
"    <em>",
"     C. difficile",
"    </em>",
"    infection, described below, are absent. Even in young children hospitalized with",
"    <em>",
"     C. difficile",
"    </em>",
"    -positive diarrhea, other causes are more likely and should be considered first [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/13/13529?source=see_link\">",
"     \"Evaluation of diarrhea in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     High suspicion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are no established standards, each of the clinical and laboratory features described below adds to the probability of",
"    <em>",
"     C. difficile",
"    </em>",
"    disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/1,4,9,10\">",
"     1,4,9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Historical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historical features that increase the probability of",
"    <em>",
"     C. difficile",
"    </em>",
"    disease include [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/1,4,9,10\">",
"     1,4,9,10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Frequent diarrhea (&gt;3",
"      <span class=\"nowrap\">",
"       stools/day)",
"      </span>",
"     </li>",
"     <li>",
"      Age greater than two years, and particularly age &gt;5 years",
"     </li>",
"     <li>",
"      Persistence of symptoms (five or more days)",
"     </li>",
"     <li>",
"      Gross blood in stools",
"     </li>",
"     <li>",
"      Antibiotic therapy, concurrently or ending within the previous 6 to 10 weeks",
"     </li>",
"     <li>",
"      Healthcare-related onset (ie, after 72 hours in hospital)",
"     </li>",
"     <li>",
"      Proton pump inhibitor therapy",
"     </li>",
"     <li>",
"      Feeding tube",
"     </li>",
"     <li>",
"      Little or no diarrhea &ndash; Severe",
"      <em>",
"       C. difficile",
"      </em>",
"      infection may at times occur with little or no diarrhea, particularly in patients with ileus or toxic megacolon. Such \"atypical\"",
"      <em>",
"       C. difficile",
"      </em>",
"      infection is usually severe and should be considered in patients with the following clinical constellations [",
"      <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Abdominal pain, fever, and elevated inflammatory markers, resembling \"acute abdomen\", particularly if bowel sounds are absent or there are findings of toxic megacolon",
"     </li>",
"     <li>",
"      Fever of unknown source without prominent intestinal symptoms",
"     </li>",
"     <li>",
"      Unexplained neutrophilia without prominent abdominal symptoms",
"     </li>",
"     <li>",
"      Cystic fibrosis with signs of inflammation and abdominal tenderness (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Cystic fibrosis'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination findings that increase the probability of",
"    <em>",
"     C. difficile",
"    </em>",
"    disease include [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/1,4,9,10\">",
"     1,4,9,10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Clinical toxicity (eg, loss of interest or activity)",
"     </li>",
"     <li>",
"      Moderate or high fever (102&deg;F [38.9&ordm;C] or higher)",
"     </li>",
"     <li>",
"      Abdominal distention",
"     </li>",
"     <li>",
"      Marked abdominal tenderness",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Ancillary tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory, radiographic, and endoscopic findings that increase the probability of",
"    <em>",
"     C. difficile",
"    </em>",
"    infection include [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/1,4,9,10\">",
"     1,4,9,10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Neutrophilia (&gt;10,000 white blood",
"      <span class=\"nowrap\">",
"       cells/microL)",
"      </span>",
"     </li>",
"     <li>",
"      Immature neutrophilia",
"      <span class=\"nowrap\">",
"       (&gt;500/microL)",
"      </span>",
"     </li>",
"     <li>",
"      Increased immature:total neutrophil ratio (&gt;0.15)",
"     </li>",
"     <li>",
"      Fecal leukocytes",
"     </li>",
"     <li>",
"      Fecal occult blood",
"     </li>",
"     <li>",
"      Elevated erythrocyte sedimentation rate or C-reactive protein",
"     </li>",
"     <li>",
"      Hypoalbuminemia",
"     </li>",
"     <li>",
"      Acidosis",
"     </li>",
"     <li>",
"      Radiographic evidence of intestinal inflammation (see",
"      <a class=\"local\" href=\"#H22\">",
"       'Imaging'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Ileus or toxic megacolon",
"     </li>",
"     <li>",
"      Pseudomembranous colitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Predisposing conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of certain predisposing conditions also should increase the index of suspicion for",
"    <em>",
"     C. difficile",
"    </em>",
"    disease (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/22/16745?source=see_link&amp;anchor=H16#H16\">",
"     \"Clostridium difficile infection in children: Microbiology, pathogenesis, and epidemiology\", section on 'Predisposing conditions'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Immune-compromised host",
"     </li>",
"     <li>",
"      Pre-existing structural or chronic inflammatory gastrointestinal disease",
"     </li>",
"     <li>",
"      Motility disorders (eg, infant botulism)",
"     </li>",
"     <li>",
"      Cystic fibrosis",
"     </li>",
"     <li>",
"      Hemolytic-uremic syndrome",
"     </li>",
"     <li>",
"      Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Immune deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of congenital and acquired immune deficiency states may predispose to",
"    <em>",
"     C. difficile",
"    </em>",
"    disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/22/16745?source=see_link&amp;anchor=H16#H16\">",
"     \"Clostridium difficile infection in children: Microbiology, pathogenesis, and epidemiology\", section on 'Predisposing conditions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     IBD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exacerbation of inflammatory bowel disease (IBD) in children is frequently associated with",
"    <em>",
"     C. difficile",
"    </em>",
"    infection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Early diagnosis and treatment may improve outcome. In adults with inflammatory bowel disease,",
"    <em>",
"     C. difficile",
"    </em>",
"    infection and relapses may be more severe and more frequent than in other clinical groups. Aggressive early diagnosis and treatment of",
"    <em>",
"     C. difficile",
"    </em>",
"    infection, including empiric treatment in selected cases, may avert colectomy and even death. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=see_link&amp;anchor=H13#H13\">",
"     \"Clostridium difficile in adults: Clinical manifestations and diagnosis\", section on 'Clostridium difficile and inflammatory bowel disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/34/20008?source=see_link&amp;anchor=H15#H15\">",
"     \"Antibiotics for treatment of inflammatory bowel diseases\", section on 'Clostridium difficile infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Hirschsprung disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether or not",
"    <em>",
"     C. difficile",
"    </em>",
"    contributes to Hirschsprung enterocolitis is not definitively known (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/22/16745?source=see_link&amp;anchor=H17#H17\">",
"     \"Clostridium difficile infection in children: Microbiology, pathogenesis, and epidemiology\", section on 'Occult underlying conditions'",
"    </a>",
"    ). However, given the mortality associated with Hirschsprung enterocolitis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/15,16\">",
"     15,16",
"    </a>",
"    ] and the likely administration of potentially aggravating antimicrobials, it is reasonable to evaluate children with moderate or severe Hirschsprung enterocolitis for",
"    <em>",
"     C. difficile",
"    </em>",
"    and to treat",
"    <em>",
"     C. difficile",
"    </em>",
"    if it is found. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41848?source=see_link&amp;anchor=H16#H16\">",
"     \"Congenital aganglionic megacolon (Hirschsprung disease)\", section on 'Enterocolitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/8/34950?source=see_link&amp;anchor=H5#H5\">",
"     \"Emergency complications of Hirschsprung disease\", section on 'Enterocolitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/5/14426?source=see_link&amp;anchor=H6#H6\">",
"     \"Clostridium difficile infection in children: Treatment and prevention\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Cystic fibrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although asymptomatic",
"    <em>",
"     C. difficile",
"    </em>",
"    colonization is common in patients with cystic fibrosis, serious",
"    <em>",
"     C. difficile",
"    </em>",
"    infection does occasionally occur.",
"    <em>",
"     C. difficile",
"    </em>",
"    should be considered in the differential diagnosis when a cystic fibrosis patient presents with acute abdominal complaints, particularly if there are signs of inflammation and if antibiotics have been administered in recent weeks.",
"   </p>",
"   <p>",
"    In patients with cystic fibrosis,",
"    <em>",
"     C. difficile",
"    </em>",
"    infection may be associated with either diarrhea or infrequent or absent stools, making the diagnosis problematic. In addition, abdominal radiographs may give a false appearance of fecal impaction suggestive of the more common acute distal intestinal obstruction syndrome, rather than",
"    <em>",
"     C. difficile",
"    </em>",
"    infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/15/19706?source=see_link&amp;anchor=H10#H10\">",
"     \"Cystic fibrosis: Overview of gastrointestinal disease\", section on 'Distal intestinal obstruction syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fever, marked abdominal tenderness, laboratory markers of inflammation (eg, neutrophilia; immature neutrophils; elevated erythrocyte sedimentation rate or C-reactive protein), or radiographic evidence of colon wall thickening (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52929 \" href=\"UTD.htm?32/51/33598\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52523 \" href=\"UTD.htm?25/62/26593\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73501 \" href=\"UTD.htm?6/46/6888\">",
"     image 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57812 \" href=\"UTD.htm?41/42/42656\">",
"     image 4",
"    </a>",
"    ) are suggestive of",
"    <em>",
"     C. difficile",
"    </em>",
"    infection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'High suspicion'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/16/11528?source=see_link\">",
"     \"Clostridium difficile infection in children: Clinical features\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early diagnosis is important in these patients because",
"    <em>",
"     C. difficile",
"    </em>",
"    infection may pursue a rapidly fulminating course. Mortality can be high, and colectomy may be required if bowel viability becomes compromised. Early empiric treatment for",
"    <em>",
"     C. difficile",
"    </em>",
"    infection is sometimes warranted in cystic fibrosis patients if delay is anticipated before diagnostic test results are available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/5/14426?source=see_link&amp;anchor=H6#H6\">",
"     \"Clostridium difficile infection in children: Treatment and prevention\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Intestinal disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     C. difficile",
"    </em>",
"    enteritis may occur at any time after colectomy or other intestinal surgery, including the immediate postoperative period [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. In patients with ileostomy, increased output and clinical evidence of inflammation should raise suspicion for",
"    <em>",
"     C. difficile",
"    </em>",
"    enteritis, which may be quite serious [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/21\">",
"     21",
"    </a>",
"    ]. Testing small bowel fluid for",
"    <em>",
"     C. difficile",
"    </em>",
"    in patients with enterostomy or during upper gastrointestinal endoscopy may be useful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Other conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other conditions reported to be associated with",
"    <em>",
"     C. difficile",
"    </em>",
"    infection include infant botulism, Henoch-Sch&ouml;nlein purpura (IgA vasculitis), and hemolytic-uremic syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/22/16745?source=see_link&amp;anchor=H16#H16\">",
"     \"Clostridium difficile infection in children: Microbiology, pathogenesis, and epidemiology\", section on 'Predisposing conditions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/36/37448?source=see_link\">",
"     \"Botulism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40729?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35704?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic evaluation for",
"    <em>",
"     C. difficile",
"    </em>",
"    infection should be pursued in the setting of clinically significant diarrhea and for diarrhea in children with predisposing conditions. The possibility of community-acquired",
"    <em>",
"     C. difficile",
"    </em>",
"    infection should be considered in children with severe diarrhea, even in the absence of prior antibiotics or other established risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/23\">",
"     23",
"    </a>",
"    ]. In children of preschool age or older,",
"    <em>",
"     C. difficile",
"    </em>",
"    should be determined only if there are definite risk factors, predisposing conditions, or signs of invasive illness (",
"    <a class=\"graphic graphic_table graphicRef71790 \" href=\"UTD.htm?35/35/36412\">",
"     table 1",
"    </a>",
"    ). Although there is no established standard, we suggest at least two or more of these indicators should lead to diagnostic testing for those older than five years, and that three or more should be present if the child is younger than five years. Simultaneous isolation of a plausible alternative enteric pathogen greatly reduces the likelihood that identified",
"    <em>",
"     C. difficile",
"    </em>",
"    toxin is meaningful. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'High suspicion'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Microbiologic, surgical, and autopsy specimens should be saved so that, if necessary, additional testing can be performed by reference laboratories with special expertise. This is particularly important if a cluster of two or more cases of",
"    <em>",
"     C. difficile",
"    </em>",
"    begins to emerge [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of",
"    <em>",
"     C. difficile",
"    </em>",
"    infection requires the presence of moderate to severe diarrhea or ileus, and either [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A stool test positive for",
"      <em>",
"       C. difficile",
"      </em>",
"      toxins or toxigenic",
"      <em>",
"       C. difficile",
"      </em>",
"      , or",
"     </li>",
"     <li>",
"      Endoscopic or histologic findings of pseudomembranous colitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Stool tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The laboratory diagnosis of",
"    <em>",
"     C. difficile",
"    </em>",
"    infection requires demonstration of",
"    <em>",
"     C. difficile",
"    </em>",
"    toxins or toxigenic",
"    <em>",
"     C. difficile",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/2\">",
"     2",
"    </a>",
"    ]. A number of tests are available, including [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/1,24\">",
"     1,24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Enzyme immunoassays for toxins A and B",
"     </li>",
"     <li>",
"      Cell culture cytotoxicity assay",
"     </li>",
"     <li>",
"      Selective anaerobic culture",
"     </li>",
"     <li>",
"      Polymerase chain reaction (PCR)",
"     </li>",
"     <li>",
"      Enzyme immunoassay for the",
"      <em>",
"       C. difficile",
"      </em>",
"      common antigen, glutamate dehydrogenase (GDH)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Only loose, watery, or semi-formed stool should ordinarily be tested for",
"    <em>",
"     C. difficile",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/24-28\">",
"     24-28",
"    </a>",
"    ]. An exception is made for patients with suspected",
"    <em>",
"     C. difficile",
"    </em>",
"    infection and ileus in whom it may be necessary to send a stool swab [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]; the laboratory should be notified, since testing stool swabs may not be a standard procedure.",
"   </p>",
"   <p>",
"    <em>",
"     C. difficile",
"    </em>",
"    toxin degrades at room temperature and may be undetectable within two hours after collection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/1\">",
"     1",
"    </a>",
"    ]. Stool specimens should be kept at 4&ordm;C if delay is anticipated.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      EIA &ndash; Fecal enzyme immunoassay (EIA) for toxins A and B is widely used for diagnosis of",
"      <em>",
"       C. difficile",
"      </em>",
"      . It is inexpensive, and results are available within hours [",
"      <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/24\">",
"       24",
"      </a>",
"      ]. However, the sensitivity of EIA is only about 75 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/24,29\">",
"       24,29",
"      </a>",
"      ]. A number of enzyme immunoassays for",
"      <em>",
"       C. difficile",
"      </em>",
"      toxin are commercially available. Most of these tests have not been validated specifically for use in young children [",
"      <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/7\">",
"       7",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      If the initial EIA test is negative, the value of additional EIA tests is uncertain. Three studies found fewer than 10 percent more cases by repeated testing [",
"      <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/30-32\">",
"       30-32",
"      </a>",
"      ], while two others found 19 percent and 20 percent more cases with one or two further tests [",
"      <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/33,34\">",
"       33,34",
"      </a>",
"      ]. The 2010 guidelines for adults discourage repeated testing [",
"      <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/24\">",
"       24",
"      </a>",
"      ]. However, we suggest that additional EIA tests are indicated if the patient is worsening or if proper specimen handling of the initial sample was uncertain.",
"     </li>",
"     <li>",
"      Cytotoxicity assay &ndash; The cytotoxicity assay is one of the \"gold standards\" for diagnosis of",
"      <em>",
"       C. difficile",
"      </em>",
"      infection [",
"      <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/35\">",
"       35",
"      </a>",
"      ]. The fecal sample is placed in cell culture and induces a cytopathic effect, which can be neutralized by pretreatment with toxin B-specific antibody. The cytotoxicity assay is more sensitive than enzyme immunoassays, but is labor intensive and takes approximately two days [",
"      <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/1,2,36\">",
"       1,2,36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Selective anaerobic culture &ndash; Culture on selective medium with toxin testing of isolated",
"      <em>",
"       C. difficile",
"      </em>",
"      is the most sensitive and specific diagnostic method. Prior treatment with heat or alcohol to select spores is sometimes used to improve yield. Culture is useful for epidemiologic studies, but is generally too slow and labor intensive for practical use.",
"     </li>",
"     <li>",
"      PCR testing &ndash; Real-time polymerase chain reaction (PCR) tests that detect toxin A and B genes are now commercially available [",
"      <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/9,37,38\">",
"       9,37,38",
"      </a>",
"      ]. Test results can be available within as little as one hour. In initial trials, PCR tests have been shown to be highly sensitive (approximately 95 percent) and specific, similar to the cytotoxicity assay, and more sensitive than enzyme immunoassays [",
"      <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/24,39-43\">",
"       24,39-43",
"      </a>",
"      ]. With further experience, PCR tests may become a test of choice, perhaps in concert with other rapid assays . PCR testing must be used judiciously, since its high sensitivity will lead to more frequent identification of incidental carriers, particularly so in younger age groups. Prospective studies in children will be needed to evaluate this issue.",
"     </li>",
"     <li>",
"      <em>",
"       C. difficile",
"      </em>",
"      common antigen &ndash; Common antigen testing detects glutamate dehydrogenase (GDH) antigen, an essential enzyme produced constitutively by all",
"      <em>",
"       C. difficile",
"      </em>",
"      isolates. The test is highly sensitive, and results are available in less than one hour. However, GDH antigen does not distinguish toxigenic from nontoxigenic strains, and its value is only as a first step in a multistep approach. The initial step involves enzyme immunoassay for GDH [",
"      <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/44\">",
"       44",
"      </a>",
"      ]. The second step, performed only in GDH-positive specimens, involves testing with more specific assays [",
"      <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/9,24\">",
"       9,24",
"      </a>",
"      ]. The utility of such multistep testing algorithms has not been evaluated in children.",
"     </li>",
"     <li>",
"      Multistep approaches &ndash; A number of multistep algorithms have been developed in an attempt to improve the accuracy of diagnostic testing for",
"      <em>",
"       C. difficile",
"      </em>",
"      infection [",
"      <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/9,24,44-47\">",
"       9,24,44-47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Choice of test method",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factors to consider when choosing a testing method include sensitivity, specificity, positive and negative predictive value, turn-around time, cost, availability, and the need for specific strain typing (eg, during a possible outbreak) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The high sensitivity and specificity of PCR, together with its rapid turn-around time, promote prompt isolation and treatment of patients with",
"    <em>",
"     C. difficile",
"    </em>",
"    infection. This would decrease the opportunity for nosocomial spread and may also improve patient outcomes. These properties also obviate any need for repeat testing, and in severe cases may avoid emergent diagnostic endoscopy.",
"   </p>",
"   <p>",
"    We suggest either PCR alone for all samples, or GDH followed by PCR if GDH is positive [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. The latter may be less expensive but takes slightly longer and may have reduced sensitivity compared with PCR alone [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/49\">",
"     49",
"    </a>",
"    ]. Interpretive standards, to avoid over-diagnosis of positive results in incidental carriers, should be made available. A frozen stool sample should be saved if a cluster of cases is suspected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Negative stool tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children with moderate to severe diarrheal illness and negative tests for",
"    <em>",
"     C. difficile",
"    </em>",
"    infection, detailed evaluation for other causes of diarrhea is of course warranted. If the suspicion for",
"    <em>",
"     C. difficile",
"    </em>",
"    is high (eg, unexplained severe antimicrobial-induced diarrhea or suggestive radiographic findings), endoscopy or imaging studies may be indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Differential diagnosis'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H22\">",
"     'Imaging'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopy is usually not needed for diagnosis and may carry a small risk for perforation. Its primary indication is for differential diagnosis in urgent situations when, despite a negative EIA toxin assay,",
"    <em>",
"     C. difficile",
"    </em>",
"    is still suspected. Sigmoidoscopy or colonoscopy may be used to demonstrate pseudomembranous colitis and to obtain fresh luminal content for",
"    <em>",
"     C. difficile",
"    </em>",
"    assay, if needed. Pseudomembranous colitis is diagnosed primarily by the observation of 2 to 5 mm yellowish plaques, which, at least in adult patients, strongly supports the diagnosis (",
"    <a class=\"graphic graphic_picture graphicRef53774 \" href=\"UTD.htm?38/28/39363\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef62422 \" href=\"UTD.htm?4/15/4337\">",
"     picture 2",
"    </a>",
"    ). Findings of typical pseudomembranous colitis are usually absent, however, in flares of inflammatory bowel disease induced by",
"    <em>",
"     C. difficile",
"    </em>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not usually necessary for diagnosis of",
"    <em>",
"     C. difficile",
"    </em>",
"    infection, imaging studies demonstrating colitis are sometimes the first indication that",
"    <em>",
"     C. difficile",
"    </em>",
"    is a possibility. Imaging can also provide useful information about disease severity. Severe",
"    <em>",
"     C. difficile",
"    </em>",
"    infection may be suggested by a thickened colon wall found on plain film, ultrasound, or computed tomography (CT) scan, the latter being the most sensitive (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52929 \" href=\"UTD.htm?32/51/33598\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52523 \" href=\"UTD.htm?25/62/26593\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73501 \" href=\"UTD.htm?6/46/6888\">",
"     image 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57812 \" href=\"UTD.htm?41/42/42656\">",
"     image 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/50\">",
"     50",
"    </a>",
"    ]. Imaging studies may demonstrate areas of mural colon thickening, which may be enough to occlude the lumen. Both ultrasound and CT also may demonstrate a characteristic (although not completely diagnostic) \"accordion sign\" created by contrast or gas trapped between swollen haustra (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73501 \" href=\"UTD.htm?6/46/6888\">",
"     image 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. Wall nodularity, pericolonic stranding, and ascites further support the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/52\">",
"     52",
"    </a>",
"    ]. Secondary pleural effusion also may be noted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     MANDATED REPORTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reporting of",
"    <em>",
"     C. difficile",
"    </em>",
"    is not currently required in the United States but may be mandated in other countries (eg, the United Kingdom) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/35,53\">",
"     35,53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     ADDITIONAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     C. difficile",
"    </em>",
"    infection may be the mode of presentation for a coexisting or underlying condition. Depending upon the associated clinical features, additional evaluation for the following conditions may be warranted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Other, and often more important, bacterial or nonbacterial pathogens (eg, rotavirus), particularly in younger children. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/13/13529?source=see_link\">",
"       \"Evaluation of diarrhea in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Congenital or acquired obstructive disorders or dysmotility syndromes, such as Hirschsprung disease or infant botulism. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41848?source=see_link\">",
"       \"Congenital aganglionic megacolon (Hirschsprung disease)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/10/166?source=see_link&amp;anchor=H14#H14\">",
"       \"Neuromuscular junction disorders in newborns and infants\", section on 'Infant botulism'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Immunodeficiencies, including transient hypogammaglobulinemia of infancy. Immunodeficiencies may predispose to both",
"      <em>",
"       C. difficile",
"      </em>",
"      infection and inflammatory bowel disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/36/41544?source=see_link\">",
"       \"Transient hypogammaglobulinemia of infancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24326?source=see_link&amp;anchor=H2#H2\">",
"       \"Primary humoral immune deficiencies: An overview\", section on 'Presentation of humoral immune deficiency'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Inflammatory bowel diseases, such as regional enteritis and ulcerative colitis, mainly in older children. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/25/27034?source=see_link\">",
"       \"Clinical features and diagnosis of inflammatory bowel disease in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of",
"    <em>",
"     C. difficile",
"    </em>",
"    infection in children depends upon the clinical syndrome (eg, diarrhea, bloody diarrhea, pseudomembranous colitis, fulminant colitis) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/9,36\">",
"     9,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Viral diarrhea &ndash; Mild",
"      <em>",
"       C. difficile",
"      </em>",
"      infection may be indistinguishable from common viral diarrhea due to agents such as rotavirus, caliciviruses, and many others. In infants and young children, mild, self-limited diarrhea is most likely to be viral. If sought,",
"      <em>",
"       C. difficile",
"      </em>",
"      commonly is found incidentally in such cases, and there are no data to suggest its presence is associated with increased severity [",
"      <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/36\">",
"       36",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/13/13529?source=see_link\">",
"       \"Evaluation of diarrhea in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/48/26376?source=see_link\">",
"       \"Clinical presentation and diagnosis of rotavirus infection\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/16/11528?source=see_link&amp;anchor=H3#H3\">",
"       \"Clostridium difficile infection in children: Clinical features\", section on 'Infants and young children'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Parasitic diarrhea &ndash; Like",
"      <em>",
"       C. difficile",
"      </em>",
"      , intestinal parasites, such as",
"      <em>",
"       Giardia intestinalis",
"      </em>",
"      ,",
"      <em>",
"       Cryptosporidium",
"      </em>",
"      , and others, may cause relatively prolonged watery diarrhea. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33224?source=see_link\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of giardiasis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/40/13961?source=see_link\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of cryptosporidiosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bacterial diarrhea &ndash; Like",
"      <em>",
"       C. difficile",
"      </em>",
"      ,",
"      <em>",
"       Salmonella",
"      </em>",
"      ,",
"      <em>",
"       Shigella",
"      </em>",
"      ,",
"      <em>",
"       Yersinia",
"      </em>",
"      ,",
"      <em>",
"       Campylobacter",
"      </em>",
"      , and toxigenic or invasive",
"      <em>",
"       Escherichia coli",
"      </em>",
"      each may present with relatively high fever, bloody diarrhea, or laboratory signs of inflammation, such as polymorphonuclear neutrophilia, immature neutrophilia, or increased immature:total neutrophil ratio. Testing for bacterial diarrhea may be warranted for children with community-acquired diarrhea. However, bacterial diarrhea other than",
"      <em>",
"       C. difficile",
"      </em>",
"      is rare among children who have been hospitalized for more than three days [",
"      <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/54\">",
"       54",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14232?source=see_link&amp;anchor=H4#H4\">",
"       \"Clinical manifestations, diagnosis and treatment of enterohemorrhagic Escherichia coli (EHEC) infection\", section on 'Clinical manifestations'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38535?source=see_link&amp;anchor=H2#H2\">",
"       \"Clinical manifestations and diagnosis of Shigella infection\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Non-infectious diarrhea",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Inflammatory bowel disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/25/27034?source=see_link\">",
"       \"Clinical features and diagnosis of inflammatory bowel disease in children and adolescents\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Neonatal necrotizing enterocolitis, which has not been associated with",
"      <em>",
"       C. difficile",
"      </em>",
"      , even though heavy colonization is common in this age group",
"     </li>",
"     <li>",
"      Gastrointestinal mucositis in cancer and other immune-compromised patients",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pseudomembranous colitis &ndash; Rarely reported cases of endoscopically typical pseudomembranous colitis in the absence of",
"      <em>",
"       C. difficile",
"      </em>",
"      include rotavirus and adenovirus [",
"      <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/55\">",
"       55",
"      </a>",
"      ],",
"      <em>",
"       E. coli",
"      </em>",
"      0157 [",
"      <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/56\">",
"       56",
"      </a>",
"      ],",
"      <em>",
"       Salmonella",
"      </em>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/57\">",
"       57",
"      </a>",
"      ],",
"      <em>",
"       Shigella",
"      </em>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/58\">",
"       58",
"      </a>",
"      ], and antimicrobial-induced",
"      <em>",
"       Staphylococcus aureus",
"      </em>",
"      enterocolitis. Such",
"      <em>",
"       S. aureus",
"      </em>",
"      strains usually produce enterotoxin, and most are methicillin resistant [",
"      <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/59\">",
"       59",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/48/26376?source=see_link\">",
"       \"Clinical presentation and diagnosis of rotavirus infection\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14232?source=see_link&amp;anchor=H4#H4\">",
"       \"Clinical manifestations, diagnosis and treatment of enterohemorrhagic Escherichia coli (EHEC) infection\", section on 'Clinical manifestations'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38535?source=see_link&amp;anchor=H2#H2\">",
"       \"Clinical manifestations and diagnosis of Shigella infection\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acute abdominal pain &ndash; Fulminant colitis must be differentiated from other causes of acute intra-abdominal disease, such as appendicitis, intussusception, etc. [",
"      <a class=\"abstract\" href=\"UTD.htm?28/6/28777/abstract/36\">",
"       36",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/20/11593?source=see_link\">",
"       \"Causes of acute abdominal pain in children and adolescents\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/61/22490?source=see_link\">",
"       \"Emergent evaluation of the child with acute abdominal pain\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of",
"      <em>",
"       Clostridium difficile",
"      </em>",
"      infection requires the presence of compatible symptoms and either a stool test positive for",
"      <em>",
"       C. difficile",
"      </em>",
"      toxins or toxigenic",
"      <em>",
"       C. difficile",
"      </em>",
"      , or endoscopic or histologic findings of pseudomembranous colitis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview of approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Testing for",
"      <em>",
"       C. difficile",
"      </em>",
"      infection in children of all ages should be limited to those with a high probability of clinically meaningful disease. In children of preschool age or older,",
"      <em>",
"       C. difficile",
"      </em>",
"      should be determined only if there are definite risk factors, predisposing conditions, or signs of invasive illness (",
"      <a class=\"graphic graphic_table graphicRef71790 \" href=\"UTD.htm?35/35/36412\">",
"       table 1",
"      </a>",
"      ). Although there is no established standard, we suggest at least two or more of these indicators should lead to diagnostic testing for those five years or older, and that three or more should be present if the child is younger than five years. Simultaneous isolation of a plausible alternative enteric pathogen greatly reduces the likelihood that identified",
"      <em>",
"       C. difficile",
"      </em>",
"      toxin is meaningful. (see",
"      <a class=\"local\" href=\"#H5\">",
"       'High suspicion'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      There should be an increased index of suspicion for",
"      <em>",
"       C. difficile",
"      </em>",
"      infection in children with known structural or inflammatory gastrointestinal disorders, immune compromise, motility disorders, Hirschsprung disease, hemolytic-uremic syndrome, Henoch-Sch&ouml;nlein purpura (IgA vasculitis), acute abdomen or ileus, cystic fibrosis, and after abdominal surgery. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Predisposing conditions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In children with a high suspicion for antimicrobial-induced",
"      <em>",
"       C. difficile",
"      </em>",
"      infection, the inducing antibiotic(s) should be discontinued, or at least the spectrum narrowed, if possible. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/5/14426?source=see_link&amp;anchor=H7#H7\">",
"       \"Clostridium difficile infection in children: Treatment and prevention\", section on 'Discontinuation of inducing antibiotics'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Stool tests for the laboratory diagnosis of",
"      <em>",
"       C. difficile",
"      </em>",
"      infection include enzyme immunoassays (EIA) for toxins A and B; cytotoxicity assay; anaerobic culture; polymerase chain reaction (PCR) for toxin A or B genes; and EIA for the common",
"      <em>",
"       C. difficile",
"      </em>",
"      antigen, glutamate dehydrogenase (GDH). We suggest either PCR alone for all samples, or GDH followed by PCR if GDH is positive. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Stool tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Any positive",
"      <em>",
"       C. difficile",
"      </em>",
"      test may be due to an incidental carrier state, analogous to",
"      <em>",
"       Streptococcus",
"      </em>",
"      in children with pharyngitis. It is important to continue to consider other causes at any age, and especially so in infants and young children. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Initial evaluation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If",
"      <em>",
"       C. difficile",
"      </em>",
"      tests are negative, and the suspicion for severe",
"      <em>",
"       C. difficile",
"      </em>",
"      remains high, a PCR assay (if available) or endoscopy may be indicated. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Negative stool tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Confirmed",
"      <em>",
"       C. difficile",
"      </em>",
"      infection in children may be the mode of presentation for an underlying condition. Depending upon the associated clinical features, evaluation may be warranted for other intestinal pathogens; congenital or acquired obstructive disorders or dysmotility syndromes; immunodeficiency; or inflammatory bowel disease. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Additional evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author gratefully acknowledges the assistance of Caryn Scoville, librarian III and Information Services librarian, University of Missouri Libraries and Brian Green, MD, Department of Radiology, University of Missouri Health Care.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American Academy of Pediatrics. Clostridium difficile. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LJ.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.285.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28777/abstract/2\">",
"      Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med 1994; 330:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28777/abstract/3\">",
"      Dubberke ER, Gerding DN, Classen D, et al. Strategies to prevent clostridium difficile infections in acute care hospitals. Infect Control Hosp Epidemiol 2008; 29 Suppl 1:S81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28777/abstract/4\">",
"      Crobach MJ, Dekkers OM, Wilcox MH, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing Clostridium difficile-infection (CDI). Clin Microbiol Infect 2009; 15:1053.",
"     </a>",
"    </li>",
"    <li>",
"     Department of Health. Health Protection Agency. Clostridium difficile infection: How to deal with the problem. Department of Health London 2008. Available at: www.hpa.org.uk/webw/HPAweb&amp;HPAwebStandard/HPAweb_C/1204186173530?p=1263812760663 (Accessed on April 01, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28777/abstract/6\">",
"      Schutze GE, Willoughby RE, Committee on Infectious Diseases, American Academy of Pediatrics. Clostridium difficile infection in infants and children. Pediatrics 2013; 131:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28777/abstract/7\">",
"      Bryant K, McDonald LC. Clostridium difficile infections in children. Pediatr Infect Dis J 2009; 28:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28777/abstract/8\">",
"      Tang P, Roscoe M, Richardson SE. Limited clinical utility of Clostridium difficile toxin testing in infants in a pediatric hospital. Diagn Microbiol Infect Dis 2005; 52:91.",
"     </a>",
"    </li>",
"    <li>",
"     Ferry G, Versalovic J. Antibiotic-associated colitis. In: Textbook of Pediatric Infectious Diseases, 6th, Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL (Eds), Saunders, Philadelphia 2009. p.653.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28777/abstract/10\">",
"      Fekety R, Shah AB. Diagnosis and treatment of Clostridium difficile colitis. JAMA 1993; 269:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28777/abstract/11\">",
"      Zahariadis G, Connon JJ, Fong IW. Fulminant Clostridium difficile colitis without diarrhea: lack of emphasis in diagnostic guidelines. Am J Gastroenterol 2002; 97:2929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28777/abstract/12\">",
"      Bulusu M, Narayan S, Shetler K, Triadafilopoulos G. Leukocytosis as a harbinger and surrogate marker of Clostridium difficile infection in hospitalized patients with diarrhea. Am J Gastroenterol 2000; 95:3137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28777/abstract/13\">",
"      Gryboski JD. Clostridium difficile in inflammatory bowel disease relapse. J Pediatr Gastroenterol Nutr 1991; 13:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28777/abstract/14\">",
"      Pascarella F, Martinelli M, Miele E, et al. Impact of Clostridium difficile infection on pediatric inflammatory bowel disease. J Pediatr 2009; 154:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28777/abstract/15\">",
"      Qualman SJ, Petric M, Karmali MA, et al. Clostridium difficile invasion and toxin circulation in fatal pediatric pseudomembranous colitis. Am J Clin Pathol 1990; 94:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28777/abstract/16\">",
"      Bagwell CE, Langham MR Jr, Mahaffey SM, et al. Pseudomembranous colitis following resection for Hirschsprung's disease. J Pediatr Surg 1992; 27:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28777/abstract/17\">",
"      Rivlin J, Lerner A, Augarten A, et al. Severe Clostridium difficile-associated colitis in young patients with cystic fibrosis. J Pediatr 1998; 132:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28777/abstract/18\">",
"      Hussain SZ, Chu C, Greenberg DP, et al. Clostridium difficile colitis in children with cystic fibrosis. Dig Dis Sci 2004; 49:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28777/abstract/19\">",
"      Yates B, Murphy DM, Fisher AJ, et al. Pseudomembranous colitis in four patients with cystic fibrosis following lung transplantation. Thorax 2007; 62:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28777/abstract/20\">",
"      Theunissen C, Knoop C, Nonhoff C, et al. Clostridium difficile colitis in cystic fibrosis patients with and without lung transplantation. Transpl Infect Dis 2008; 10:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28777/abstract/21\">",
"      Williams RN, Hemingway D, Miller AS. Enteral Clostridium difficile, an emerging cause for high-output ileostomy. J Clin Pathol 2009; 62:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28777/abstract/22\">",
"      Causey MW, Spencer MP, Steele SR. Clostridium difficile enteritis after colectomy. Am Surg 2009; 75:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28777/abstract/23\">",
"      Centers for Disease Control and Prevention (CDC). Surveillance for community-associated Clostridium difficile--Connecticut, 2006. MMWR Morb Mortal Wkly Rep 2008; 57:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28777/abstract/24\">",
"      Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28777/abstract/25\">",
"      Gerding DN, Johnson S, Peterson LR, et al. Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol 1995; 16:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28777/abstract/26\">",
"      Sunenshine RH, McDonald LC. Clostridium difficile-associated disease: new challenges from an established pathogen. Cleve Clin J Med 2006; 73:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28777/abstract/27\">",
"      Gerding DN. Diagnosis of Clostridium difficile--associated disease: patient selection and test perfection. Am J Med 1996; 100:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28777/abstract/28\">",
"      Katz DA, Lynch ME, Littenberg B. Clinical prediction rules to optimize cytotoxin testing for Clostridium difficile in hospitalized patients with diarrhea. Am J Med 1996; 100:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28777/abstract/29\">",
"      Swindells J, Brenwald N, Reading N, Oppenheim B. Evaluation of diagnostic tests for Clostridium difficile infection. J Clin Microbiol 2010; 48:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28777/abstract/30\">",
"      Mohan SS, McDermott BP, Parchuri S, Cunha BA. Lack of value of repeat stool testing for Clostridium difficile toxin. Am J Med 2006; 119:356.e7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28777/abstract/31\">",
"      Renshaw AA, Stelling JM, Doolittle MH. The lack of value of repeated Clostridium difficile cytotoxicity assays. Arch Pathol Lab Med 1996; 120:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28777/abstract/32\">",
"      Aichinger E, Schleck CD, Harmsen WS, et al. Nonutility of repeat laboratory testing for detection of Clostridium difficile by use of PCR or enzyme immunoassay. J Clin Microbiol 2008; 46:3795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28777/abstract/33\">",
"      Manabe YC, Vinetz JM, Moore RD, et al. Clostridium difficile colitis: an efficient clinical approach to diagnosis. Ann Intern Med 1995; 123:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28777/abstract/34\">",
"      Gade R, Turett G. The utility of repeated stool toxin testing for diagnosing Clostridium difficile colitis. South Med J 2009; 102:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28777/abstract/35\">",
"      Shannon-Lowe J, Matheson NJ, Cooke FJ, Aliyu SH. Prevention and medical management of Clostridium difficile infection. BMJ 2010; 340:c1296.",
"     </a>",
"    </li>",
"    <li>",
"     Singh N, Hyun DY. Clostridium difficile. In: Principles and Practice of Pediatric Infectious Diseases, 4th, Long SS, Pickering LK, Prober CG.  (Eds), Elsevier Saunders, Edinburgh 2012. p.977.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28777/abstract/37\">",
"      B&eacute;langer SD, Boissinot M, Clairoux N, et al. Rapid detection of Clostridium difficile in feces by real-time PCR. J Clin Microbiol 2003; 41:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28777/abstract/38\">",
"      van den Berg RJ, Bruijnesteijn van Coppenraet LS, Gerritsen HJ, et al. Prospective multicenter evaluation of a new immunoassay and real-time PCR for rapid diagnosis of Clostridium difficile-associated diarrhea in hospitalized patients. J Clin Microbiol 2005; 43:5338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28777/abstract/39\">",
"      Kvach EJ, Ferguson D, Riska PF, Landry ML. Comparison of BD GeneOhm Cdiff real-time PCR assay with a two-step algorithm and a toxin A/B enzyme-linked immunosorbent assay for diagnosis of toxigenic Clostridium difficile infection. J Clin Microbiol 2010; 48:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28777/abstract/40\">",
"      Stamper PD, Babiker W, Alcabasa R, et al. Evaluation of a new commercial TaqMan PCR assay for direct detection of the clostridium difficile toxin B gene in clinical stool specimens. J Clin Microbiol 2009; 47:3846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28777/abstract/41\">",
"      Eastwood K, Else P, Charlett A, Wilcox M. Comparison of nine commercially available Clostridium difficile toxin detection assays, a real-time PCR assay for C. difficile tcdB, and a glutamate dehydrogenase detection assay to cytotoxin testing and cytotoxigenic culture methods. J Clin Microbiol 2009; 47:3211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28777/abstract/42\">",
"      Stamper PD, Alcabasa R, Aird D, et al. Comparison of a commercial real-time PCR assay for tcdB detection to a cell culture cytotoxicity assay and toxigenic culture for direct detection of toxin-producing Clostridium difficile in clinical samples. J Clin Microbiol 2009; 47:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28777/abstract/43\">",
"      van den Berg RJ, Vaessen N, Endtz HP, et al. Evaluation of real-time PCR and conventional diagnostic methods for the detection of Clostridium difficile-associated diarrhoea in a prospective multicentre study. J Med Microbiol 2007; 56:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28777/abstract/44\">",
"      Wilkins TD, Lyerly DM. Clostridium difficile testing: after 20 years, still challenging. J Clin Microbiol 2003; 41:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28777/abstract/45\">",
"      Ticehurst JR, Aird DZ, Dam LM, et al. Effective detection of toxigenic Clostridium difficile by a two-step algorithm including tests for antigen and cytotoxin. J Clin Microbiol 2006; 44:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28777/abstract/46\">",
"      Reller ME, Lema CA, Perl TM, et al. Yield of stool culture with isolate toxin testing versus a two-step algorithm including stool toxin testing for detection of toxigenic Clostridium difficile. J Clin Microbiol 2007; 45:3601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28777/abstract/47\">",
"      Fenner L, Widmer AF, Goy G, et al. Rapid and reliable diagnostic algorithm for detection of Clostridium difficile. J Clin Microbiol 2008; 46:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28777/abstract/48\">",
"      Goldenberg SD, Cliff PR, Smith S, et al. Two-step glutamate dehydrogenase antigen real-time polymerase chain reaction assay for detection of toxigenic Clostridium difficile. J Hosp Infect 2010; 74:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28777/abstract/49\">",
"      Novak-Weekley SM, Marlowe EM, Miller JM, et al. Clostridium difficile testing in the clinical laboratory by use of multiple testing algorithms. J Clin Microbiol 2010; 48:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28777/abstract/50\">",
"      Razzaq R, Sukumar SA. Ultrasound diagnosis of clinically undetected Clostridium difficile toxin colitis. Clin Radiol 2006; 61:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28777/abstract/51\">",
"      Blickman JG, Boland GW, Cleveland RH, et al. Pseudomembranous colitis: CT findings in children. Pediatr Radiol 1995; 25 Suppl 1:S157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28777/abstract/52\">",
"      Kirkpatrick ID, Greenberg HM. Evaluating the CT diagnosis of Clostridium difficile colitis: should CT guide therapy? AJR Am J Roentgenol 2001; 176:635.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Nationally notifiable infectious conditions, United States 2010. Available at: www.cdc.gov/ncphi/disss/nndss/phs/infdis2010.htm (Accessed on March 31, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28777/abstract/54\">",
"      Zaidi AK, Macone A, Goldmann AD. Impact of simple screening criteria on utilization of low-yield bacterial stool cultures in a Children's Hospital. Pediatrics 1999; 103:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28777/abstract/55\">",
"      Wenzl TG, Kusenbach G, Skopnik H. Pseudomembranous viral colitis. J Pediatr Gastroenterol Nutr 2000; 30:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28777/abstract/56\">",
"      Uc A, Mitros FA, Kao SC, Sanders KD. Pseudomembranous colitis with Escherichia coli O157:H7. J Pediatr Gastroenterol Nutr 1997; 24:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28777/abstract/57\">",
"      Beck A, McNeil C, Abdelsayed G, et al. Salmonella pseudomembranous colitis. Conn Med 2007; 71:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28777/abstract/58\">",
"      Kelber M, Ament ME. Shigella dysenteriae I: a forgotten cause of pseudomembranous colitis. J Pediatr 1976; 89:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28777/abstract/59\">",
"      Gravet A, Rondeau M, Harf-Monteil C, et al. Predominant Staphylococcus aureus isolated from antibiotic-associated diarrhea is clinically relevant and produces enterotoxin A and the bicomponent toxin LukE-lukD. J Clin Microbiol 1999; 37:4012.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6049 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-D8E5382BBA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_6_28777=[""].join("\n");
var outline_f28_6_28777=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW OF APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INITIAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Low suspicion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      High suspicion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Historical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Ancillary tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Predisposing conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Immune deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - IBD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Hirschsprung disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Cystic fibrosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Intestinal disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Other conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIAGNOSTIC TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Stool tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Choice of test method",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Negative stool tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Endoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      MANDATED REPORTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      ADDITIONAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6049\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6049|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?32/51/33598\" title=\"diagnostic image 1\">",
"      Thumbprinting C difficile",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?25/62/26593\" title=\"diagnostic image 2\">",
"      C difficile sonogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?6/46/6888\" title=\"diagnostic image 3\">",
"      C difficile colitis child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/42/42656\" title=\"diagnostic image 4\">",
"      C difficile colitis CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6049|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/28/39363\" title=\"picture 1\">",
"      Pseudomembranous colitis scope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/15/4337\" title=\"picture 2\">",
"      Pseudomembranous colitis Gross",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6049|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/35/36412\" title=\"table 1\">",
"      Indicators of Clostridium difficile infection in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/34/20008?source=related_link\">",
"      Antibiotics for treatment of inflammatory bowel diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/36/37448?source=related_link\">",
"      Botulism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/20/11593?source=related_link\">",
"      Causes of acute abdominal pain in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/25/27034?source=related_link\">",
"      Clinical features and diagnosis of inflammatory bowel disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40729?source=related_link\">",
"      Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35704?source=related_link\">",
"      Clinical manifestations and diagnosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38535?source=related_link\">",
"      Clinical manifestations and diagnosis of Shigella infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14232?source=related_link\">",
"      Clinical manifestations, diagnosis and treatment of enterohemorrhagic Escherichia coli (EHEC) infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/48/26376?source=related_link\">",
"      Clinical presentation and diagnosis of rotavirus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=related_link\">",
"      Clostridium difficile in adults: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36137?source=related_link\">",
"      Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/29/20954?source=related_link\">",
"      Clostridium difficile in adults: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/16/11528?source=related_link\">",
"      Clostridium difficile infection in children: Clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/22/16745?source=related_link\">",
"      Clostridium difficile infection in children: Microbiology, pathogenesis, and epidemiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/5/14426?source=related_link\">",
"      Clostridium difficile infection in children: Treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41848?source=related_link\">",
"      Congenital aganglionic megacolon (Hirschsprung disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/15/19706?source=related_link\">",
"      Cystic fibrosis: Overview of gastrointestinal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/8/34950?source=related_link\">",
"      Emergency complications of Hirschsprung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/61/22490?source=related_link\">",
"      Emergent evaluation of the child with acute abdominal pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/40/13961?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of cryptosporidiosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33224?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of giardiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/13/13529?source=related_link\">",
"      Evaluation of diarrhea in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/10/166?source=related_link\">",
"      Neuromuscular junction disorders in newborns and infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24326?source=related_link\">",
"      Primary humoral immune deficiencies: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/36/41544?source=related_link\">",
"      Transient hypogammaglobulinemia of infancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_6_28778="Prevention of hepatocellular carcinoma and recommendations for surveillance in adults with chronic liver disease";
var content_f28_6_28778=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention of hepatocellular carcinoma and recommendations for surveillance in adults with chronic liver disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/6/28778/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/6/28778/contributors\">",
"     Massimo Colombo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/6/28778/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/6/28778/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/6/28778/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/6/28778/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/6/28778/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic liver disease is the major risk factor for the development of hepatocellular carcinoma (HCC) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/1\">",
"     1",
"    </a>",
"    ]. Preventing or treating liver disease can decrease the risk of HCC. In addition, surveillance of at-risk patients with modern imaging techniques permits the identification and characterization of early tumors that are smaller than 2 cm, which may have a better prognosis than larger lesions. The development of effective treatments for early-stage HCC has provided additional support for early detection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/3/43063?source=see_link\">",
"     \"Overview of treatment approaches for hepatocellular carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the evidence regarding surveillance for HCC in patients with chronic liver disease and provide suggestions on the selection of patients for surveillance, approaches to surveillance, and additional testing to confirm the presence of HCC. The recommendations provided below are consistent with",
"    <a class=\"external\" href=\"file://www.aasld.org/practiceguidelines/Documents/Bookmarked Practice Guidelines/HCCUpdate2010.pdf\">",
"     guidelines",
"    </a>",
"    issued by the American Association of Liver Diseases in 2005 and updated in 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues related to surveillance and screening for HCC in general, the treatment of HCC, and the prognosis of patients with HCC are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34986?source=see_link&amp;anchor=H28#H28\">",
"     \"Clinical features and diagnosis of primary hepatocellular carcinoma\", section on 'Screening and surveillance'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/3/43063?source=see_link\">",
"     \"Overview of treatment approaches for hepatocellular carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/24/25992?source=see_link\">",
"     \"Staging and prognostic factors in hepatocellular carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23128081\">",
"    <span class=\"h1\">",
"     PREVENTION OF HEPATOCELLULAR CARCINOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;HCC is associated with, among other things, hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection, exposure to environmental toxins, and hereditary hemochromatosis. Attempts to prevent HCC should focus on preventing infection with HBV and HCV, treating patients with viral hepatitis who are candidates for treatment, avoiding environmental toxins, and removing excess iron from patients with hereditary hemochromatosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=see_link&amp;anchor=H5#H5\">",
"     \"Epidemiology and etiologic associations of hepatocellular carcinoma\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23128089\">",
"    <span class=\"h2\">",
"     HCC related to hepatitis B virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis B virus (HBV) is an important cause of hepatocellular carcinoma (HCC). Key to prevention of HCC is vaccination against HBV, which is recommended for all newborns and individuals who are at increased risk for infection. Studies in Taiwan, where universal HBV vaccination was introduced in the early 1980's, have documented a significant decrease in the incidence of HCC in initially children, and now in adolescents as well [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=see_link&amp;anchor=H6#H6\">",
"     \"Epidemiology and etiologic associations of hepatocellular carcinoma\", section on 'Hepatitis B'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31690?source=see_link\">",
"     \"Hepatitis B virus vaccination\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional measures to prevent the transmission of HBV include screening donated blood for bloodborne infections and the use of passive immunization with hepatitis B immunoglobulin for patients exposed to HBV patients (particularly children in whom chronic infection is more likely to develop). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/31/26106?source=see_link\">",
"     \"Procedures used for blood donor screening: Protection of potential blood donors and recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23416?source=see_link&amp;anchor=H19#H19\">",
"     \"Management of healthcare workers exposed to hepatitis B virus or hepatitis C virus\", section on 'HBV infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Finally, antiviral therapy should be considered in patients with chronic HBV who are treatment candidates since a response to treatment is associated with a lower risk of HCC [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=see_link&amp;anchor=H6#H6\">",
"     \"Epidemiology and etiologic associations of hepatocellular carcinoma\", section on 'Hepatitis B'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24378?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of the management of hepatitis B and case examples\", section on 'Who should be treated and how'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H162498317\">",
"    <span class=\"h2\">",
"     HCC related cirrhosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with HCC have underlying cirrhosis, and treatment aimed at preventing the development of cirrhosis will decrease the risk of HCC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=see_link&amp;anchor=H5#H5\">",
"     \"Epidemiology and etiologic associations of hepatocellular carcinoma\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23128130\">",
"    <span class=\"h3\">",
"     HCC related to hepatitis C virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis C virus (HCV) is a common cause of cirrhosis, which is a risk factor for HCC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=see_link&amp;anchor=H11#H11\">",
"     \"Epidemiology and etiologic associations of hepatocellular carcinoma\", section on 'Hepatitis C'",
"    </a>",
"    .) As with HBV, interventions that may decrease the risk of HCV infection include encouraging safe injection practices for health care providers and injection drug users and screening donated blood for bloodborne pathogens. (See",
"    <a class=\"local\" href=\"#H23128089\">",
"     'HCC related to hepatitis B virus'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Safe injection practices include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Avoiding the unnecessary injections",
"     </li>",
"     <li>",
"      Using needles and syringes only once, or if that is not possible, properly sterilizing needles and syringes that have to be reused",
"     </li>",
"     <li>",
"      Avoiding the of use of multi-dose vials",
"     </li>",
"     <li>",
"      Proper disposal of used needles",
"     </li>",
"     <li>",
"      Needle and syringe exchange programs for injection drug users",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Successful treatment of patients with HCV may prevent the development of cirrhosis and HCC [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/7-11\">",
"     7-11",
"    </a>",
"    ]. As a result, patients at risk for HCV infection should be screened for the infection and offered treatment if they are candidates. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41849?source=see_link&amp;anchor=H2#H2\">",
"     \"Screening for and diagnosis of chronic hepatitis C virus infection\", section on 'Who should be tested'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/45/43735?source=see_link\">",
"     \"Overview of the management of chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=see_link&amp;anchor=H11#H11\">",
"     \"Epidemiology and etiologic associations of hepatocellular carcinoma\", section on 'Hepatitis C'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H162498331\">",
"    <span class=\"h3\">",
"     Other causes of cirrhosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous other diseases are associated with the development of cirrhosis, putting patients at increased risk for HCC. These include alcoholic liver disease, nonalcoholic steatohepatitis, autoimmune hepatitis, primary sclerosing cholangitis, primary biliary cirrhosis, Wilson disease, hereditary hemochromatosis, and alpha-1 antitrypsin deficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23194?source=see_link&amp;anchor=H14#H14\">",
"     \"Diagnostic approach to the patient with cirrhosis\", section on 'Testing for specific diseases'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While treatments for many of these disorders are available, they are of varying efficacy, and in some cases (eg, alpha-1 antitrypsin deficiency) there are no treatments that are effective for preventing cirrhosis. The treatments for these diseases are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22104?source=see_link\">",
"     \"Prognosis and management of alcoholic fatty liver disease and alcoholic cirrhosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/20/23882?source=see_link\">",
"     \"Natural history and management of nonalcoholic fatty liver disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/7/40058?source=see_link\">",
"     \"Treatment of autoimmune hepatitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41097?source=see_link\">",
"     \"Treatment of primary sclerosing cholangitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/19/34105?source=see_link\">",
"     \"Overview of the treatment of primary biliary cirrhosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/11/23737?source=see_link\">",
"     \"Treatment of Wilson disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18952?source=see_link\">",
"     \"Treatment of hereditary hemochromatosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18136?source=see_link&amp;anchor=H2#H2\">",
"     \"Extrapulmonary manifestations of alpha-1 antitrypsin deficiency\", section on 'Hepatic disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43701?source=see_link&amp;anchor=H5#H5\">",
"     \"Congestive hepatopathy\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23128383\">",
"    <span class=\"h2\">",
"     HCC related to environmental factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Environmental factors that may increase the risk of HCC in patients with other risk factors include food contaminated with aflatoxin and smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/12\">",
"     12",
"    </a>",
"    ]. Decreasing exposure to these factors thus may decrease the risk of HCC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=see_link&amp;anchor=H13#H13\">",
"     \"Epidemiology and etiologic associations of hepatocellular carcinoma\", section on 'Tobacco and alcohol abuse'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=see_link&amp;anchor=H146270166#H146270166\">",
"     \"Epidemiology and etiologic associations of hepatocellular carcinoma\", section on 'Environmental toxins'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Aflatoxin B is produced predominantly by strains of Aspergillus found on crops such as corn, soybeans, and peanuts. While industrialized countries screen for aflatoxin, resource-poor countries may not [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/12\">",
"     12",
"    </a>",
"    ]. In addition, crops that are sold locally or regionally without going through governmental screening may also be contaminated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H162498503\">",
"    <span class=\"h2\">",
"     Diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetes mellitus has been associated with HCC, and treatment with a thiazolidinedione or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    has been associated with a decreased risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=see_link&amp;anchor=H14#H14\">",
"     \"Epidemiology and etiologic associations of hepatocellular carcinoma\", section on 'Diabetes mellitus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112724546\">",
"    <span class=\"h2\">",
"     Chemoprevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , but not nonaspirin nonsteroidal anti-inflammatory drugs, was associated with a decreased risk of HCC and death from chronic liver disease in the National Institutes of Health-AARP Diet and Health Study of patients between the ages of 50 and 71 years [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/13\">",
"     13",
"    </a>",
"    ]. The overall incidence of HCC was small (9 per 100,000 person-years), but the risk was decreased among those who used aspirin compared with those who did not (relative risk = 0.59, 95% confidence interval 0.45-0.77). The study did not report on the effect specifically in patients with chronic liver disease or cirrhosis.",
"   </p>",
"   <p>",
"    However, NSAIDs are hepatotoxic, and their use in patients with cirrhosis is associated with variceal hemorrhage, impaired renal function, and the development of diuretic resistant ascites. As a result, it is generally recommended that NSAIDs be avoided in patients with chronic liver disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/49/10007?source=see_link&amp;anchor=H2#H2\">",
"     \"Management of pain in patients with cirrhosis\", section on 'Nonselective NSAIDs'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=see_link&amp;anchor=H6#H6\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\", section on 'Hepatic injury'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61643912\">",
"    <span class=\"h1\">",
"     PATIENTS WHO REQUIRE SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surveillance for hepatocellular carcinoma (HCC) is recommended for many hepatitis B virus (HBV) carriers and for all patients with cirrhosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61643920\">",
"    <span class=\"h2\">",
"     Hepatitis B carriers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cost-effectiveness analyses suggest that surveillance for HCC in patients who are hepatitis B carriers is cost-effective once the annual incidence of HCC exceeds 0.2 percent (",
"    <a class=\"graphic graphic_table graphicRef68371 \" href=\"UTD.htm?37/36/38476\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Cost-effectiveness'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The American Association of Liver Diseases (AASLD) guidelines suggest surveillance in [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Asian men over the age of 40 years",
"     </li>",
"     <li>",
"      Asian women over the age of 50 years",
"     </li>",
"     <li>",
"      Patients with HBV and cirrhosis",
"     </li>",
"     <li>",
"      Africans and North American blacks",
"     </li>",
"     <li>",
"      Patients with a family history of HCC",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Caucasian patients with a high viral load and active inflammation (elevated serum alanine aminotransferase [ALT]) for several years are probably also at risk for HCC, although it is not certain at what age the risk starts to become significant [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/2\">",
"     2",
"    </a>",
"    ]. The AASLD guidelines do not specify what age to start surveillance in Caucasian patients with active hepatitis B. In Caucasians with a high viral load and active inflammation, we suggest starting surveillance at the age of 40 years for men and 50 years for women. (See",
"    <a class=\"local\" href=\"#H61643944\">",
"     'Caucasians'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61643936\">",
"    <span class=\"h3\">",
"     Asians",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of HCC in Asian patients with HBV is higher than that seen in Caucasian patients (0.4 to 0.6 percent per year compared with less than 0.2 percent per year) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. The incidence in male HBV carriers from Southeast Asia starts to exceed 0.2 percent around the age of 40 years and is the basis for the recommendation that surveillance start in Asian men at age 40 years [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/16\">",
"     16",
"    </a>",
"    ]. The incidence in Asian women is lower, but it is not well defined. As a result, the recommendation is that Asian women begin surveillance at age 50 years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61644755\">",
"    <span class=\"h3\">",
"     Africans/patients of African descent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with HBV who are African appear to get HCC at a younger age than other carriers [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. As a result, we begin surveillance in adults of African descent at the time of HBV diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61643944\">",
"    <span class=\"h3\">",
"     Caucasians",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of HCC in Caucasian carriers of HBV without cirrhosis is less than 0.2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/14\">",
"     14",
"    </a>",
"    ]. Whether to perform surveillance in Caucasian patients with HBV depends upon disease activity. Surveillance should be performed in patients with long-standing evidence of active hepatitis B (elevated serum ALT",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    high HBV DNA levels). There is no clear definition of what constitutes a high viral load, though a viral load &gt;100,000",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    (20,000",
"    <span class=\"nowrap\">",
"     IU/mL)",
"    </span>",
"    is a risk factor for disease progression and HCC in Asian patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/19,20\">",
"     19,20",
"    </a>",
"    ], and it is the cutoff value suggested by the National Institutes of Health to define active chronic HBV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/21\">",
"     21",
"    </a>",
"    ]. While the AASLD guidelines do not specify what age to start surveillance in Caucasian patients with active hepatitis B, we suggest starting surveillance at the age of 40 years for men and 50 years for women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42279?source=see_link&amp;anchor=H7#H7\">",
"     \"Serologic diagnosis of hepatitis B virus infection\", section on 'Serum HBV DNA assays'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with inactive hepatitis (long-term normal ALT and low HBV DNA levels) and",
"    <strong>",
"     without",
"    </strong>",
"    cirrhosis, the incidence of HCC is low [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. As a result, surveillance in such patients is not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61643968\">",
"    <span class=\"h3\">",
"     HBV with cirrhosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with HBV who develop HCC, 70 to 90 percent of cases occur in patients with cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/25\">",
"     25",
"    </a>",
"    ]. In such patients, if not already underway, we begin surveillance at the time of the diagnosis of cirrhosis. (See",
"    <a class=\"local\" href=\"#H61643928\">",
"     'Patients with cirrhosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61643960\">",
"    <span class=\"h3\">",
"     Patients with a family history of HCC",
"    </span>",
"    &nbsp;&mdash;&nbsp;HCC is more common in HBV carriers with a family history of HCC [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/26\">",
"     26",
"    </a>",
"    ]. In a study of 5238 HBV carriers (553 with HCC and 4685 without HCC), the risk of HCC was significantly higher in those with a family history of HCC (adjusted rate ratio [ARR] 2.4) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/26\">",
"     26",
"    </a>",
"    ]. If the carrier had two or more affected family members, the risk was even higher (ARR 5.6). By the age of 70 years, the cumulative risk of HCC was significantly higher among those with an affected family member compared with patients without an affected family member (23.6 versus 8.9 percent). However, there are no guidelines about when to begin surveillance in such patients. Our approach is to begin surveillance in adults once the family history of HCC has been identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61644540\">",
"    <span class=\"h3\">",
"     Patients receiving treatment for HBV or who clear the virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of HCC in patients who have undergone treatment for chronic HBV is unclear. Some studies suggest a reduced incidence of HCC with HBV treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/27,28\">",
"     27,28",
"    </a>",
"    ], whereas others do not [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/29-31\">",
"     29-31",
"    </a>",
"    ], particularly once cirrhosis is established. We agree with the current AASLD recommendation that patients should undergo surveillance if they are otherwise candidates, even if they have cleared the virus [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61643928\">",
"    <span class=\"h2\">",
"     Patients with cirrhosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surveillance for HCC is recommended in all patients with cirrhosis and should start once the diagnosis of cirrhosis is made [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/2\">",
"     2",
"    </a>",
"    ]. However, it should be noted that this recommendation is based upon a randomized trial showing a benefit of surveillance in patients with chronic HBV, with or without cirrhosis. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Impact of surveillance on disease-specific mortality'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In patients with cirrhosis, surveillance becomes cost-effective once the annual incidence of HCC exceeds 1.5 to 2 percent. The incidence of HCC is 3 to 8 percent per year among patients with cirrhosis from HBV, HCV, or primary biliary cirrhosis (PBC) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/2\">",
"     2",
"    </a>",
"    ]. Data also support surveillance in patients with cirrhosis from genetic hemochromatosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/32-35\">",
"     32-35",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Cost-effectiveness'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients with cirrhosis and HBV or HCV who have cleared the virus (either spontaneously or in response to treatment) are probably at decreased risk of developing HCC [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/36\">",
"     36",
"    </a>",
"    ]. However, the magnitude of the decrease is unclear, and it is recommended that such patients continue to undergo surveillance.",
"   </p>",
"   <p>",
"    There are insufficient data regarding the incidence of HCC in patients with cirrhosis related to nonalcoholic fatty liver disease (with rates ranging from 2 percent at 7 years to 13 percent at 3 years in various studies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/37\">",
"     37",
"    </a>",
"    ]) or alpha 1-antitrypsin deficiency, and the incidence of HCC in patients with cirrhosis related to autoimmune hepatitis was estimated in one study to be 1.1 percent per year [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/38\">",
"     38",
"    </a>",
"    ], which is below the threshold value of 1.5 percent per year.",
"   </p>",
"   <p>",
"    The incidence of HCC in patients with alcoholic cirrhosis is not clear. Studies suggest that patients who consume large amounts of alcohol are at increased risk for HCC but do not report the rates of HCC among patients with alcoholic cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Studies looking at the incidence of HCC among patients with cirrhosis have reached variable conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/41-47\">",
"     41-47",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A Danish registry-based study found that among 8482 patients with alcoholic cirrhosis, the five-year cumulative HCC risk was 1.0 to 1.9 percent, below the 1.5 percent per year threshold [",
"      <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 450 patients between the ages of 40 and 75 years who were undergoing surveillance, the annual incidence of HCC was 2.6 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/47\">",
"       47",
"      </a>",
"      ]. Factors associated with an increased risk of HCC were age &ge;55 years and a platelet count of less than",
"      <span class=\"nowrap\">",
"       125,000/microL.",
"      </span>",
"      Patients with neither risk factor had an annual incidence of HCC of 0.3 percent, compared with 2.6 percent for those with one risk factor and 4.8 percent for those with two risk factors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The incidence of HCC in alcoholic cirrhosis appears to vary geographically, so local incidences should be taken into account when developing screening recommendations.",
"   </p>",
"   <p>",
"    Despite screening recommendations, most patients with cirrhosis who are at-risk for HCC do not receive regular surveillance. In two large series from Veterans Affairs facilities in the United States, regular surveillance was performed in only 2 to 12 percent of patients with cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Factors associated with regular surveillance included the presence of fewer medical and psychological comorbid conditions, varices, and compensated liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/48\">",
"     48",
"    </a>",
"    ]. A review from the SEER Medicare databases found that less than 20 percent of patients with cirrhosis who developed HCC had undergone regular surveillance [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61644279\">",
"    <span class=\"h2\">",
"     Co-infection with HIV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver disease is more rapidly progressive in patients who are co-infected with HIV and either HBV or HCV. In addition, when such patients develop cirrhosis, they are at increased risk of HCC [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/51\">",
"     51",
"    </a>",
"    ], and once HCC develops, it appears to be more aggressive than in patients who do not have HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. There are no guidelines about when to begin surveillance in such patients. As a result, we use the same approach to surveillance as in patients without HIV co-infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30202?source=see_link&amp;anchor=H1560506340#H1560506340\">",
"     \"HIV infection and malignancy: Management considerations\", section on 'Hepatocellular carcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61644067\">",
"    <span class=\"h1\">",
"     PATIENTS WHO DO NOT REQUIRE SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;While surveillance for hepatocellular carcinoma (HCC) is recommended for all patients with cirrhosis, regardless of the etiology, not all hepatitis B virus (HBV) carriers require surveillance. As noted above, Caucasian patients with no or low HBV activity and no cirrhosis are at low-risk for HCC, and surveillance is generally not recommended in such patients. (See",
"    <a class=\"local\" href=\"#H61643944\">",
"     'Caucasians'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In general, surveillance is not recommended for patients with liver disease who do not have cirrhosis or who are not HBV carriers meeting surveillance guidelines. (See",
"    <a class=\"local\" href=\"#H61643920\">",
"     'Hepatitis B carriers'",
"    </a>",
"    above.) There is an increased risk of HCC in patients with HCV who have stage 3 fibrosis, as well as in those with non-cirrhotic nonalcoholic fatty liver disease, but the benefit of surveillance is not clear, and we do not routinely perform surveillance in such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/2\">",
"     2",
"    </a>",
"    ]. In some countries, the incidence of HCC in alcoholic cirrhosis is lower than anticipated and the value of screening in these populations is therefore uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61645279\">",
"    <span class=\"h1\">",
"     SURVEILLANCE METHODS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2010 American Association for the Study of Liver Diseases (AASLD) guidelines on the management of hepatocellular carcinoma (HCC) recommend that surveillance be performed using ultrasonography at six-month intervals [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/2\">",
"     2",
"    </a>",
"    ]. The sensitivity of ultrasound for detecting HCC is 94 percent, though it drops to 63 percent for detecting early HCC [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The six-month interval is based primarily on observational data, the expected growth rates of HCC [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/55-60\">",
"     55-60",
"    </a>",
"    ], and preliminary data suggesting that survival is better when surveillance is performed every six months rather than every 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/61\">",
"     61",
"    </a>",
"    ]. The surveillance interval is a function of the tumor growth rate, not the degree of risk of developing HCC. Thus, the surveillance interval does not need to be shortened for patients at higher-risk for HCC.",
"   </p>",
"   <p>",
"    One trial examined three-month screening intervals and found that while more lesions 10 mm in diameter or less were found with the shortened interval compared with a six-month screening interval, there were no differences in clinically relevant outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/62\">",
"     62",
"    </a>",
"    ]. These results support the AASLD recommendations that screening should be conducted every six months:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The study assigned 1278 patients with compensated cirrhosis to ultrasound screening either every three or six months [",
"      <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/62\">",
"       62",
"      </a>",
"      ]. Focal lesions were detected in 358 patients (28 percent), 123 of which were confirmed to be HCC (10 percent). There was no difference between those screened every three months and those screened every six months in cumulative focal lesion detection rates (20 versus 13 percent at 24 months and 36 versus 33 percent at 60 months). However, lesions in patients who were screened every three months were more likely to be 10 mm or smaller at the time of detection (41 versus 28 percent). There were no differences between the groups in cumulative HCC incidence (4 versus 3 percent at 24 months and 10 versus 12 percent at 60 months), liver decompensation (15 percent in each group), liver transplantation (3 versus 2 percent), or survival (96 versus 94 percent at 24 months and 85 verus 86 percent at 60 months).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other tests that have been proposed for surveillance, such as the ratio of the L3 fraction of alpha-fetoprotein (AFP) to total AFP, des-gamma-carboxy prothrombin, and many other serum proteins or RNA molecules. However, none of these has been adequately studied as a surveillance test, and they cannot be recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34986?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical features and diagnosis of primary hepatocellular carcinoma\", section on 'Serum markers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The AASLD recommendations stress that the guiding principle should be to use the best available surveillance test regularly; as a result, strategies such as alternating AFP and ultrasonography at intervals have no basis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/2\">",
"     2",
"    </a>",
"    ]. The combined use of AFP and ultrasonography increases detection rates, but it also increases costs and false-positive rates and is not recommended by the AASLD. Because of its poor sensitivity and specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/55,63\">",
"     55,63",
"    </a>",
"    ], alpha-fetoprotein testing alone should",
"    <strong>",
"     not",
"    </strong>",
"    be used unless ultrasound is unavailable [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Computed tomographic scanning is",
"    <strong>",
"     not",
"    </strong>",
"    recommended for surveillance because of a high false-positive rate and the risks associated with cumulative radiation exposure from repeated scans [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/60\">",
"     60",
"    </a>",
"    ]. It is also not cost-effective [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/65\">",
"     65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=see_link\">",
"     \"Radiation-related risks of imaging studies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     IMPACT OF SURVEILLANCE ON DISEASE-SPECIFIC MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have examined the effects of surveillance for hepatocellular carcinoma (HCC) in patients with liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/66-80\">",
"     66-80",
"    </a>",
"    ]. Many observational studies of surveillance find that HCC is diagnosed at an earlier stage (stage migration) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/72,77,81-84\">",
"     72,77,81-84",
"    </a>",
"    ], and uncontrolled studies have suggested that survival is improved [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/71,85\">",
"     71,85",
"    </a>",
"    ]. However, few of these studies accounted for lead-time bias, which could lead to the false impression that survival is improved.",
"   </p>",
"   <p>",
"    However, a randomized trial also showed a benefit for surveillance and provides the most definitive support for surveillance in patients with chronic hepatitis B virus (HBV) infection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/78\">",
"     78",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The study included 19,200 Chinese patients ages 35 to 59 years with chronic HBV who were randomly assigned to surveillance (with an alpha-fetoprotein level and ultrasound every six months) or observation for up to 20 years. Mortality due to HCC was significantly lower after five years in the screened group (83 versus 132 per 100,000, mortality rate ratio of 0.63, 95% CI 0.41-0.98). The mortality benefit was attributed mainly to detection of tumors in relatively early stages.",
"      <br/>",
"      <br/>",
"      The main form of therapy for HCC offered in this trial was resection. Because HCC may develop in chronic HBV in the absence of cirrhosis, many patients may have had preserved liver function and thus been able to tolerate resection. Different results might have been obtained in a population of patients with other forms of liver disease (such as hepatitis C) in which HCC typically develops only in patients who have progressed to cirrhosis. Such patients may not be able to tolerate resection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12858?source=see_link\">",
"       \"Assessing surgical risk in patients with liver disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31530?source=see_link&amp;anchor=H9#H9\">",
"       \"Clinical manifestations and natural history of chronic hepatitis C virus infection\", section on 'Hepatocellular carcinoma'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, some have questioned the methodology of the study and the generalizability of its results [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/86\">",
"     86",
"    </a>",
"    ]. Methodologic problems include the fact that patients who were randomized to surveillance but then declined to undergo testing were excluded from the analysis. In addition, the study only reports mortality related to HCC, and not all-cause mortality. Whether the results of the study are generalizable is also not clear. The patients in the study were primarily HBsAg positive patients, and the authors did not report how many had cirrhosis. As noted above, patients without cirrhosis may better tolerate treatment for HCC than those with cirrhosis. In addition, small HCCs may be harder to detect in patients with cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/87\">",
"     87",
"    </a>",
"    ]. It is therefore important to know the proportion of the study participants with cirrhosis in order to interpret the results. Since the majority of Western patients undergoing HCC surveillance have cirrhosis due to causes other than HBV, it is not clear that the results of surveillance in a Western population will be as good as those seen in the Chinese study.",
"   </p>",
"   <p>",
"    Unfortunately, there are no comparable studies for other forms of chronic liver disease. Despite the uncertain benefit in patients who do not have chronic HBV, surveillance is recommended by the AASLD for patients with a number of different liver diseases that cause cirrhosis because of an established increased risk of HCC [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/2,88\">",
"     2,88",
"    </a>",
"    ]. Additional studies are needed to determine whether the results seen in a group of patients primarily with chronic HBV (with or without cirrhosis) are reproducible in patients with cirrhosis due to various causes. (See",
"    <a class=\"local\" href=\"#H61643912\">",
"     'Patients who require surveillance'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PREDICTING RISK IN INDIVIDUAL PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surveillance efforts could be improved if the risk of hepatocellular carcinoma (HCC) could be predicted with sufficient accuracy in individual patients. A number of risk factors for HCC have been identified and in some cases have been incorporated into risk scores, although many have not been extensively-validated [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/19,42,89-100\">",
"     19,42,89-100",
"    </a>",
"    ]. One study proposed a nomogram that predicted individual risk in patients with chronic hepatitis B virus (HBV, genotypes B and C) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/101\">",
"     101",
"    </a>",
"    ]. This nomogram has now been validated [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/100\">",
"     100",
"    </a>",
"    ] and a score developed using the data. The major drawback is that the score was developed in Asia and has been validated in Asia, where more patients are infected with hepatitis B genotypes B and C. Although the relationship probably also holds for other genotypes, the cut-points have not been determined, so this score is only useful in an Asian population. However, since this accounts for the majority of hepatitis B carriers in North America, the score has wide applicability. Another study developed a 17-point risk score that accurately predicted risk of HCC in patients with HBV [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HBV genotype is important in assessing risk for HCC. The prevalence of specific genotypes varies geographically [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/102-104\">",
"     102-104",
"    </a>",
"    ]. Genotype A is found mainly in Northern Europe, North America, India, and Africa, whereas genotypes B and C are prevalent in Asia, and genotype D is more common in Southern Europe, the Middle East, and India. Patients with genotype C are at higher risk for HCC than patients with genotype B, and patients with genotype D are at higher risk than patients with genotype A [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/98,105,106\">",
"     98,105,106",
"    </a>",
"    ]. Generally, a patient's country of origin can be used as a surrogate for his or her genotype. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/52/36681?source=see_link\">",
"     \"Clinical significance of hepatitis B virus genotypes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of HCC in an individual patient may progress with advancing liver disease, but it may not be practical to monitor patients for a change in risk and modify surveillance strategies accordingly. Thus, surveillance recommendations are based mainly upon an overall assessment of the expected incidence of HCC in specific populations of patients with liver disease. (See",
"    <a class=\"local\" href=\"#H61643912\">",
"     'Patients who require surveillance'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H61645279\">",
"     'Surveillance methods'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     COST-EFFECTIVENESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have evaluated the cost-effectiveness of surveillance for hepatocellular carcinoma (HCC). While the models focused on different populations and interventions, most found that some form of surveillance was cost-effective but that the cost-effectiveness depended mainly upon the expected incidence of HCC [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/107-110\">",
"     107-110",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Interventions are often considered to be cost-effective if they cost less than $50,000 per year of life gained [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/111\">",
"     111",
"    </a>",
"    ]. As a general rule, surveillance appears to be cost-effective in patients with cirrhosis who have an expected annual incidence of HCC exceeding 1.5 percent per year. The incidence of HCC in various forms of cirrhotic liver disease ranges from 3 to 8 percent, making surveillance cost-effective for many patients with cirrhosis (",
"    <a class=\"graphic graphic_table graphicRef68371 \" href=\"UTD.htm?37/36/38476\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/33,39,79,95,109,112-117\">",
"     33,39,79,95,109,112-117",
"    </a>",
"    ]. For patients with hepatitis B, surveillance appears to be cost-effective once the incidence of HCC exceeds 0.2 percent per year. (See",
"    <a class=\"local\" href=\"#H61643912\">",
"     'Patients who require surveillance'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EVALUATION OF NODULES DISCOVERED ON ULTRASOUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal evaluation of a liver nodule found on ultrasound depends upon the lesion size [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/2\">",
"     2",
"    </a>",
"    ]. We agree with the following approach (",
"    <a class=\"graphic graphic_algorithm graphicRef76105 \" href=\"UTD.htm?22/51/23358\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/99\">",
"     99",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nodules smaller than 1 cm are usually",
"      <strong>",
"       not",
"      </strong>",
"      hepatocellular carcinoma (HCC). Such lesions should be monitored at short intervals (eg, every three months) with ultrasound until they are proven to be stable or disappear (up to 24 months).",
"     </li>",
"     <li>",
"      Nodules larger than 1 cm should be evaluated with either a four-phase computed tomographic (CT) scan or dynamic contrast-enhanced magnetic resonance imaging (MRI). The diagnosis is confirmed if the appearance is typical for HCC (arterial hypervascularity and venous phase washout). If the appearance is not typical, the alternate procedure should be performed (eg, CT scan if the first test was an MRI). Again, the diagnosis is confirmed if the appearance is typical for HCC; if not, a biopsy is required. This approach has appeared to be effective in validation studies [",
"      <a class=\"abstract\" href=\"UTD.htm?28/6/28778/abstract/118,119\">",
"       118,119",
"      </a>",
"      ]. However, it is important to note that a negative biopsy does not exclude HCC, and further monitoring (eg, ultrasound at three to six month intervals) is required. If the lesion enlarges during follow-up but remains atypical for HCC, a repeat biopsy is recommended. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34986?source=see_link&amp;anchor=H11#H11\">",
"       \"Clinical features and diagnosis of primary hepatocellular carcinoma\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hepatocellular carcinoma (HCC) is associated with, among other things, hepatitis B virus (HBV) infection, cirrhosis (eg, due to hepatitis C virus [HCV] infection), and exposure to environmental toxins. Attempts to prevent HCC should focus on preventing infection with HBV and HCV, treating patients with viral hepatitis who are candidates for treatment, and attempting to prevent the development of cirrhosis in patients with liver disease. (See",
"      <a class=\"local\" href=\"#H23128081\">",
"       'Prevention of hepatocellular carcinoma'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=see_link&amp;anchor=H5#H5\">",
"       \"Epidemiology and etiologic associations of hepatocellular carcinoma\", section on 'Risk factors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Our approach to surveillance for HCC is consistent with guidelines issued by the American Association for the Study of Liver Diseases.",
"     </li>",
"     <li>",
"      We recommend that patients with chronic hepatitis B virus (HBV) infection who are at increased risk for HCC undergo surveillance (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Patients with chronic HBV who are at increased risk for HCC include (see",
"      <a class=\"local\" href=\"#H61643920\">",
"       'Hepatitis B carriers'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Impact of surveillance on disease-specific mortality'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Asian men over the age of 40 years",
"     </li>",
"     <li>",
"      Asian women over the age of 50 years",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Africans/North",
"      </span>",
"      American blacks",
"     </li>",
"     <li>",
"      Patients with a family history of HCC",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In Caucasian patients with a high viral load and active inflammation for several years, we suggest starting surveillance at the age of 40 years for men and 50 years for women (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Such patients are likely at increased risk for HCC, although it is not certain at what age the risk starts to become significant. (See",
"      <a class=\"local\" href=\"#H61643944\">",
"       'Caucasians'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that all patients with cirrhosis, regardless of etiology, undergo surveillance for HCC (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). However, this recommendation is based upon a benefit of surveillance demonstrated in a randomized trial of patients with chronic HBV, with or without cirrhosis. Whether similar results will be seen in patients with cirrhosis due to various causes is not known, and future studies may alter this suggestion. (See",
"      <a class=\"local\" href=\"#H61643928\">",
"       'Patients with cirrhosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that surveillance be carried out with ultrasonography rather than combined ultrasonography and serum alpha-fetoprotein (AFP) determination (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The combined use of AFP and ultrasonography increases detection rates but also increases costs and false-positive rates. (See",
"      <a class=\"local\" href=\"#H61645279\">",
"       'Surveillance methods'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that surveillance be performed with ultrasonography every six months rather than annually (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H61645279\">",
"       'Surveillance methods'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with abnormal results on surveillance should undergo additional investigation depending upon the clinical setting and the size of the lesion (",
"      <a class=\"graphic graphic_algorithm graphicRef76105 \" href=\"UTD.htm?22/51/23358\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Evaluation of nodules discovered on ultrasound'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34986?source=see_link\">",
"       \"Clinical features and diagnosis of primary hepatocellular carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1323271164\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author and UpToDate would like to thank Dr. Morris Sherman, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/1\">",
"      Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379:1245.",
"     </a>",
"    </li>",
"    <li>",
"     AASLD Practice Guideline, Management of Hepatocellular Carcinoma: An Update. Bruix, J, Sherman, M. file://www.aasld.org/practiceguidelines/Documents/Bookmarked%20Practice%20Guidelines/HCCUpdate2010.pdf  (Accessed on August 02, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/3\">",
"      Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005; 42:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/4\">",
"      Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/5\">",
"      Chang MH, You SL, Chen CJ, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 2009; 101:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/6\">",
"      Sung JJ, Tsoi KK, Wong VW, et al. Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008; 28:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/7\">",
"      Takimoto M, Ohkoshi S, Ichida T, et al. Interferon inhibits progression of liver fibrosis and reduces the risk of hepatocarcinogenesis in patients with chronic hepatitis C: a retrospective multicenter analysis of 652 patients. Dig Dis Sci 2002; 47:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/8\">",
"      Omata M, Yoshida H. Resolution of liver cirrhosis and prevention of hepatocellular carcinoma by interferon therapy against chronic hepatitis C. Scand J Gastroenterol Suppl 2003; :47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/9\">",
"      Singal AK, Singh A, Jaganmohan S, et al. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 2010; 8:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/10\">",
"      Ogawa E, Furusyo N, Kajiwara E, et al. Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study. J Hepatol 2013; 58:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/11\">",
"      Morgan RL, Baack B, Smith BD, et al. Eradication of Hepatitis C Virus Infection and the Development of Hepatocellular Carcinoma: A Meta-analysis of Observational Studies. Ann Intern Med 2013; 158:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/12\">",
"      Kew MC. Prevention of hepatocellular carcinoma. Ann Hepatol 2010; 9:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/13\">",
"      Sahasrabuddhe VV, Gunja MZ, Graubard BI, et al. Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma. J Natl Cancer Inst 2012; 104:1808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/14\">",
"      Kew MC. Epidemiology of chronic hepatitis B virus infection, hepatocellular carcinoma, and hepatitis B virus-induced hepatocellular carcinoma. Pathol Biol (Paris) 2010; 58:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/15\">",
"      Sakuma K, Saitoh N, Kasai M, et al. Relative risks of death due to liver disease among Japanese male adults having various statuses for hepatitis B s and e antigen/antibody in serum: a prospective study. Hepatology 1988; 8:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/16\">",
"      Beasly R. Hepatitis B virus as the etiologic agent in hepatocellular carcinoma. Hepatology 1982; 2:21S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/17\">",
"      Kew MC, Marcus R, Geddes EW. Some characteristics of Mozambican Shangaans with primary hepatocellular cancer. S Afr Med J 1977; 51:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/18\">",
"      Kew MC, Macerollo P. Effect of age on the etiologic role of the hepatitis B virus in hepatocellular carcinoma in blacks. Gastroenterology 1988; 94:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/19\">",
"      Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/20\">",
"      Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/21\">",
"      Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000--summary of a workshop. Gastroenterology 2001; 120:1828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/22\">",
"      Manno M, Camm&agrave; C, Schepis F, et al. Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years. Gastroenterology 2004; 127:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/23\">",
"      de Franchis R, Meucci G, Vecchi M, et al. The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med 1993; 118:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/24\">",
"      Bellentani S DMG, Miglioli L, Croce L, et al. Natural history of HBV infection: A nine years follow-up of the Dionysius cohort. J Hepatol 2002; 36:228S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/25\">",
"      Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988; 61:1942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/26\">",
"      Yu MW, Chang HC, Liaw YF, et al. Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. J Natl Cancer Inst 2000; 92:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/27\">",
"      Lin SM, Sheen IS, Chien RN, et al. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999; 29:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/28\">",
"      Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/29\">",
"      Yuen MF, Hui CK, Cheng CC, et al. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 2001; 34:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/30\">",
"      Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/31\">",
"      Papatheodoridis GV, Manolakopoulos S, Touloumi G, et al. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study. Gut 2011; 60:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/32\">",
"      Elmberg M, Hultcrantz R, Ekbom A, et al. Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology 2003; 125:1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/33\">",
"      Hsing AW, McLaughlin JK, Olsen JH, et al. Cancer risk following primary hemochromatosis: a population-based cohort study in Denmark. Int J Cancer 1995; 60:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/34\">",
"      Sch&ouml;niger-Hekele M, M&uuml;ller C, Kutilek M, et al. Hepatocellular carcinoma in Austria: aetiological and clinical characteristics at presentation. Eur J Gastroenterol Hepatol 2000; 12:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/35\">",
"      Fracanzani AL, Conte D, Fraquelli M, et al. Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. Hepatology 2001; 33:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/36\">",
"      Fattovich G, Giustina G, Sanchez-Tapias J, et al. Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP). Am J Gastroenterol 1998; 93:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/37\">",
"      White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol 2012; 10:1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/38\">",
"      Yeoman AD, Al-Chalabi T, Karani JB, et al. Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: Implications for follow-up and screening. Hepatology 2008; 48:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/39\">",
"      Hassan MM, Hwang LY, Hatten CJ, et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002; 36:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/40\">",
"      Donato F, Tagger A, Gelatti U, et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002; 155:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/41\">",
"      Jepsen P, Ott P, Andersen PK, et al. Risk for hepatocellular carcinoma in patients with alcoholic cirrhosis: a Danish nationwide cohort study. Ann Intern Med 2012; 156:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/42\">",
"      Vel&aacute;zquez RF, Rodr&iacute;guez M, Navascu&eacute;s CA, et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 2003; 37:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/43\">",
"      Serra MA, Escudero A, Rodr&iacute;guez F, et al. Effect of hepatitis C virus infection and abstinence from alcohol on survival in patients with alcoholic cirrhosis. J Clin Gastroenterol 2003; 36:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/44\">",
"      Henrion J, Libon E, De Maeght S, et al. [Screening for hepatocarcinoma in a cohort with cirrhosis mainly of alcoholic origin]. Gastroenterol Clin Biol 2003; 27:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/45\">",
"      Miyakawa H, Izumi N, Marumo F, Sato C. Roles of alcohol, hepatitis virus infection, and gender in the development of hepatocellular carcinoma in patients with liver cirrhosis. Alcohol Clin Exp Res 1996; 20:91A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/46\">",
"      Uetake S, Yamauchi M, Itoh S, et al. Analysis of risk factors for hepatocellular carcinoma in patients with HBs antigen- and anti-HCV antibody-negative alcoholic cirrhosis: clinical significance of prior hepatitis B virus infection. Alcohol Clin Exp Res 2003; 27:47S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/47\">",
"      Mancebo A, Gonz&aacute;lez-Di&eacute;guez ML, Cadah&iacute;a V, et al. Annual incidence of hepatocellular carcinoma among patients with alcoholic cirrhosis and identification of risk groups. Clin Gastroenterol Hepatol 2013; 11:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/48\">",
"      Davila JA, Henderson L, Kramer JR, et al. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med 2011; 154:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/49\">",
"      El-Serag HB, Kramer JR, Chen GJ, et al. Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV-infected patients in the USA. Gut 2011; 60:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/50\">",
"      Davila JA, Morgan RO, Richardson PA, et al. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology 2010; 52:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/51\">",
"      Giordano TP, Kramer JR, Souchek J, et al. Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: a cohort study, 1992-2001. Arch Intern Med 2004; 164:2349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/52\">",
"      Puoti M, Bruno R, Soriano V, et al. Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS 2004; 18:2285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/53\">",
"      Br&auml;u N, Fox RK, Xiao P, et al. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol 2007; 47:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/54\">",
"      Garc&iacute;a-Samaniego J, Rodr&iacute;guez M, Berenguer J, et al. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol 2001; 96:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/55\">",
"      Singal A, Volk ML, Waljee A, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009; 30:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/56\">",
"      Trevisani F, De Notariis S, Rapaccini G, et al. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol 2002; 97:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/57\">",
"      Santagostino E, Colombo M, Rivi M, et al. A 6-month versus a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus. Blood 2003; 102:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/58\">",
"      Ebara M, Ohto M, Shinagawa T, et al. Natural history of minute hepatocellular carcinoma smaller than three centimeters complicating cirrhosis. A study in 22 patients. Gastroenterology 1986; 90:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/59\">",
"      Sheu JC, Sung JL, Chen DS, et al. Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology 1985; 89:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/60\">",
"      Miller WJ, Baron RL, Dodd GD 3rd, Federle MP. Malignancies in patients with cirrhosis: CT sensitivity and specificity in 200 consecutive transplant patients. Radiology 1994; 193:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/61\">",
"      Kim DK, Ahn SH, Palk YH, et al. Semiannual survillance for hepatocellular carcinoma improved patient survival compared to annual survillance (korean experience). Hepatology 2007; 46:403A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/62\">",
"      Trinchet JC, Chaffaut C, Bourcier V, et al. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology 2011; 54:1987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/63\">",
"      Lok AS, Sterling RK, Everhart JE, et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 2010; 138:493.",
"     </a>",
"    </li>",
"    <li>",
"     Lok, ASF, McMahon, BJ. Chronic hepatitis B: Update 2009 file://publish.aasld.org/Pages/Default.aspx (Accessed on September 08, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/65\">",
"      Andersson KL, Salomon JA, Goldie SJ, Chung RT. Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2008; 6:1418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/66\">",
"      Saab S, Ly D, Nieto J, et al. Hepatocellular carcinoma screening in patients waiting for liver transplantation: a decision analytic model. Liver Transpl 2003; 9:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/67\">",
"      Tradati F, Colombo M, Mannucci PM, et al. A prospective multicenter study of hepatocellular carcinoma in italian hemophiliacs with chronic hepatitis C. The Study Group of the Association of Italian Hemophilia Centers. Blood 1998; 91:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/68\">",
"      Sherman M, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995; 22:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/69\">",
"      McMahon BJ, Alberts SR, Wainwright RB, et al. Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers. Arch Intern Med 1990; 150:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/70\">",
"      Pateron D, Ganne N, Trinchet JC, et al. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol 1994; 20:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/71\">",
"      Bolondi L, Sofia S, Siringo S, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001; 48:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/72\">",
"      McMahon BJ, Bulkow L, Harpster A, et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology 2000; 32:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/73\">",
"      Oka H, Tamori A, Kuroki T, et al. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 1994; 19:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/74\">",
"      Patel D, Terrault NA, Yao FY, et al. Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 2005; 3:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/75\">",
"      De Masi S, Tosti ME, Mele A. Screening for hepatocellular carcinoma. Dig Liver Dis 2005; 37:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/76\">",
"      Tong MJ, Blatt LM, Kao VW. Surveillance for hepatocellular carcinoma in patients with chronic viral hepatitis in the United States of America. J Gastroenterol Hepatol 2001; 16:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/77\">",
"      Leykum LK, El-Serag HB, Cornell J, Papadopoulos KP. Screening for hepatocellular carcinoma among veterans with hepatitis C on disease stage, treatment received, and survival. Clin Gastroenterol Hepatol 2007; 5:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/78\">",
"      Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/79\">",
"      Wong GL, Wong VW, Tan GM, et al. Surveillance programme for hepatocellular carcinoma improves the survival of patients with chronic viral hepatitis. Liver Int 2008; 28:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/80\">",
"      Santi V, Trevisani F, Gramenzi A, et al. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol 2010; 53:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/81\">",
"      Stravitz RT, Heuman DM, Chand N, et al. Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med 2008; 121:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/82\">",
"      Wong LL, Limm WM, Severino R, Wong LM. Improved survival with screening for hepatocellular carcinoma. Liver Transpl 2000; 6:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/83\">",
"      Oka H, Kurioka N, Kim K, et al. Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. Hepatology 1990; 12:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/84\">",
"      Wun YT, Dickinson JA. Alpha-fetoprotein and/or liver ultrasonography for liver cancer screening in patients with chronic hepatitis B. Cochrane Database Syst Rev 2003; :CD002799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/85\">",
"      Sangiovanni A, Del Ninno E, Fasani P, et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 2004; 126:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/86\">",
"      Lederle FA, Pocha C. Screening for liver cancer: the rush to judgment. Ann Intern Med 2012; 156:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/87\">",
"      Teefey SA, Hildeboldt CC, Dehdashti F, et al. Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET. Radiology 2003; 226:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/88\">",
"      Lindor KD, Gershwin ME, Poupon R, et al. Primary biliary cirrhosis. Hepatology 2009; 50:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/89\">",
"      Serfaty L, Auma&icirc;tre H, Chazouill&egrave;res O, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998; 27:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/90\">",
"      Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/91\">",
"      Bonis PA, Tong MJ, Blatt LM, et al. A predictive model for the development of hepatocellular carcinoma, liver failure, or liver transplantation for patients presenting to clinic with chronic hepatitis C. Am J Gastroenterol 1999; 94:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/92\">",
"      de Jongh FE, Janssen HL, de Man RA, et al. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992; 103:1630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/93\">",
"      Realdi G, Fattovich G, Hadziyannis S, et al. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 1994; 21:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/94\">",
"      Di Marco V, Lo Iacono O, Camm&agrave; C, et al. The long-term course of chronic hepatitis B. Hepatology 1999; 30:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/95\">",
"      Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/96\">",
"      Yu MW, Yeh SH, Chen PJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 2005; 97:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/97\">",
"      Chen CJ, Yang HI, Iloeje UH, et al. A risk function nomogram for predicting hcc in patients with chronic hepatitis B: The REVEAL-HBV study. J Hepatol 2007; 46(Suppl 1):S180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/98\">",
"      Yuen MF, Tanaka Y, Fong DY, et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol 2009; 50:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/99\">",
"      Lok AS, Seeff LB, Morgan TR, et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009; 136:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/100\">",
"      Yang HI, Yuen MF, Chan HL, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol 2011; 12:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/101\">",
"      Yang HI, Sherman M, Su J, et al. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol 2010; 28:2437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/102\">",
"      Stuyver L, De Gendt S, Van Geyt C, et al. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J Gen Virol 2000; 81:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/103\">",
"      Norder H, Hammas B, Lee SD, et al. Genetic relatedness of hepatitis B viral strains of diverse geographical origin and natural variations in the primary structure of the surface antigen. J Gen Virol 1993; 74 ( Pt 7):1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/104\">",
"      Lindh M, Andersson AS, Gusdal A. Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus--large-scale analysis using a new genotyping method. J Infect Dis 1997; 175:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/105\">",
"      S&aacute;nchez-Tapias JM, Costa J, Mas A, et al. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology 2002; 123:1848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/106\">",
"      Yang HI, Yeh SH, Chen PJ, et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2008; 100:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/107\">",
"      Arguedas MR, Chen VK, Eloubeidi MA, Fallon MB. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol 2003; 98:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/108\">",
"      Lin OS, Keeffe EB, Sanders GD, Owens DK. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment Pharmacol Ther 2004; 19:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/109\">",
"      Sarasin FP, Giostra E, Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am J Med 1996; 101:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/110\">",
"      Thompson Coon J, Rogers G, Hewson P, et al. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis. Health Technol Assess 2007; 11:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/111\">",
"      Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992; 146:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/112\">",
"      Beasley RP. Hepatitis B virus as the etiologic agent in hepatocellular carcinoma. Hepatology 1982; 2(Suppl):21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/113\">",
"      Yu MW, Chang HC, Chen PJ, et al. Increased risk for hepatitis B-related liver cirrhosis in relatives of patients with hepatocellular carcinoma in northern Taiwan. Int J Epidemiol 2002; 31:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/114\">",
"      Degos F, Christidis C, Ganne-Carrie N, et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 2000; 47:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/115\">",
"      Kobayashi M, Ikeda K, Hosaka T, et al. Natural history of compensated cirrhosis in the Child-Pugh class A compared between 490 patients with hepatitis C and 167 with B virus infections. J Med Virol 2006; 78:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/116\">",
"      Benvegn&ugrave; L, Gios M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 2004; 53:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/117\">",
"      Elzouki AN, Eriksson S. Risk of hepatobiliary disease in adults with severe alpha 1-antitrypsin deficiency (PiZZ): is chronic viral hepatitis B or C an additional risk factor for cirrhosis and hepatocellular carcinoma? Eur J Gastroenterol Hepatol 1996; 8:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/118\">",
"      Khalili K, Jang HJ, Haider MA, et al. Implementation of AASLD hepatocellular carcinoma practice guideline in North America: two years of experience. J Hepatol 2011; 4:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/6/28778/abstract/119\">",
"      Sangiovanni A, Manini MA, Iavarone M, et al. The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut 2010; 59:638.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3583 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-58.240.98.179-1360C6F796-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_6_28778=[""].join("\n");
var outline_f28_6_28778=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23128081\">",
"      PREVENTION OF HEPATOCELLULAR CARCINOMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23128089\">",
"      HCC related to hepatitis B virus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H162498317\">",
"      HCC related cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23128130\">",
"      - HCC related to hepatitis C virus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H162498331\">",
"      - Other causes of cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23128383\">",
"      HCC related to environmental factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H162498503\">",
"      Diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H112724546\">",
"      Chemoprevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H61643912\">",
"      PATIENTS WHO REQUIRE SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H61643920\">",
"      Hepatitis B carriers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H61643936\">",
"      - Asians",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H61644755\">",
"      - Africans/patients of African descent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H61643944\">",
"      - Caucasians",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H61643968\">",
"      - HBV with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H61643960\">",
"      - Patients with a family history of HCC",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H61644540\">",
"      - Patients receiving treatment for HBV or who clear the virus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H61643928\">",
"      Patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H61644279\">",
"      Co-infection with HIV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H61644067\">",
"      PATIENTS WHO DO NOT REQUIRE SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H61645279\">",
"      SURVEILLANCE METHODS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      IMPACT OF SURVEILLANCE ON DISEASE-SPECIFIC MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PREDICTING RISK IN INDIVIDUAL PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      COST-EFFECTIVENESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EVALUATION OF NODULES DISCOVERED ON ULTRASOUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1323271164\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3583\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3583|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?22/51/23358\" title=\"algorithm 1\">",
"      Diagnostic algorithm for HCC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3583|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/36/38476\" title=\"table 1\">",
"      HCC surveillance recommendations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12858?source=related_link\">",
"      Assessing surgical risk in patients with liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34986?source=related_link\">",
"      Clinical features and diagnosis of primary hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31530?source=related_link\">",
"      Clinical manifestations and natural history of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/52/36681?source=related_link\">",
"      Clinical significance of hepatitis B virus genotypes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43701?source=related_link\">",
"      Congestive hepatopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23194?source=related_link\">",
"      Diagnostic approach to the patient with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=related_link\">",
"      Epidemiology and etiologic associations of hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18136?source=related_link\">",
"      Extrapulmonary manifestations of alpha-1 antitrypsin deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30202?source=related_link\">",
"      HIV infection and malignancy: Management considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31690?source=related_link\">",
"      Hepatitis B virus vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23416?source=related_link\">",
"      Management of healthcare workers exposed to hepatitis B virus or hepatitis C virus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/49/10007?source=related_link\">",
"      Management of pain in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/20/23882?source=related_link\">",
"      Natural history and management of nonalcoholic fatty liver disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=related_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/45/43735?source=related_link\">",
"      Overview of the management of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24378?source=related_link\">",
"      Overview of the management of hepatitis B and case examples",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/19/34105?source=related_link\">",
"      Overview of the treatment of primary biliary cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/3/43063?source=related_link\">",
"      Overview of treatment approaches for hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/31/26106?source=related_link\">",
"      Procedures used for blood donor screening: Protection of potential blood donors and recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22104?source=related_link\">",
"      Prognosis and management of alcoholic fatty liver disease and alcoholic cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=related_link\">",
"      Radiation-related risks of imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41849?source=related_link\">",
"      Screening for and diagnosis of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42279?source=related_link\">",
"      Serologic diagnosis of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/24/25992?source=related_link\">",
"      Staging and prognostic factors in hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/11/23737?source=related_link\">",
"      Treatment of Wilson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/7/40058?source=related_link\">",
"      Treatment of autoimmune hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18952?source=related_link\">",
"      Treatment of hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41097?source=related_link\">",
"      Treatment of primary sclerosing cholangitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_6_28779="Digitalis kinetics";
var content_f28_6_28779=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F60113&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F60113&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pharmacokinetic comparison of digoxin and digitoxin",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Digoxin",
"       </td>",
"       <td class=\"subtitle1\">",
"        Digitoxin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bioavailability (percent)",
"       </td>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        90",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plasma binding (percent)",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        95",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        VD (L/kg)",
"       </td>",
"       <td>",
"        5.6 L/kg",
"       </td>",
"       <td>",
"        0.56 L/kg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Half life (hours)*",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        161",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Desired therapeutic concentrations",
"       </td>",
"       <td>",
"        1 ng/mL",
"       </td>",
"       <td>",
"        10 ng/mL",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Assumes normal renal function.",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        Lapostolle F, Baud FJ, Borron SW, M&eacute;garbane B. Digitalis glycosides. In: Critical Care Toxicology: Diagnosis and Management of the Critically Poisoned Patient, Brent J, Wallace KL, Burkhart K, et al (Eds), Elsevier Mosby, Philadelphia 2004. p.393.",
"       </li>",
"       <li>",
"        Holford NHG. Pharmacokinetics and pharmacodynamics: Rational dosing and the time course of drug action. In: Basic and Clinical Pharmacology, 8th ed, Katzung BG (Ed), McGraw Hill, New York 2001. p.35.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_6_28779=[""].join("\n");
var outline_f28_6_28779=null;
var title_f28_6_28780="Breast RT occult prim BC";
var content_f28_6_28780=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F65411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F65411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Results of whole breast irradiation for node-positive occult primary breast cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Author, year",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of patients",
"       </td>",
"       <td class=\"subtitle1\">",
"        Median follow-up",
"       </td>",
"       <td class=\"subtitle1\">",
"        Breast treatment",
"       </td>",
"       <td class=\"subtitle1\">",
"        Breast-only control, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Survival",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vilcoq, J; 1982",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        &gt;5 yr",
"       </td>",
"       <td>",
"        XRT",
"       </td>",
"       <td>",
"        73",
"       </td>",
"       <td>",
"        10/11 (5 year)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Ellerbroek, N; 1990",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td rowspan=\"3\">",
"        133 months",
"       </td>",
"       <td>",
"        XRT",
"       </td>",
"       <td>",
"        83",
"       </td>",
"       <td>",
"        - *",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        43",
"       </td>",
"       <td>",
"        - *",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        Mastectomy",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"       <td>",
"        - *",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Foroudi, F; 2000",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        73 months",
"       </td>",
"       <td>",
"        XRT",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        11/12 (5 year)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Vlastos, G; 2001",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td rowspan=\"2\">",
"        7 years",
"       </td>",
"       <td>",
"        XRT",
"       </td>",
"       <td>",
"        92",
"       </td>",
"       <td>",
"        79 percent (5 year)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        Mastectomy",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        75 percent (5 year)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medina-Franco, H; 2002",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        48 months",
"       </td>",
"       <td>",
"        XRT",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        100 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Varadarajan, R; 2006",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        57 months",
"       </td>",
"       <td>",
"        XRT",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        100 percent",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     XRT: whole breast radiation therapy; N/A: not available.",
"     <br>",
"      * Survival described as \"no different\" when patients undergoing mastectomy were compared to those who did not undergo mastectomy. Actuarial survival for entire group was 72 percent at five years and 65 percent at 10 years.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_6_28780=[""].join("\n");
var outline_f28_6_28780=null;
var title_f28_6_28781="Rx recs antiemetic IV chemo";
var content_f28_6_28781=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F72865&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F72865&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommended antiemetic treatment for single-day, intravenously administered chemotherapy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Risk category",
"       </td>",
"       <td class=\"subtitle1\">",
"        Agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dosing on day of chemotherapy",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dosing on subsequent days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"12\">",
"        <strong>",
"         High emetic risk",
"        </strong>",
"        *",
"        <br/>",
"        (&gt;90 percent)",
"       </td>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        NK",
"        <sub>",
"         1",
"        </sub>",
"        antagonist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Aprepitant",
"       </td>",
"       <td>",
"        125 mg oral",
"       </td>",
"       <td>",
"        80 mg oral daily; days 2 and 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fosaprepitant",
"       </td>",
"       <td>",
"        150 mg IV",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        PLUS 5-HT",
"        <sub>",
"         3",
"        </sub>",
"        antagonist (one of following)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Granisetron",
"       </td>",
"       <td>",
"        2 mg oral; 1 mg or 0.01 mg/kg IV",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ondansetron",
"       </td>",
"       <td>",
"        8 mg oral twice daily; 8 mg or 0.15 mg/kg IV",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Palonosetron",
"       </td>",
"       <td>",
"        0.5 mg oral; 0.25 mg IV",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dolasetron",
"       </td>",
"       <td>",
"        100 mg oral ONLY",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tropisetron",
"       </td>",
"       <td>",
"        5 mg oral; 5 mg IV",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ramosetron",
"       </td>",
"       <td>",
"        0.3 mg IV",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        PLUS glucocorticoid",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dexamethasone",
"       </td>",
"       <td>",
"        12 mg oral or IV",
"       </td>",
"       <td>",
"        8 mg oral or IV daily; days 2-3 or days 2-4",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        <strong>",
"         Moderate emetic risk",
"        </strong>",
"        <sup>",
"         &Delta;",
"        </sup>",
"        <br/>",
"        (31-90 percent)",
"       </td>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        5-HT",
"        <sub>",
"         3",
"        </sub>",
"        antagonist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Palonosetron",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        0.5 mg oral; 0.25 mg IV",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        PLUS glucocorticoid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dexamethasone",
"       </td>",
"       <td>",
"        8 mg oral or IV",
"       </td>",
"       <td>",
"        8 mg oral or IV daily; days 2 and 3",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        <strong>",
"         Low emetic risk",
"        </strong>",
"        <br/>",
"        (10-30 percent)",
"       </td>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Glucocorticoid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dexamethasone",
"       </td>",
"       <td>",
"        8 mg oral or IV",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Minimal emetic risk",
"        </strong>",
"        <br/>",
"        (&lt;10 percent)",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    NOTE. For patients receiving multiday chemotherapy, clinicians must first determine the emetic risk of the agent(s) included in the regimen. Patients should receive the agent of the highest therapeutic index daily during chemotherapy and for 2 days thereafter. Patients can also be offered the granisetron transdermal patch that delivers therapy over multiple days rather than taking a serotonin antagonist daily.",
"    <div class=\"footnotes\">",
"     NK",
"     <sub>",
"      1",
"     </sub>",
"     : neurokinin 1; IV: intravenous; 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     : 5-hydroxytryptamine-3.",
"     <br>",
"      * Includes combination of an anthracycline and cyclophosphamide.",
"      <br>",
"       <sup>",
"        <font class=\"bullet\">",
"         &bull;",
"        </font>",
"       </sup>",
"       The dexamethasone dose is for patients who are receiving the recommended three-drug regimen for highly emetic chemotherapy. If patients do not receive aprepitant, the dexamethasone dose should be adjusted to 20 mg on day 1 and 16 mg on days 2 to 4.",
"       <br>",
"        <sup>",
"         &Delta;",
"        </sup>",
"        Clinicians who choose to use an NK",
"        <sub>",
"         1",
"        </sub>",
"        antagonist should follow high emetic risk chemotherapy dosing. Importantly, corticosteroid is only given on day 1; dexamethasone dose is lower (12 mg).",
"        <br>",
"         <sup>",
"          &loz;",
"         </sup>",
"         If palonosetron is not available, substitute a first-generation 5HT-3 antagonist, preferably granisetron or ondansetron.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     From: Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2011. PMID:21947834. Adapted and reprinted with permission. Copyright &copy; 2011 American Society of Clinical Oncology. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_6_28781=[""].join("\n");
var outline_f28_6_28781=null;
var title_f28_6_28782="Contents: Thoracic surgery";
var content_f28_6_28782=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?5/48/5902\">",
"       General Surgery",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Thoracic surgery",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Thoracic surgery",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Lung cancer",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/45/9946\">",
"           Bronchioloalveolar carcinoma, including adenocarcinoma in situ",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/26/20900\">",
"           Cryoablation of lung tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/31/44537\">",
"           Diagnostic evaluation and management of the solitary pulmonary nodule",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/5/1114\">",
"           Management of stage I and stage II non-small cell lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/36/39498\">",
"           Management of stage III non-small cell lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/2/15400\">",
"           Preoperative evaluation for lung resection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/42/25255\">",
"           Radiofrequency ablation of lung tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/36/38469\">",
"           Role of surgery in multimodality therapy for small cell lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/36/32329\">",
"           Sequelae and complications of pneumonectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/47/17143\">",
"           Stereotactic body radiation therapy for primary and metastatic lung tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/32/13834\">",
"           Surgical resection of pulmonary metastases: Benefits; indications; preoperative evaluation and techniques",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/15/13560\">",
"           Surgical resection of pulmonary metastases: Outcomes by histology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/40/44680\">",
"           Surgical treatment and other localized therapy for metastatic soft tissue sarcoma",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pleural disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/24/36232\">",
"           Chemical pleurodesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/20/37192\">",
"           Etiology, clinical presentation, and diagnosis of chylothorax",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/32/31241\">",
"           Management of chylothorax",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/6/13416\">",
"           Management of malignant pleural effusions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/29/37334\">",
"           Management of refractory nonmalignant pleural effusions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/27/28089\">",
"           Parapneumonic effusion and empyema in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/3/10297\">",
"           Primary spontaneous pneumothorax in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Postoperative complications",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/10/11434\">",
"           Overview of the management of postoperative pulmonary complications",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Thoracic diagnosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/28/41414\">",
"           An overview of medical thoracoscopy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/43/17080\">",
"           Computed tomographic and positron emission tomographic scanning of pulmonary nodules",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/23/12663\">",
"           Diagnostic thoracentesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/0/26634\">",
"           Differential diagnosis of chest pain in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/32/19976\">",
"           Endobronchial ultrasound: Indications, advantages, and complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/5/25688\">",
"           Endoscopic therapy for gastroesophageal reflux disease: Sewing and full-thickness plication techniques",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/24/14727\">",
"           Etiology and evaluation of hemoptysis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/18/5418\">",
"           Evaluation of subacute and chronic cough in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/16/28938\">",
"           Evaluation of the adult with dyspnea in the emergency department",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/15/38135\">",
"           Flexible bronchoscopy: Indications and contraindications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/29/16858\">",
"           High resolution computed tomography of the lungs",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/19/22838\">",
"           Imaging of pneumothorax",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/59/42933\">",
"           Indications for diagnostic thoracoscopy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/9/12442\">",
"           Overview of upper gastrointestinal endoscopy (esophagogastroduodenoscopy)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/45/39637\">",
"           Therapeutic uses of medical thoracoscopy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Thoracic surgery",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/27/32183\">",
"           Surgical management of mediastinal lymphadenopathy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Thoracic trauma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/39/34426\">",
"           Initial evaluation and management of blunt thoracic trauma in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/21/23898\">",
"           Initial evaluation and management of penetrating thoracic trauma in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Thoracostomy and thoracentesis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/12/1226\">",
"           Placement and management of thoracostomy tubes",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-282678A033-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f28_6_28782=[""].join("\n");
var outline_f28_6_28782=null;
var title_f28_6_28783="Papular urticaria 2";
var content_f28_6_28783=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F50494&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F50494&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Papular urticaria",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This healthy 4-year-old boy developed a recurrent pruritic eruption on his arms and legs. Covered areas were only rarely involved. Note the healing lesions with post-inflammatory hyperpigmentation and violaceous centers.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Bernard Cohen, MD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_6_28783=[""].join("\n");
var outline_f28_6_28783=null;
